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The functional role of human growth hormone (hGH) in the progression of 
cancer has been extensively studied. However, the specific functional role of 
hGH in colorectal cancer (CRC) remains largely to be determined. In addition 
to pituitary synthesis and secretion of hGH, it is also expressed in specific 
cancers and functions as an autocrine/paracrine growth factor. Autocrine hGH 
has been demonstrated to stimulate oncogenicity and epithelial-mesenchymal 
transition (EMT) in mammary carcinoma cells, and its expression is correlated 
with lymph node metastasis as well as poor survival outcomes. Similarly in 
endometrial carcinoma cells, autocrine hGH has been reported to stimulate 
oncogenicity and associated with myometrial invasion and poor survival.  This 
study determined the role of autocrine hGH in oncogenicity, EMT and 
metastatic potential, as well as cancer stem cell-like behavior in CRC.  
By use of CRC cell lines, I demonstrated that autocrine hGH promoted cell 
proliferation, survival and anchorage-independent growth in CRC cells. 
Autocrine hGH also stimulated CRC cell phenotypic conversion, migration 
and invasion. Furthermore, autocrine hGH increased the expression of the 
mesenchymal marker FN1, and decreased the expression of epithelial markers 
E-CADHERIN and OCCLUDIN in CRC cells. Simultaneously, autocrine 
hGH promoted cell attachment to, and transmigration through, an endothelial 
cell layer. Autocrine hGH activated the MAPK/ERK pathway in CRC cells 
and utilized the MAPK/ERK pathway to decrease E-CADHERIN expression 
and increase FN1 expression. Consequently, autocrine hGH-stimulated effects 
 XIV 
in CRC cells were abrogated by the inhibition of MAPK/ERK pathway. In 
addition, the loss of E-CADHERIN and the increase of FN1 were required for 
the autocrine hGH-stimulated CRC cell migration and invasion. Additionally, 
autocrine hGH promoted tumor growth of CRC cells with increased cell 
proliferation and survival in xenograft models in vivo. Simultaneously, 
autocrine hGH activated ERK1/2 pathway, stimulated EMT with increased 
expression of FN1 and decreased expression of E-CADHERIN, and stimulated 
local invasion of CRC cells in xenograft models in vivo. Moreover, autocrine 
hGH decreased CRC cell sensitivity to 5-FU and promoted colonosphere 
formation. Autocrine hGH also significantly increased the expression of 
cancer stem cell (CSC) markers and ALDH1+ CSC population in a E-
CADHERIN-dependent manner in CRC cells.  
The results described in this thesis demonstrated the functional role of 
autocrine hGH in CRC progression, suggesting that inhibition of hGH 
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Chapter 1 Introduction 
 
Growth hormone (GH) is pituitary secreted hormone, which known to be the 
major regulator of post-natal growth and its significant benefits to the clinical 
use are also well established. However, recent evidence suggests a role of GH 
in progression of various malignancies including mammary and colorectal 
carcinoma. The aim of this thesis is to investigate the role of autocrine human 
GH (hGH) in oncogenicity, invasiveness and cancer stem cell (CSC)-like cell 
behavior in colorectal cancer. This introduction will be divided into six parts. 
The first two parts describe the hallmarks of cancer, and also provide an 
introduction of colorectal cancer. The third section describes the biology of 
GH and its role in cancer. The fourth and fifth parts discuss two processes 
involved in tumor metastasis and self-renewal respectively, as well as 
epithelial-mesenchymal transition (EMT) and signaling pathways responsible 
in the regulation of these processes. Finally, the aim of the study in this thesis 
is presented in the last part. 
 
1.1 Hallmarks of cancer 
Cancer is a family of disease in which abnormal cells begin to proliferate and 
divide in an uncontrolled manner. Under normal cellular conditions, the 
proliferation, differentiation, and survival are tightly regulated to meet the 
needs of the organism. While, in the case of cancer, this regulation is lost. 
Thus, cells become resistant to cell death and divide without control, 
 2 
ultimately invade other tissue, even spread to other parts of the body through 
circulation, interfering with the function of normal tissues and organs. 
Hanahan and Weinberg published two important articles conceptualizing the 
hallmarks of cancer that provides a framework or summaries of research data 
to describe the characteristics of a cancer cell. In 2000, they grouped the 
common characteristics of cancer cells based on a few general cell biology 
properties and published as a review in journal Cell (Hanahan and Weinberg, 
2000). In this review, they described six hallmarks including “self-sufficiency 
in growth signals, insensitivity to antigrowth signals, evading apoptosis, 
limitless replicative potential, sustained angiogenesis and tissue invasion and 
metastasis”, which were shared by most and perhaps all types of human 
cancers. Recently, in 2011, they updated their theory with additional concepts 
to the list of the framework, and also highlight the significance of tumor 
microenvironment in the process of tumorigenesis (Fig. 1.1) (Hanahan and 
Weinberg, 2011).  
 
1.1.1 Sustaining proliferative signaling 
In cancer cells, the proliferative signals, which instruct the progression of cell 
growth and division, become deregulated. The production and release of these 
signals are usually strictly controlled in normal tissues to maintain the cell 
number in a homeostatic status and ensure tissue proper behavior. The 
liberation from regulation in tumor cells allows them to generate the signals in 
their own destinies. Cancer cells attain the capacity to sustain proliferative 
signaling through several alternative ways including producing growth factor 
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ligands themselves and stimulating in autocrine fashion, stimulating normal 
cells to support cancer cells with supplying growth factors, raising the level of 
receptor proteins, altering the structure of receptor to facilitate ligand-
independent firmness, and activating downstream pathways of these receptors 
(Hanahan and Weinberg, 2011). 
 
1.1.2 Evading growth suppressors 
Within normal tissues, multiple tumor suppressors operate to curb cell growth 
and proliferation to maintain tissue homeostasis. However, cancer cells can 
evade these suppressors and overcome the negative regulation of cell 
proliferation. Two prototypical mechanisms to evade anti-proliferative signals 
are the disrupted function of two tumor suppressors, the retinoblastoma 
protein (Rb) and the tumor protein 53 (p53). The protein Rb inhibits 
proliferation by inhibiting the function of the transcription factor E2F, thus 
mediates the expression of genes involved in the cell cycle from G1 into S 
phase (Weinberg, 1995). The p53 transcription factor regulates a program of 
gene expression that is associated with cell cycle arrest or apoptosis (Giaccia 
and Kastan, 1998, Levine, 1997). Cancer cells with the mutant function of Rb 
and p53, obtain the capability to ignore growth suppressor signals and sustain 




1.1.3 Resisting cell death 
Besides growth suppressors, apoptosis represents another major obstacle to 
cancer cell proliferation. Apoptosis is essential for normal tissue development 
to eliminate the damaged, mutant and aged cells, and thus maintain tissue 
homeostasis. In cancer, cells developed alternative strategies to evade 
apoptosis, which mainly result from mutation and DNA damage. Mutation of 
the oncogene B-cell lymphoma 2 (Bcl-2) (Adams and Cory, 2007) and DNA 
damage-caused loss of p53 tumor suppressor function (Junttila and Evan, 2009) 
can lead to resistance of apoptosis in cancer cells. 
 
1.1.4 Enabling replicative immortality  
Unlimited replicative potential has been widely accepted to be the marked 
capability of cancer cells. Normal cells have limited cell cycles because of 
senescence and crisis. In contrast, cancer cells can escape from senescence and 
crisis, and acquire the ability to divide well without limitation, which is termed 
immortalization. Telomeres, special chromatin structures that are essential to 
protect the ends of chromosomes, have been discovered its central role 
involved in the capability for replicative immortality (Blasco, 2005, Shay and 
Wright, 2000). Normally, telomeres are shortened progressively in non-
immortalized cells, which results in loss of telomere protection, triggering into 
crisis. In cancer cells, telomeres are maintained mainly through the activity of 
enzyme telomerase, which is up regulated in cancer cells while almost absent 
in normal cells. 
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1.1.5 Inducing angiogenesis 
In normal tissues, the supplies of oxygen and nutrients, and the elimination of 
carbon dioxide and metabolic wastes by the vasculature are essentially 
important for cell growth and survival. The physiological process where new 
blood vessels are formed is termed as angiogenesis, which is also required for 
cancer expansion and metastasis during tumor development (Hanahan and 
Folkman, 1996). In cancer, the angiogenic switch mostly appears to be 
activated by changing the balance between angiogenic inducer and inhibitor 
(Banerjee et al., 2007). 
Two well-known angiogenic inducers, vascular endothelial growth factor 
(VEGF) and fibroblast growth factor (FGF), have been reported to stimulate 
angiogenesis in many tumor cells, where their expression is upregulated 
(Baeriswyl and Christofori, 2009, Ferrara, 2009, Carmeliet, 2005). In contrast, 
the expression of thrombospondin-1 (TSP-1), a prototype of angiogenesis 
inhibitor, can be downregulated by oncogene signaling to induce angiogenesis 
in tumors (Kazerounian et al., 2008).  
 
1.1.6 Activating invasion and metastasis 
Primary tumors account for a small part of cancer deaths, while the majority 
cause of cancer deaths is metastasis (Ruiter et al., 2001). The capability for 
invasion and metastasis allows malignant cells to escape from primary tumor 
site, and spread to surrounding tissues, or even enter into lymphatic or blood 
vessels to gain access to other organs and colonize to form secondary tumor 
(Nguyen et al., 2009). During the process of metastasis, invasive cells may 
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develop several alterations. The most typical alteration is the loss of E-
CADHERIN. E-CADHERIN is a key molecule for cell-cell adhesion and 
served as a suppressor of invasion and metastasis, thus its down-regulation or 
inactivation in cancer presents an important role in the acquisition of this 
hallmark capability (Berx and van Roy, 2009). This part will be particularly 
discussed in section 1.4. 
 
1.1.7 Enabling characteristics and emerging hallmark 
Hallmarks of cancer described above are required for cancer cells to allow 
their survival, proliferation and dissemination during the development of 
tumorigenesis. Besides these six hallmarks, there are additional characteristics 
and hallmarks recently discussed by Hanahan and Weinberg (Hanahan and 
Weinberg, 2011) (Figure 1.1). Acquisition of multiple hallmarks is mainly 
dependent on genome instability, which generates random mutations in the 
genome and results in genetic alteration that make cells develop those features 
capabilities. Another enabling characteristic is tumor-promoting inflammation, 
which can provide bioactive molecules to the tumor microevironment, such as 
growth factors, survival factors and proangiogenic factors, to support cancer 
multiple hallmark capabilities. Other than that, two additional hallmarks are 
functionally essential for cancer development. One is reprogramming energy 
metabolism, which can support sustaining cell growth and proliferation. 
Another is evading immune destruction, which helps cancer cells escaping 
attack from the immune system. These two capabilities may contribute to the 
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progression of various types of cancers, and have been considered as emerging 
hallmarks of cancer. 
 
Figure 1.1 Hallmarks of cancer (Hanahan and Weinberg, 2011) (Hanahan 
and Weinberg, 2011).  
This framework consists six hallmarks, containing sustaining proliferative 
signaling, evading growth suppressors, resisting cell death and enabling 
replicative immortality, as well as two enabling characteristics and emerging 
hallmark. 
 
1.2 Colorectal cancer 
Colorectal cancer (CRC) develops from abnormal proliferation of cells in the 
colon or the rectum. Colon and rectum are portions of the gastrointestinal 
system, which processes digestion of food for energy and eliminates the solid 
waste out of the body. Most colorectal cancers develop from adenomatous 
polyps, most of which are benign or premalignant but become cancerous over 
time without detection. Colorectal cancer has been one of the more common 
cancers worldwide recent years, and contributes to cancer mortality. 
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1.2.1 Progression and staging of colorectal cancer 
The development of colorectal cancer is slow, which may last for 10 to 20 
years (Winawer and Zauber, 2002). During this period, colonic mucosa 
progresses through a series of morphologic changes, which may lead to an 
invasive carcinoma as a final consequence. Colorectal cancer mostly begins 
from a polyp (non-cancerous growth) on the inner lining of the colon or 
rectum (Stryker et al., 1987). Adenoma is the most common type of polyp and 
arises from glandular cells of colorectum. Cancers developed from adenomas 
are called adenocarcinomas, and approximately 96% of the colorectal cancers 
are adenocarcinomas (Stewart et al., 2006).  
Although all the adenomas have the capacity to develop to the cancers, not all 
of them will progress to invasive carcinomas (Levine and Ahnen, 2006, Risio, 
2010), or even more aggressive, metastatic carcinomas, which acquire the 
capability to spread to the distant sites of the body via blood vessels and 
lymph nodes. The stage for colorectal cancer is usually based on the pattern of 
spread and correlated with the clinical prognosis and diagnosis. There are 
several staging systems for the classification of colorectal cancer, such as 
TNM system and Dukes system, both of which are commonly used in the 
clinical studies. According to the TNM system, the colorectal cancer, in 
general, can be classified into five stages: 
• Stage 0: Cancers are found locally and not beyond the wall of the colon or 
rectum 
• Stage I: Cancers are found to invade into the colon or rectum wall, but not 
through the wall to spread to surrounding tissues 
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• Stage II: Cancers have grown beyond the colon or rectum wall and 
invaded neighbouring tissues, but not disseminate to the lymph nodes 
• Stage III: Cancers have disseminated to lymph nodes 
• Stage IV: Cancers are found to metastasize to distant sites, for example, 
lung and liver 
 
1.2.2 Colorectal cancer rates and risk factors 
According to the GLOBOCAN 2008 Estimates, more than one million new 
colorectal cancer cases and 600 thousand deaths have occurred in 2008, 
ranking to the third most common male cancers and the second most common 
female cancers worldwide (Jemal et al., 2011). The incidence rates of 
colorectal cancer exhibit regional or country-specific trends. The highest 
incidence rates are observed in Europe, North America, Australia and New 
Zealand, while the lowest in Africa and South-Central Asia (Jemal et al., 
2011). The colorectal cancer incidence rates have been reported to increase in 
some economically transition countries (Plesko et al., 2008, Kuriki and Tajima, 
2006, Yang et al., 2006b, Cress et al., 2006). Interestingly, decreasing 
incidence rates of colorectal cancer have been detected in the United States in 
both males and females recently, which may owe to the advanced detection 
tool, such as cancer screening (Center et al., 2009, Edwards et al., 2010). In 
addition, the death rates of colorectal cancer have been reduced these years in 
several Western countries with improved treatment and early detection (Center 
et al., 2009, Mitry et al., 2002, Sant et al., 2001). 
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In Singapore, based on the data from the National Registry of Diseases Office, 
colorectal cancer accounts for 17.5% and 13.6% of all cancers in males and 
females respectively, ranking as the most common male cancers and second 
most common female cancers during the period from 2008-2012 (Singapore 
Cancer Registry Interim Annual Registry Report. Trends in Cancer Incidence 
in Singapore 2008-2012. National Registry of Disease Office. Singapore: 
Ministry of Health.). During this period, a total of 8,733 new cases of 
colorectal cancer are diagnosed, and the incidence rates for both genders have 
increased consistently over past four decades, which may be due to 
environmental and lifestyle changes (Teo and Soo, 2013, Singapore Cancer 
Registry Interim Annual Registry Report. Trends in Cancer Incidence in 
Singapore 2008-2012. National Registry of Disease Office. Singapore: 
Ministry of Health.). Moreover, colorectal cancer is the top ranked cancers 
with highest cancer mortality rates in Singapore. Fortunately, with the 
advances in treatment, the age-standardized mortality rate of colorectal cancer 
has decreased during recent years. However, there are more than three 
thousand deaths caused by colorectal cancer during 2008-2012 in Singapore 
(Singapore Cancer Registry Interim Annual Registry Report. Trends in Cancer 
Incidence in Singapore 2008-2012. National Registry of Disease Office. 
Singapore: Ministry of Health.). Thus, studies on the colorectal cancer are 
required for a better diagnosis or prognosis. 
There are various factors that influence the risk of colorectal cancers, 
including age, heredity and family history, personal medical history, as well as 
behavioral risk factors. Colorectal cancer is predominately occured in older 
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age groups, with ninety percent of the colorectal cancers occurring in persons 
over 50 years of age (American Cancer Society. Colorectal Cancer Facts & 
Figures 2014-2016. Atlanta, GA: American Cancer Society; 2014). Although 
the incidence rates increase with age, colorectal cancer also occurs in younger 
people, especially for those with a family history of this disease. Heredity, like 
all the cancers, occurs in colorectal cancers, though it represents about 5% of 
all cases (Lynch and de la Chapelle, 2003). Individuals diagnosed with Lynch 
syndrome (Hereditary non-polyposis colorectal cancer) have higher risk to 
develop the colorectal cancer (Win et al., 2012, Stoffel et al., 2009). In 
addition, people with a personal history of colorectal disease, such as 
adenomatous polyps or inflammatory colorectal disease, have a higher risk to 
develop colorectal cancer (Bernstein et al., 2001, Schatzkin et al., 1994). 
Moreover, personal behaviors such as diet (Aune et al., 2011, Cross et al., 
2010), smoking (Liang et al., 2009, Paskett et al., 2007), alcohol (Ferrari et al., 
2007, Cho et al., 2004) and obesity (Bardou et al., 2013), also affect the risk of 
colorectal cancer.  
 
1.2.3 Colorectal cancer detection and treatment 
The advances in detection and treatment of CRC significantly contribute to the 
decrease of the mortality rate (Edwards et al., 2010). Screening is the most 
common method for the detection of CRC. From 1993 through 2001, 
screening with flexible sigmoidoscopy was correlated with reduction in 
colorectal cancer incidence and mortality (Schoen et al., 2012). Other than 
sigmoidoscopy, there are several other options for CRC screening, primary 
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colonoscopy, but also double-contrast barium enema (DCBE) or computed 
tomographic colonography (CTC). 
The treatment for the CRC is highly dependent on the stage and location of the 
cancer. For the early stage colorectal cancer, removing the tumor by surgery is 
usually the major treatment. Additional treatments including chemotherapy 
and radiation are usually performed as an adjuvant therapy to prevent 
recurrence and metastasis. However in the later stage of the colorectal cancer, 
surgery cannot prevent the recurrence of the advanced CRC due to the 
metastasis. Approximately 15-25% of CRC diagnoses are in the metastatic 
stage and majority of these metastases are unresectable (Manfredi et al., 2006, 
Nordlinger et al., 2007, Scheele et al., 1995). In this stage, systemic therapies, 
which combine chemotherapy, radiation and biologically targeted therapies, 
will be used for the best overall outcome.  
The major advance in systemic therapies for metastatic CRC (mCRC) is the 
usage of 5-fluorouracil (5-FU), irinotecan and oxaliplatin. These drugs may be 
given alone or in combination and improve the treatment with increased 
overall survival (OS), overall response rates (ORR) and relapse-free survival 
(PFS) (Falcone et al., 2007, Douillard et al., 2000, Saltz et al., 2000, Raymond 
et al., 1998, Armand et al., 1995). Recently, three therapeutic antibodies, 
bevacizumab, cetuximab and panitumumab, have been approved by the US 
Food and Drug Administration (FDA) for anti-CRC treatment (American 
Cancer Society. Colorectal Cancer Facts & Figures 2014-2016. Atlanta, GA: 
American Cancer Society; 2014). Bevacizumab, a monoclonal IgG1 antibody 
against VEGF, can induce cell proliferation and vascularization by binding to 
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its receptor. A number of trials have demonstrated that patients with mCRC in 
bevacizumab therapy have significant improved clinical outcomes 
(Degirmenci et al., 2010, Lee et al., 2010, Kocakova et al., 2009, Hurwitz et 
al., 2004). Panitumumab and cetuximab are both monoclonal antibodies that 
target the epidermal growth factor recepor (EGFR), which is overly expressed 
in 60-80% of CRC cases (Porebska et al., 2000). Cetuximab was firstly used 
as an adjuvant therapy in patients who are refractory to the standard 
chemotherapy, or as a single agent in those intolerant to the standard 
chemotherapy (Van Cutsem et al., 2009, Lenz et al., 2006, Cunningham et al., 
2004, Jonker et al., 2007). Panitumumab is also utilized as a treatment for 
mCRC and improves the PFS when used together with standard chemotherapy 
in patients with wild-type KRAS (Douillard et al., 2010, Van Cutsem et al., 
2007). 
Although the mortality of CRC is reduced with above improvements in the 
past few decades, a large amount of patients cannot benefit from these 
therapies and even suffer from the side effects or experience lethal adverse 
drug events (Gill et al., 2004). Thus, new biologically targeted therapies with 
improved efficacy are required for the better clinical outcomes. 
 
1.3 Growth hormone 
Growth hormone (GH), officially known as somatotropin, is a pituitary 
peptide hormone that functions as the major regulator of postnatal growth in 
humans and other animals. In the early 1900s, the growth promoting capacity 
of the pituitary gland was demonstrated and later in 1945, the growth factor 
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named GH was firstly isolated from bovine pituitary glands (Evans, 1946, 
Evans and Long, 1922). Since then, a lot of studies have been done to 
investigate the effect of GH on growth regulation, or even in cancer 
development. 
 
1.3.1 Growth hormone gene and protein 
The gene encoding human growth hormone (hGH) is located on the long arm 
of chromosome 17 with approximately 3000 nucleotides long (Miller and 
Eberhardt, 1983). The hGH locus consists of five related genes: GH-N 
(normal), CS-L (chorionic somatomammotropin-like), CS-A (chorionic 
somatommammotropin-A), GH-V (variant) and CS-B (somatomammotropin-B) 
(Hirt et al., 1987). More than 92% sequence identity occurs in the coding and 
flanking regions of these five genes in humans, while each is expressed in a 
tissue-specific pattern. For example, the hGH protein encoded by the  (GH1) 
gene is expressed in the pituitary gland, while the GH-V is encoded by the 
GH-V (GH2) gene is expressed in the placenta tissue (Cooke et al., 1988, 
Frankenne et al., 1987). Most of the circulating GH in serum is encoded by 
GH-N gene, which is approximately 2.6kb in length and includes five exons 
and four introns (Kopchick and Andry, 2000, Lewis et al., 1994) (Figure 1.2). 
The hGH gene gives rise to a 22-KDa protein, as well as a 20-KDa protein 
with alternative mRNA splicing (Okada and Kopchick, 2001, Lewis et al., 
1994). The 22-KDa GH is the predominant form in plasma and comprises 




Figure 1.2 The components of the hGH gene cluster (Kopchick and Andry, 
2000) (Kopchick and Andry, 2000).  
The GH gene cluster includes five related genes: GH-N, CS-L, CS-A, GH-V 
and CS-B. The GH-N gene includes five exons and four introns. 
 
1.3.2 Secretion and regulation 
GH is mainly synthesized, stored and secreted by the somatotroph cells, which 
is abundantly present in the anterior pituitary gland (Kopchick and Andry, 
2000). The secretion of GH is regulated by the neuroendocrine complex, 
which includes two main hypothalamic peptides, GH releasing hormone 
(GHRH) and somatostatin (SS) (somatotropin release-inhibiting factor) 
(Tannenbaum, 1991) (Figure 1.3). GHRH stimulates the synthesis and 
secretion of the GH while SS prevents GH releasing from the pituitary. Serum 
GH regulates proliferation of its target tissues, which include liver, muscle, 
bone as well as adipose by binding to its cell surface receptors. The secretion 
of GH from pituitary increases serum GH concentration, which promotes 
insulin-like growth factor 1 (IGF-1) release into the circulation from target 
tissues such as liver. The resultant increase in serum IGF-1 concentration can 
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produce growth-promoting effects, and in turn with GH, stimulates growth and 
development of the target tissues (Green et al., 1985). In addition, high serum 
GH level will inhibit its own secretion from anterior pituitary either by 
inhibiting the synthesis and secretion of GHRH, or stimulating the synthesis 
and secretion of SS. Moreover, the high level of serum IGF-I promoted by GH, 
in a long feedback loop manner, will also inhibit the secretion of GH. 
 
Figure 1.3 GH secretion and regulation. GHRH and SS that synthesized 
in the hypothalamus regulate the secretion of GH.  
GHRH stimulates GH to be released from the anterior pituitary, while SS 
inhibits its release. Serum GH promotes the release of IGF-1 from liver and 
stimulates tissue growth and development. High level of serum GH inhibits its 
own secretion by inhibiting GHRH expression or promoting SS expression. 




GH is traditionally thought to be an endocrine factor secreted by somatotroph 
cells of the anterior hypophysis. However, over past two decades, it has been 
accepted that GH can also be expressed in several extrapituitary sites, which 
include central nervous system (CNS) (Gossard et al., 1987, Hojvat et al., 
1982), endothelial cells of blood vessels (Wu et al., 1996), fibroblasts 
(Palmetshofer et al., 1995), epithelial cells of the thymus (Maggiano et al., 
1994, Martin-Fontecha et al., 1993) and mammary gland (Mol et al., 1996, 
Mol et al., 1995), and also gonads from both sexes (Izadyar et al., 1999, 
Untergasser et al., 1997). GH produced by local tissue acts in an 
autocrine/paracrine pattern and its regulation differs from that produced by 
pituitary gland (Hojvat et al., 1986). The physiological role of autocrine or 
paracrine GH provides the specific needs of the local tissue or supply GH in 
some somatic compartments, such as CNS, where serum GH is not able to 
approach (Liu et al., 1997). Such autocrine/paracrine mechanism for GH 
provides individual tissue with more precise regulation of growth and 
differentiation, and exhibits different growth related effects compared to 
endocrine GH that produced from pituitary. 
 
1.3.3 Growth hormone mediated signal transduction 
The action of GH is dependent the hormone interacting with growth hormone 
receptor (GHR), which is expressed in many tissues (Liu et al., 1997). 
Additionally, GH can also bind to the prolactin receptor (PRLR) (Mertani et 
al., 1998, Wennbo and Tornell, 2000), which shares 32% extracellular domain 
identity with GHR in human (Boutin et al., 1989). The extracellular interaction 
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of GH and its receptor activates the intracellular signaling pathways, and then 
leads to various growth effects. Knowledge of GH-GHR binding mechanisms 
and following signal transduction provides a better understanding of the 
biologic effect of GH. 
 
1.3.3.1 Growth hormone receptor 
GHR is a member of the type I cytokine receptor family, which also includes 
the PRLR, erythropoietin receptor and leukemia inhibitory factor receptor 
(Goffin and Kelly, 1997).  The class I cytokine receptors are transmembrane 
receptors sharing following characteristics: a single hydrophobic 
transmembrane domain; limited amino acid homology in the extracellular 
domain; pairs of cysteine residues in the extracellular domain, as well as a 
conserved tryptophan residue in proximity to the second cysteine in the N-
terminal fibronectin domain; a WSXWS (tryptophan, serine, any amino acid, 
tryptophan, serine) like motif in the C-terminal fibronectin domain; absence of 
intrinsic tyrosine kinase activity and two proline-rich domains, which are 
termed as Box 1 and 2 in the intracellular domain (Zhu et al., 2001, Kopchick 
and Andry, 2000). The molecular mass of GHR is 70KDa, and have been 
determined larger experimentally because of the posttranslational 
modifications (Harding et al., 1994, Zhou et al., 1994, Wang et al., 1994). 
GHR consists of five N-linked glycosylation sites and has the conserved 
substitutions YXXFS in the WSXWS-like motif domain (Argetsinger and 
Carter-Su, 1996). Box 1 in GHR is one binding site for Janus kinase 2 (JAK2). 
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Box1 is essential for the most GH-stimulated signaling transduction (Carter-
Su et al., 1996).  
GHR has been determined to be present as a homodimer on the cell surface in 
response to GH binding to its extracellular domain, providing the signal to 
trigger the activation of the intracellular domain and then generate the 
biological response (Zhu et al., 2001). The activation of GHR signaling is go 
through a two-step process in which GH binds to the first receptor molecule 
via site-1 with high affinity, followed by binding of the GH site-2 with low 
affinity to a second GHR molecule, leading to receptor dimerization and 
conformational change (Fuh et al., 1992) (Figure 1.4A). This model has been 
supported by the function of a GH analogue with site-2 mutated, which is 
named G120R, to disrupt the action of GH and act as a GHR receptor 
antagonist (Fuh et al., 1992). Current studies demonstrated that GHR is 
present as a preformed dimer on the cell membrane surface in the absence of 
the GH, leading a new model of GHR activation, and suggest that 
conformational changes rather than receptor dimerization stimulate the signal 




Figure 1.4 Models for GHR activation (adapted from Kaabi, 2012 (Kaabi, 
2012) ).  
(A) The early model for GHR activation is based on GH-induced receptor 
dimerization through two-step process. GH binds to the first receptor molecule 
via site-1, which attracts the second molecular binding via site-2, leading to 
receptor dimerization and signaling transduction. (B) A new model for GHR 
activation is based on current findings that GHR exists as a homodimer on the 
cell membrane in the absence of the GH, suggesting ligand-induced 
conformational changes rather than receptor dimerization, stimulate the signal 
activation. 
 
An important variant of the GHR is the GH binding protein (GHBP), which is 
comprised of the extracellular domain of GHR. GHBP is generated by two 
species-dependent mechanisms: alternative splicing of GHR mRNA in rodents 
(rat and mouse) (Baumbach et al., 1989, Smith et al., 1989), and proteolytic 
cleavage of membrane-bound GHR molecules in humans and rabbits (Ross et 
al., 1997). Approximately half of hGH circulated in the plasma is in a complex 
form binding with the GHBP under physiologic conditions (Baumann et al., 
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1988). It’s still unclear about the exact function of the circulating GHBP, 
however it is believed that the GHBP may function as a reservoir, maintaining 
a releasable quantity of GH when there is low supply of serum GH. The 
finding that GHBP contributes to a longer half-life of GH supported the 
potential role of the GHBP in the serum to diminish the clearance rate and GH 
degradation (Amit et al., 2000). 
 
1.3.3.2 Growth hormone mediated signal pathways 
As a member of cytokine receptors family, GHR has no intrinsic kinase 
activity. Instead, it recruits and activates various receptor and non-receptor 
cytoplasmic tyrosine kinases for signal transduction (Liu et al., 1998). Among 
these, JAK2 is the predominant non-receptor tyrosine kinase utilized by GHR 
(Argetsinger et al., 1993), even though JAK1 and JAK3 also have been 
reported their importance in the GH signal transduction (Smit et al., 1996, 
Johnston et al., 1994). In an inactivated state, JAK2 is weakly associated with 
the GHR in the Box 1 region, while in response to the binding of GH and its 
receptor, two molecules of JAK2 are placed into close proximity by the 
conformational change in GHR, which causes JAK2 to transphosphorylate and 
activate each other.  The activated JAKs phosphorylate several tyrosine 
residues present on the intracellular domain of the GHR that provides a 
docking site for other signaling molecules, which contain Src homology 2 
(SH2), such as signal transducer and activator of transcription protein (STAT) 
(Postel-Vinay and Kelly, 1996). The STAT proteins, especially STAT5a and b, 
are tightly mediated by GH-GHR-activated JAK2 and regulate genes involved 
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in GH actions (Tang et al., 2010c, Choi and Waxman, 2000, Herrington et al., 
2000). 
Additionally, GH signals can also be transduced through other pathways, such 
as mitogen-activated protein kinase (MAPK) pathway and 
phosphatidylinositol 3’-Kinase (PI-3K) pathway (Lanning and Carter-Su, 2006) 
(Figure 1.5).  
 
Figure 1.5 Schematic representation of GH signaling pathway (adapted 
from Fernandez-Perez et al., 2013 (Fernandez-Perez et al., 2013)).  
GH binds to a performed GHR homodimer, which activates JAK2 tyrosine 
kinase. Activation of JAK2 results in a phosphorylation of several tyrosine 
residues in the intracellular domain of GHR, which provides a docking site for 
other signaling molecules containing Src homology 2 (SH2), such as STATs.  
MAPK and PI-3K pathways can also activated by JAK2 through adaptor SHC 
and insulin receptor substrate IRS respectively. In addition, MAPK pathway 
can also be activated by Src kinase in a JAK2-independent manner. GH, 
growth hormone; JAK2, Janus kinase 2; IRS, insulin receptor substrate; Src, 
proto-oncogene tyrosine-protein kinase; STAT, signal transducers and 
activators of transcription protein; PI-3K, phosphoinositide 3-kinase; MAPK, 
mitogen-activated protein kinase. 
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MAPKs, which belong to serine and threonine protein kinases family, regulate 
varied cellular effects including proliferation, differentiation and apoptosis 
(Pearson et al., 2001). GH has been reported to stimulate the phosphorylation 
of the adapter protein Shc through GHR-activated JAK2, and then Shc binds 
to growth factor receptor-bound protein 2 (Grb2) and the guanine nucleotide 
exchange factor SOS to activate proteins Ras, Raf, as well as the mitogen-
activated protein kinase/extracellular-regulated protein kinase (MEK) and 
finally extracellular signal-regualted kinase (ERKs) (Winston and Hunter, 
1995, VanderKuur et al., 1995, Winston and Bertics, 1992). Other studies 
suggested that GH might also mediate ERKs in a JAK2-independent, Src-
dependent manner (Zhu et al., 2002) or via a c-Src-FAK-Grb2 complex (Zhu 
et al., 2001).  
The role of the PI-3K pathway in GH signaling transduction has also been 
demonstrated. One of the potential mechanisms is that GH activates PI-3K by 
phosphorylation of the insulin receptor substrate (IRS) protein, which 
mediates the transduction of insulin signaling (Argetsinger et al., 1995, 
Ridderstrale et al., 1995, Souza et al., 1994). Activation of the PI-3K signaling 
pathway also can partially regulate the MAPK signaling stimulated by GH 
(Kilgour et al., 1996). A recent study suggested that GH-induced PI-3K 
signaling might be mediated by JAK2 in macrophages, in which JAK2 
inhibition results in a significant decrease of the GH-induced PI-3K 
phosphorylation (Tripathi and Sodhi, 2009). 
 
 24 
1.3.4 Biological effects of GH 
GH is a key endocrine regulator of the postnatal growth as well as cellular 
metabolism. Growth hormone stimulates differentiation and cell proliferation 
in target tissues, resulting in tissue hypertrophy and hyperplasia. GH promotes 
the bone growth in hypophysectomized rats (Isaksson et al., 1982) and 
stimulates the growth of cultured chondrocytes, which is isolated from the ear 
and epiphysis  of the rabbit (Madsen et al., 1983). These effects regulated by 
GH exert either directly on target tissues or indirectly through the action of 
GH-induced IGF-1 (Strobl and Thomas, 1994). In addition, GH has metabolic 
effects on target tissues through the interaction with GHR (Casanueva, 1992, 
Davidson, 1987). GH has been reported to regulate carbohydrate metabolism 
in two opposite actions: an early insulin-like effect to transform glucose to 
glycogen for storage, and a later anti-insulin effects (Casanueva, 1992). GH 
also promotes protein synthesis that increases nitrogen retention, lean muscle 
mass, electrolyte balance and mineral metabolism (Corpas et al., 1993, Strobl 
and Thomas, 1994). 
Abnormal secretion pattern of GH occurs in several physiological states 
including acromegaly, dwarfism, diabetes and obesity. Hypersecretion of GH 
caused by pituitary disorder can result in gigantism and acromegaly in adults 
(Colao et al., 1997) with abnormal growth of bone. In contrast, hyposecretion 
of GH results in dwarfism that may happen in childhood or in adults. Elevated 
levels of GH has been detected during starvation and in diabetes (Asplin et al., 
1989, Ho et al., 1988), and is one of the factors proposed to contribute the 
microvascular complication of diabetes (Holly et al., 1988). In addition, 
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decreased secretion of GH has been observed in obese individuals, and they 
exhibit a blunted growth hormone secretory response to the stimuli including 
insulin, glucagon, leading to a failed GH regulation (Veldhuis et al., 1991). 
Current studies also suggest the important role of GH in cancer development, 
which will be discussed in section 1.3.5. 
 
1.3.5 Growth hormone and cancer 
The role of GH in the cancer development has obtained much interest in recent 
years, and the correlation between IGF-I/GH axis and cancer in animals and 
humans has been well established (Chhabra et al., 2011, Clayton et al., 2011, 
Perry et al., 2006). Early in 1950s, an epidemiological study with the 
observation that hypophysectomy reduced breast cancer progression in women 
suggest the potential relationship between this axis and malignant growth 
(Luft and Olivecrona, 1957). Nowadays, substantial evidence indicates the 
important role of GH including systemic circulating and extrapituitary 
expression of GH as well as IGF-1 in the progression and pathogenesis of 
cancer. Such studies include an increased cancer risk in transgenic animals 
with elevated GH levels and humans with acromegaly (Chhabra et al., 2011, 
Renehan and Brennan, 2008). In addition, GH expression is increased in 
proliferative disorders (Raccurt et al., 2002, Mertani et al., 1998) of mammary 
gland in humans and enhances cell proliferation, survival and oncogenicity in 
breast cancer (Perry et al., 2008, Perry et al., 2006). These studies suggest that 
abnormal expression of GH is associated with cancer risk in both animals and 
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humans. This section will focus on evidence demonstrating the effect of GH 
on cancer development and progression. 
 
1.3.5.1 Animal studies 
Abundant evidence for the role of GH in cancer development has been 
demonstrated from animal studies. An early study has demonstrated that the 
administration of SS in rats, which suppressed the secretion of GH, resulted in 
the reduction of mammary carcinogenesis (Rose et al., 1983). In dogs and cats, 
administration of progestins increases the level of serum GH, which is 
produced by mammary gland, resulting in an acromegaly-like appearance 
(Mol et al., 1996). In addition to the acromegaly-like phenotype observed, 
administration of progestins also have been observed to enhanced the 
formation of mammary tumors, which may be associated with locally 
increased GH expression (Rijnberk et al., 2003, Mol et al., 1996). Moreover, 
increased serum GH has been shown to stimulate mammary gland hyperplasia 
in aging monkeys, independently from IGF-1 (Ng et al., 1997).  
Further evidence were obtained from xenograft studies in lit mice with 
naturally occurring mutation in the GH axis resulting in loss of function of the 
GHRH receptor, which then leads to a secondary inhibition of GH and IGF-1 
(Yang et al., 1996). These studies have demonstrated that breast cancer growth 
is significantly reduced when transplanting human mammary carcinoma cells 
into lit/lit mice compared to control hosts. Similar effect has been 
demonstrated that GH/IGF-I deficiency in lit/lit animals reduces the growth of 
five different human sarcomas with xenotransplantation (Yang et al., 1996). 
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Bugni et al. demonstrated that GH deficiency suppressed liver tumor 
development in mice (Bugni et al., 2001). Similarly, the GH deficiency 
resulted from GH gene mutation in the Spontaneous Dwarf rat (SDR) has been 
investigated to exhibit a significant decrease in mammary carcinogenesis 
induced by chemicals (Thordarson et al., 2004, Swanson and Unterman, 2002, 
Ramsey et al., 2002). Other evidence from transgenic animal models also 
suggests the potential role of GH in cancer development. Transgenic GHR 
knockout mice with overexpression of GH have been investigated to exhibit 
increased circulating IGF-I, associated with hyperplasia in mammary gland 
(Tornell et al., 1992). However, the same group later shown that this effect 
was regulated by hGH binding to the mouse PRLR instead of GHR (Tornell et 
al., 1992). In addition, mice transgenic with a GH antagonist exhibit lower 
levels of IGF-1, smaller body size and weight, as well as decreased chemically 
induced tumor incidence (Pollak et al., 2001). Furthermore, interruption of the 
GH signaling by disruption of GHR gene also significantly inhibits 
carcinogenesis (Zhang et al., 2007, Wang et al., 2005).  
 
1.3.5.2 Clinical studies 
While animal studies demonstrated the potential role of GH in cancer 
progression, there are limited clinical data supporting this observation in 
human. However, an increasing number of studies have presented the potential 
role of hGH in human malignancy recently.  
It has been shown that increased levels of serum hGH associated with 
increased risk of various cancers, such as cancers of the breast, lung, gastric 
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and large bowel (Emerman et al., 1985, Mazzoccoli et al., 1999, Triantafillidis 
et al., 2003). Similarly, the elevated expression of IGF-I stimulated by serum 
hGH is demonstrated to be linked to malignancy in some studies (Yakar et al., 
2005, Laban et al., 2003, Khandwala et al., 2000). Furthermore, some studies 
have demonstrated that the hGHBP/hGH complex is correlated with the risk of 
female breast cancer (Pazaitou-Panayiotou et al., 2007). 
hGH is known as a major mediator to regulate the longitudinal growth and 
development. Increasing adult height has been demonstrated correlated with 
increasing cancer risk of many cancers, such as breast, prostate, ovary and 
colorectal cancer (Albanes et al., 1988, Gunnell et al., 2001, Olsen et al., 2008, 
Schouten et al., 2008, Pischon et al., 2006). Recently, large-scale cohort 
studies have been performed to study the relationship between height and 
cancer (Collaboration, 2012, Green et al., 2011). In the Million Women Study 
held by UK’s National Health Service (NHS), increased risk was observed in 
15 to 17 cancer sites, especially in ten sites including colon, rectum, breast, 
endometrium, ovary, malignant melanoma, kidney, CNS, non-Hodgkin 
lymphoma and leukaemia with increasing height in these million women 
(Green et al., 2011). Another large-scale studies in 2012 with one million 
participants also demonstrated that the height was associated with the cancer 
risk of colorectum, breast, pancreas, endocrine and nervous systems, ovary, 
prostate, blood and lung (Collaboration, 2012). These studies suggest the 
strong correlation of adult height with cancer risk. However, the mechanisms 
are still unclear. GH/IGF-I axis, which has emerged as the major factor 
strongly correlated with childhood growth, and associated with the cancer risk 
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in adulthood (Clayton et al., 2011), has been the focus of attention on its 
potential mechanistic relevance (Renehan, 2011).  
Much more clinical correlations between hGH and cancer are from the studies 
of acromegaly, a chronic disease which is caused by the hypersecretion of 
hGH and consequently, of IGF-I. Acromegaly has been demonstrated to 
associate with an increase in morbidity and mortality risk, and a number of 
studies indicate that patients with acromegaly exhibit higher risk of developing 
both benign and malignant tumors, especially colorectal and thyroid 
neoplasms (Ruchala et al., 2012, Jenkins, 2004). In addition, the increased risk 
of tumors in breast, prostate, CNS and urinary system has also been indicated 
in acromegaly patients (Ruchala et al., 2012). In contrast, patients with Laron 
syndrome where there is a GH gene deletion, GHRH receptor defects and 
IGF-I resistance have been observed to be resistant to cancer (Shevah and 
Laron, 2007). 
Several clinical studies have suggested the association between the expression 
of GH with the patient outcomes. A small study conducted by Ratkaj et al. has 
observed that the GH expression is found in nearly 50% of metastatic breast 
carcinoma samples, but no correlation was found between the expression of 
GH and the clinicopathological parameters including tumor size, histological 
grade and other features (Ratkaj et al., 2010). However, in a large study, Wu et 
al. observed that the hGH and hPRL expression in mammary and endometrial 
cancer is correlated with tumor stage as well as lymph node metastasis 
significantly (Wu et al., 2011). Additionally, patients whose carcinomas were 
positive for hGH expression have lower 5-year overall survival rate and worse 
 30 
relapse-free survival comparing to the those whose tumors were GH-negative 
(Wu et al., 2011). 
 
1.3.5.3 Autocrine hGH and cancer 
It has been known that GH is also expressed in several extrapituitary sites. 
Increased expression of GH or GHR has been indicated in many cancers such 
as prostate, melanoma, breast, endometrial, lung as well as colorectal cancer 
(Perry et al., 2006, Chhabra et al., 2011), suggesting a potential role of 
autocrine hGH in oncogenesis. Numbers of studies have been conducted in a 
cell-based model to indicate the critical oncogenic role of autocrine hGH in 
cancer, especially in breast cancer. 
One of the important roles of autocrine hGH in cancer is its ability to promote 
proliferative and anti-apoptotic effect. Kaulsay et al. have demonstrated the 
functional effect of autocrine expression of hGH on enhancing proliferation in 
a breast cancer cell line, MCF-7 (Kaulsay et al., 1999). In their study, MCF-7 
cells with stable transfection of the functional hGH gene exhibited a 
significantly increase in proliferation compared to the cells with transfection 
of non-functional hGH or the untransfected parental control cells. Interestingly, 
no exogenous IGF-1 expression was observed in these cells, suggesting that 
the proliferative effect was IGF-1 independent and specific to the autocrine 
production of hGH. Treatment of hGHR antagonist, hGH-G120R, 
significantly suppressed the proliferative effects induced by hGH, confirming 
the potential role of autocrine hGH (Kaulsay et al., 1999). Another mechanism 
may be due to the hGH-regulated factor CHOP, which has been demonstrated 
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to enhance cell survival from apoptosis via p38 MAPK pathway in MCF-7 
cells (Mertani et al., 2001). In addition, elevated hGH expression has been 
demonstrted in different progressive disorders of mammary gland, including 
benign tissue, pre-invasive tumor and invasive carcinoma, compared to the 
primary epithelial cells in normal human mammary gland (Raccurt et al., 
2002), also delineating its pathophysiological role in the neoplastic 
progression. 
Another crucial role of autocrine hGH in cancer is the ability to stimulate 
phenotypic conversion and metastasis. Phenotypic conversion is one of the 
important features in the cancer progression, in which cells lose their well-
differentiated epithelioid morphology and change to a less-differentiated 
mesenchymal morphology. Mukhina et al. have demonstrated that forced 
expression of hGH in MCF-7 cells alters cell morphology and promotes a 
mesenchymal phenotype, which is thought to be undergoing EMT (Mukhina 
et al., 2004). Autocrine expression of hGH in MCF-7 cells resulted in an 
invasive phenotype with increased cell abilities of migration and invasion in 
vitro, as well as local invasion in vivo. These phenomena are observed 
together with the downregulated expression of epithelial markers (E-cadherin, 
occludin), and upregulated expression of mesenchymal markers (vimentin, 
fibronectin), suggesting the role of autocrine hGH in EMT. At the same time, 
enhanced Matrix Metalloproteinase 2 and 9 (MMP2 and MMP9), which are 
associated with metastasis, are observed in the MCF-7 cells with autocrine 
expression of hGH, suggesting the potential role of autocrine hGH in 
metastasis (Mukhina et al., 2004).  
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The most impressive observation in hGH is its ability to contribute to the 
oncogenic transformation of an immortalized human mammary epithelial cell 
line (MCF-10A). Zhu et al. have shown that autocrine hGH in MCF-10A, 
stimulates anchorage-independent cell growth, which is one of the 
characteristics of oncogenically transformed cells (Zhu et al., 2005a). 
Moreover, MCF-10A cells with forced expression of hGH exhibit limited 
intercellular contact and dramatic tumor formation in vivo. Thus, hGH may be 
considered as an oncogene with its ability of oncogenic transformation. 
Another study conducted on endometrial carcinoma cells, also demonstrates 
the role of hGH in oncogenicity (Pandey et al., 2008). In this study, autocrine 
hGH promotes cell anchorage-independent growth, cell migration and cell 
invasion in vitro. Furthermore, autocrine hGH in endometrial carcinoma cells 
enhances tumor formation in mice. While these oncogenic effects are 
significantly suppressed by the treatment of functional antagonism of hGH 
(Pandey et al., 2008). 
In addition, recent studies demonstrated the effects of hGH on tumor 
angiogenesis and chemoresistance. Angiogenesis plays a critical function in 
caner development, as well as metastatic dissemination (Banerjee et al., 2007). 
Brunet-Dunand et al. have demonstrated that autocrine hGH expression in 
breast cancer cells stimulates proliferation and survival, as well as migration 
and invasion of the human microvascular endothelial cell HMEC-1 (Brunet-
Dunand et al., 2009). In this study, mammary carcinoma cells secreted hGH 
has been demonstrated to stimulate HMEC-1 in vitro tube formation with 
increased expression of endothelial growth factor-A (VEGF-A), which acts as 
 33 
a key molecule in regulation of normal as well as pathological angiogenesis, 
resulting in an increase in the microvessel formation in both tumor blood and 
lymphatic in vivo (Brunet-Dunand et al., 2009). Chemo-resistance is the major 
cause leading to the failure of cancer therapy (Perry et al., 2008). Recently, 
autocrine hGH has been investigated of its role in drug resistance. Bougen et 
al. demonstrated that autocrine hGH reduced the DNA double-stand breaks 
induced by mitomycin C (MMC), an alkylating agent commonly used to treat 
advanced metastatic mammary cancer, and also decreased MMC-induced cell 
apoptosis (Bougen et al., 2011). In addition, autocrine hGH has also been 
investigated to protect cancer cells from other therapies, such as radiotherapy, 
leading to a poor survival outcome (Bougen et al., 2012). 
 
1.3.6 Growth hormone and colorectal cancer 
Limited evidence is reported in the correlation of GH and CRC, while several 
epidemiologic studies have suggested a potential effect of GH on the 
development of CRC. Among them, studies on acromegalic patients provide 
an association between the cancer risk of CRC and acromegaly with 
hypersecretion of GH.  A study based on a group of 129 patients with 
acromegaly has demonstrated a significantly higher incidence of colorectal 
carcinoma compared to the normal group (Jenkins et al., 1997). However, a 
study based on a group at 115 subjects demonstrated no significant increased 
cancer risk in acromegalic patients (Renehan et al., 2000). A study conducted 
by Rokkas et al. demonstrated that acromegalic patients exhibit higher 
colorectal adenomatous, hyperplastic polyps and colorectal cancer risks, 
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compared to the control groups (Rokkas et al., 2008). Unlike the studies 
conducted in small scale, this study is particularly valuable with the large 
number of subjects, prospective character and the proper control groups. There 
are several potential mechanisms involved in the correlation of increased risk 
of CRC in acromegaly, including a direct GH action and an indirect GH action 
(Renehan and Brennan, 2008). The major cause of the acromegaly is the 
hypersecretion of GH, which has been universally found to perform its action 
via GHR in colonic epithelium. Moreover, it has been demonstrated that 
increased concentration of serum IGF-1, which is induced by GH, is correlated 
with increased CRC risks (Jenkins et al., 2000). 
Although a number of studies on acromegaly have suggested the relationship 
between GH and CRC, few studies have reported the expression of GH in 
CRC. Recently, our collaborators have demonstrated that hGH is frequently 
expressed in CRC compared to the normal tissue (unpublished data).  In 
addition, the higher levels of GHR expression have been observed in CRC 
compared to the normal mucous tissue, and the expression of GHR is 
significantly associated with tumor size, tumor differentiation and pathological 
stage (Wu et al., 2007, Yang et al., 2005). A recent study observed that 
inhibition of GHR by siRNA in human colorectal carcinoma cells resulted in 
an anti-tumor effect in nude mice (Zhou et al., 2013). However, few studies 
have reported its specific role in colorectal tissues, especially its effect on the 
CRC progression.  
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1.4 Metastasis and EMT 
Metastasis is the dissemination of tumor cells from a primary site to distant 
sites, becoming the major obstacle for cancer treatment (Geiger and Peeper, 
2009). Although the primary tumors can be cured by surgical resection and 
adjuvant therapy, the later stage tumors, especially metastatic tumors are 
largely incurable. More than 90% of cancer-associated mortality is attributable 
to metastasis (Steeg, 2006, Gupta and Massague, 2006). Thus, an effective 
treatment of cancer is largely dependent on the capacity to prevent metastasis. 
This section will discuss the mechanisms underlying metastasis and the 
relationship between metastasis and cancer, in particular colorectal cancer. 
 
1.4.1 Mechanisms 
Metastasis is a multi-step progression, which can be conceptually organized 
into two major phases: physical translocation from primary tumor to distant 
organ and colonization of the disseminated cells at the metastatic site (Chaffer 
and Weinberg, 2011). In detail, metastasis consists of a complex succession of 
cell biological events, starting from epithelial cells in primary tumors and 
following with locally invasion of the neighboring tissues; intravasation into 
the blood and lymph vessels; survival in the circulation; extravasation from 
vessels into distant tissues; survival and colonization at the metastatic sites, 
thereby generating macrometastases/secondary tumors (Valastyan and 




Figure 1.6 Process of metastasis (Valastyan et al., 2011)(Valastyan and 
Weinberg, 2011).  
The process of metastasis consists of a series of cell biological events, starting 
from epithelial cells in primary tumors and following with locally invasion, 
intravasation, survival in the circulation, arrest at a distant organ site, 
extravasation, survival and colonization at the metastatic sites, thereby 
generating secondary tumors.  
 
1.4.1.1 Local invasion and EMT 
Most solid tumors are originated from epithelial tissues, which are insulated 
from the stroma by the basement membrane (BM) and exhibit a well 
organized morphology with rigid sheets of cells (Geiger and Peeper, 2009). 
BM is important for the organization of epithelial tissues and acts as a 
mechanical barrier to prevent malignant cells from invading to other tissues 
(Valastyan and Weinberg, 2011). As a tumor in situ progresses to an invasive 
carcinoma, the epithelial tumors may go through a phenotypic change known 
as epithelial-mesenchymal transition (EMT) in order to break through this 
barrier to disseminate into surrounding tissues. During the EMT, well-
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organized epithelial cells acquire mesenchymal morphology that attributes 
with loss of adhesion, tight junctions and cell polarity, inducing cellular 
invasiveness (Thiery et al., 2009).  
EMT is a process where epithelial cells lose the cell polarity, which is 
essential for intercellular contact and cell adhesion with the basement 
membrane, while assume mesenchymal phenotypes including increased cell 
migratory and invasive capacity, as well as enhanced resistance to apoptosis 
(Thiery et al., 2009). EMT plays a fundamental role in the tissues and organs 
formation during embryonic development (Nieto, 2011). EMT is also 
associated tissue regeneration during wound healing in adulthood (Kalluri and 
Weinberg, 2009). More recent studies have demonstrated its pivotal role in 
cancer progression (Thiery, 2002). EMT is characterized by decreased 
expression of epithelial proteins, such as E-CADHERIN, CYTOKERATINS, 
CLAUDINS, OCCLUDIN or CATENIN, and increased expression of 
mesenchymal proteins, including N-CADHERIN, LAMININ β1, VIMENTIN 
or TENASCIN C (Christofori, 2006, Thiery, 2002). Among these proteins, E-
CADHERIN is thought to be a key molecular marker of the epithelial state 
and loss of E-CADHERIN expression is the most prominent phenomenon 
during EMT. EMT can be stimulated by intrinsic signals, like gene mutations, 
as well as extrinsic signals, like growth factor signaling including 
transforming growth factor β (TGF-β) (Zavadil and Bottinger, 2005), 
epidermal growth factor (EGF) (Lo et al., 2007), insulin-like growth factor 
(IGF) (Graham et al., 2008), hepatocyte growth factor (HGF) (Savagner et al., 
1997) and fibroblast growth factor (FGF) (Acevedo et al., 2007). Moreover, 
 38 
Notch signaling and the components of extracellular matrix (ECM) including 
hyaluronan and collagen I, are also able to induce EMT (Leong et al., 2007, 
Zoltan-Jones et al., 2003, Shintani et al., 2008). With the various signals 
stimulating EMT, many downstream pathways are activated, including Wnt/β-
catenin, Notch, Hedgehog, NF-κB, PI-3K and MAPK pathways (Massague, 
2008, Huber et al., 2005, Huber et al., 2004, Bakin et al., 2000, Bakin et al., 
2002), following with activation of transcription factors, including TWIST, 
ZEB1, ZEB2, SNAIL and SLUG, enabling cells of epithelial phenotype to 
acquire mesenchymal properties. Some of these factors directly suppress E-
CADHERIN expression by binding to the transcriptional start site of E-
CADHERIN gene (Thiery, 2002). The various upstream and downstream 
signals suggest the complexity of EMT, which is not a simple process to 
increase cell invasiveness, but a central process in cancer developmental 
progression (Yilmaz and Christofori, 2009). EMT plays essential role in 
metastasis, however some studies have demonstrated some aggressive tumors 
do not have the characteristics of EMT. These studies suggest that not all of 
invasive tumors undergo EMT, and some of them may undergo a partial EMT 
or even an alternative process (Tarin et al., 2005, Friedl, 2004, Wicki et al., 
2006).  
Once the tumor cells acquire invasive capability to disrupt the basement 
membrane via undergoing EMT or other processes, they invade into the 
stroma. Studies have demonstrated that the stromal cells have functional role 
in enhancing invasiveness of these carcinoma cells. For example, the 
invasiveness of breast cancer can be enhanced by the surrounding adipocytes 
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via interleukin-6 (IL-6) secretion (Dirat et al., 2011). In addition, DeNardo et 
al. have demonstrated that stromal CD4+ T-lymphocytes can induce tumor-
associated macrophages (TAMs) to trigger EGFR signaling that eventually 
promote invasion and subsequent metastasis of mammary carcinoma cells 
(DeNardo et al., 2009). These findings suggest the interactions between the 
tumor and its microenvironment such as neighbouring stroma and the 
functional role of the surrounding stroma in the progression of tumor cells 
metastasis. 
 
1.4.1.2 Intravasation-survival in the circulation-extravasation 
Intravasation is the process that locally invasive tumor cells begin to gain 
entry into the lymphatic or blood vessels by crossing the walls of these vessels, 
which are mainly formed by pericyte and endothelial cells. Intravasation 
ensures tumor cells to approach to the circulation and subsequently 
metastasize to a distant site. The intravasation can be promoted by growth 
factors, such as TGF-β by increasing cell motility and invasiveness in 
mammary carcinoma cells (Giampieri et al., 2009). Moreover, an estrogen-
regulated growth factor, ARTEMIN (ARTN), has been demonstrated recently 
to stimulate mammary carcinoma intravasation through the endothelial cell 
barrier in a TWIST1-dependent manner (Banerjee et al., 2011). Besides that, 
tumor cell intravasation can also be stimulated via the microenvironment. 
Studies have observed that TAMs has an essential effect on intravasation. In 
transgenic breast cancer model and xenograft model, perivascular TAMs in 
mammary tumors have been observed to promote carcinoma cell intravasation 
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through the blood vessels with a paracrine signaling loop with the secretion of 
EGF by TAMs and colony-stimulating factor-1 (CSF-1) from tumor cells 
(Wyckoff et al., 2007, Wyckoff et al., 2004). Another potential mechanism to 
promote intravasation is the functional action of VEGFs to stimulate new 
blood vessels formation by carcinoma cells with the local microenvironment 
(Valastyan and Weinberg, 2011). This process is known as neoangiogenesis. 
The blood vessels generated by tumor cells are highly leaky and easy for 
reconfiguration, which may provide the entry for the intravasation (Carmeliet 
and Jain, 2011). A study performed by Gupta et al. has supported this notion. 
This study has demonstrated that the ability of the epidermal growth factor 
receptor (EGFR) ligand epiregulin, matrix metalloproteinases 1 and 2 (MMP-1 
and MMP-2) and the cyclooxygenase-2 (COX-2) to promote tumor cell 
intravasation in breast cancer is associated with the capability to induce the 
leaky blood vessel formation by neoangiogenesis (Gupta et al., 2007).  
Once tumor cells successfully intravasate into the lymphatic or blood vessels, 
they can widely disseminate to other body parts via circulation. The detection 
of circulating tumor cells (CTCs) has been observed through advanced 
technology (Nagrath et al., 2007, Pantel et al., 2008, Stott et al., 2010). In 
order to reach the distant sites for metastasis, these CTCs must survive in the 
circulation with various stresses, such as the absence of anchorage, which may 
induce anoikis and thereby undergo apoptosis (Guo and Giancotti, 2004). The 
mechanisms for CTCs survival from the matrix detachment still remain 
unclear. Some of the studies have demonstrated that the tyrosine kinase TrkB, 
which is required for metastatic progression, also plays as a suppressor of 
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anoikis (Douma et al., 2004). In addition, CTCs also have to overcome the 
damage from hemodynamic shear forces and overcome immune surveillance 
(Valastyan and Weinberg, 2011). Some studies suggest that the tissue factor 
protein distributed on the surface of tumor cells attracts clouds of aggregating 
platelets, which allows the tumor cells to shelter themselves from the 
microenvironmental forces and the attack from immune system (Joyce and 
Pollard, 2009).  
Once attached in the microvasculature of the distant sites, CTCs may 
proliferate intraluminally and eventually rupture the wall of surrounding 
vessels (Al-Mehdi et al., 2000), or alternatively, penetrate the wall of vessels 
and invade into the foreign parenchyma, a process termed as extravasation. 
The mechanisms contributing tumor cell extravasation differs from those 
contributing of cell intravasation. The TAMs that promote cell intravasation, 
as described above, seem not equally promote the extravasation of the 
disseminated tumor cells, and the populations of macrophage present in the 
metastatic sites are functionally and phenotypically different from those 
present in the primary tumors (Qian and Pollard, 2010). In addition, primary 
tumors may create a tortuous and leaky neovasculature to facilitate the 
intravasation, whereas the vessels in distant organs are highly functional and 
lowly permeable. For extravasation, tumor cells must overcome these physical 
barriers. Studies have demonstrated that tumor cells can secrete some factors 
to perturb the microenvironment of the distant sites and increase the vascular 
permeability. For example, protein angiopoietin-like 4 (Angptl4) induced by 
TGF-β can disrupt the cell junctions of endothelial cells in blood vessels to 
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facilitate the tumor cell invade into the parenchyma of lung (Padua et al., 
2008). Inflammatory monocytes stimulate the extravasation of mammary 
cancer in the lungs through the secretion of VEGF (Qian et al., 2011). 
Moreover, the characteristics of the specific tissue microenviroments may also 
affect the extravasation of the disseminated tumor cells.  Angptl4, which 
promotes mammary carcinoma cells extravasation in the lungs, but failed in 
the bone (Padua et al., 2008). 
 
1.4.1.3 Colonization  
Although the disseminated carcinoma cells may successfully reach the 
metastatic sites, they are still far from achieving metastatic spread. 
Colonization in the foreign tissue seems not a simple task for the tumor cells. 
Before colonization, disseminated tumor cells must survival in the foreign 
microenvironment, which is greatly different from primary microenvironment 
of tumor site. Some studies have proposed that tumor cells may adapt to the 
new microenvironment via the establishment of a “premetastatic niches”, 
which is formed by invading bone marrow-derived cells (BMDCs) (Psaila and 
Lyden, 2009, Erler et al., 2009). Erler et al. have found that lysyl oxidase 
(LOX) secreted by primary tumor cells is an essential regulator for the 
formation of premetastatic niche. Moreover, LOX modifies the local 
microenvironment by changing the components of the ECM and promotes the 
invasion and recruitment of tumor cells to the premetastatic sites (Erler et al., 
2009). Studies with mouse models have demonstrated that factors secreted 
from primary tumors can prime distant sites to be ready to accept metastatic 
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carcinoma cells (Psaila and Lyden, 2009). Most importantly, these events 
seem to occur before the arrival of disseminated cells at the metastatic sites.  
The certain mechanisms of the disseminated cells to survive in the metastatic 
sites are still in cloud. Nevertheless, it is evident that tumor cells may establish 
various actions or strategies to adapt the new or foreign microenvironment.  
A “seed and soil” hypothesis (Paget, 1889), which articulated by Stephen 
Paget early in 1889, may provide an explanation for this adaption of tumor 
cells and their disseminated sites. Scientists including Stephen observed that it 
is preferential to metastasize to the liver and bone for breast cancer, whereas 
CRC preferentially spreads to the liver, and prostate cancer preferentially 
spreads to the bone (Paget, 1889, Hess et al., 2006, Fidler, 2003). These 
observations suggest that the colonization can be influenced by the tumor cell, 
as well as the microenvironment of disseminated sites.  
Secondary tumors are thought to arise from the proliferation of the 
disseminated cells in the metastatic sites, which is a highly inefficient process. 
Tumor cells survived from the foreign microenvironment may suffer from 
slow nutrition supply, long-term dormancy, or even loss in overall cell number 
because of apoptosis in the colonization sites (Chambers et al., 2002). In the 
metastatic sites, the survivors may co-exist in three distinct states: (1) as 
dormant and quiescent solitary cells; (2) as dormant and pre-angiogenic 
micrometastases, in which cell proliferation may be balanced by apoptosis; (3) 
as actively proliferative and vascularized macrometastases (Goss and 
Chambers, 2010). Carcinoma cells in macrometastases have the ability to 
acquire mitogenic signals from the foreign microenvironment, and also have 
 44 
the necessary blood supply to support their proliferation (Aguirre-Ghiso, 
2007). The quiescent solitary cells in the metastatic sites also can be released 
from dormancy and enter into an actively growing state, which may result 
from the changes in local microenvironment (Chaffer and Weinberg, 2011). 
Moreover, increasing evidence demonstrates that quiescent cells are present 
simultaneously with actively growing cells in the metastases (Goss and 
Chambers, 2010). However, the mechanisms underlying the switch between 
dormancy and proliferation are still in cloud. Some suppose that the immune 
system may be responsible for the dormant state of metastases (Koebel et al., 
2007). Interestingly, some transcriptional factors, such as SNAIL, can induce 
immunosuppression to promote tumor growth in the metastases (Kudo-Saito et 
al., 2009). Hence, colonization at distant organs is a complex process, in 
which disseminated tumor cells must go through multistep, cell-biological 
events with the accumulation of genetic mutations or epigenetic alterations, 
and also the co-option of microenvironment in the metastatic sites. 
 
1.4.2 Treatments of metastasis 
Metastasis is the major cause of cancer death, thus anti-metastatic therapeutics 
is required with great need. The classic treatments for metastasis are 
radiotherapy and chemotherapy, which mainly aim to prevent the proliferation 
of cancer cells via inhibiting DNA replication, DNA repair, or perturbing the 
cell cycle (Eccles and Welch, 2007). Since the 1990s, chemotherapy based on 
fluorouracil (5-FU) has successfully improved the survival rate of the patients 
with metastatic carcinomas (Andre et al., 1999). Furthermore, combination of 
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5-FU with irinotecan or oxaliplatin significantly increases the overall survival 
rate compared to the usage of 5-FU alone (Grothey et al., 2004). However, it’s 
impossible to predict whether the chemotherapy will be effective for 
individuals. Due to the low efficiency of the chemotherapy, novel therapeutics 
is required for the treatment of metastasis. Recently, a newer strategy has been 
developed against metastasis: targeted treatment, which is based on the 
molecular pathology of metastasis or the agents targeting metastatic signaling 
pathways.  
One of the targeted therapies is Anti-angiogenesis therapy. Angiogenesis is 
important for the growth and spread of tumors during metastasis via building 
new blood vessels from preexisting vessels. Inhibition of this process gives a 
new strategy in the treatment of metastasis. In angiogenesis, VEGFs play an 
important role to stimulate signals that mediate this process. Drugs inhibiting 
VEGF pathway have been utilized as a treatment of metastasis.  For example, 
bevacizumab, an anti-VEGF antibody, has been clinically utilized for the 
treatment of various metastatic cancers, as well as non-metastatic cancers 
(Cheng et al., 2013, Panares and Garcia, 2007, Kramer and Lipp, 2007). 
Additionally, vascular disrupting agents, for example combretastatin A4 
(Salmon and Siemann, 2007), and other agents targeting the receptors of 
VEGFs (Moreira et al., 2007) are also potential treatment for the metastasis. 
However, some studies in mice suggest an adverse effect of anti-angiogenic 
therapy, in which inhibition of VEGF signal transduction inhibits tumor 
growth, however promotes invasion and metastasis, resulting in decreased 
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overall survival rate (Paez-Ribes et al., 2009, Ebos et al., 2009). The 
mechanism under this phenomenon still needs further investigation. 
Another targeted therapy that has been performed clinically is anti-growth 
factor receptors treatment. The receptors of growth factor are essential for 
tumor cell survival and proliferation at the primary site, as well as for tumor 
metastasis, and simultaneously, theses receptors also contribute to cell 
invasiveness (Christofori, 2006). Thus, inhibiting the function of growth factor 
receptors becomes a novel therapy to treat metastasis. Anti-EGFR treatment is 
widely used for advanced carcinomas including metastatic carcinomas, such as 
Cetuximab (anti-EGFR monoclonal antibody). EGFR is a transmembrane 
glycoprotein belonging to the epidermal growth factor receptor (ErbB) family 
of receptors, which can activate various downstream signaling pathways, su ch 
as the JAK/STAT, MAPK, and PI-3K/AKT pathways, presenting an important 
role for EGFR in proliferation, survival, invasiveness and metastasis 
(Seshacharyulu et al., 2012). Antibodies against ErbB2 increase the 
effectiveness of the chemotherapy in the metastatic breast cancer patients with 
ErbB2 overexpression (Slamon et al., 2001), and these antibody therapies 
increase patients survival rate and decrease relapse as an adjuvant treatment 
after the surgical removal of primary tumor (Romond et al., 2005, Piccart-
Gebhart et al., 2005). 
The more specific treatments developed in bone metastasis aim to interrupt the 
interactions between tumor cells and microenvironment. The signaling 
processes involved in such interactions become the potential target to treat 
metastasis. Bisphosphonates is clinically used to treat bone metastasis by 
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inhibit osteoclasts and some derivatives (Vessella and Corey, 2006). 
Interference with endothelin-1, which is essential for bone formation and 
osteoclast proliferation, may also potentially inhibit osteoclastic bone 
metastasis (Vessella and Corey, 2006). 
In addition, inhibitors against proteinases like MMPs have also been examined 
as anticancer agents clinically, but mostly failed in clinical trials (Coussens et 
al., 2002). Different MMPs can act as both protumor and antitumor effects 
(Lopez-Otin and Matrisian, 2007), which may be the main cause of the failure 
in clinical trails. Therefore, novel inhibitors targeting specific MMPs would be 
more effective, and appropriate cancer patient populations should be selected 
carefully. 
Over decades, a large amount of work has been performed to seek for the 
more effective treatments for metastasis. In principle, metastatic-specific 
genes, molecules in signaling pathways mediating metastasis, or even the 
factors regulating the microenvironment in metastatic sites would act as the 
potential targets against metastasis. Recent studies are also learning the 
potential correlation between cancer stem cells and metastasis, which will be 
discussed in section 1.5, in order to develop another therapeutics to fight 
against metastasis. 
 
1.5 Cancer stem cell 
For decades, cancer has been recognized as a heterogeneous population of 
cells. The bulk of a tumor consists of post-mitotic cells, differentiated cells, as 
well as a small part of rapidly proliferating cells, which terms cancer stem 
 48 
cells (CSCs) (Clevers, 2011). CSCs possess the properties associated with 
normal stem cells, specifically the capability of self-renewal, as well as the 
potential to give rise to the phenotypically diverse tumor cell population 
(Bjerkvig et al., 2005). A major challenge caused by CSCs is the local relapse 
and metastasis, which lead to poor clinical outcomes. A better understanding 
of cancer stem cell may potentially contribute to novel effective antitumor 
therapies. This section will provide a general introduction of cancer stem cell, 
and its role in cancer as well as metastasis. 
 
1.5.1 Cellular origin of cancer stem cell 
The origin of CSCs has not been definitively determined. The possible origin 
of CSCs leans to tissue-specific stem cells, or the somatic cells that undergo 
trans-differentiation processes (Bjerkvig et al., 2005) (Figure 1.7).  
Except embryonic stem cells in blastocyst, stem cells have been observed to 
exist in a small population in various tissues (Kolios and Moodley, 2013, 
Ratajczak et al., 2007). Currently studies have indicated that the 
microenvironment can regulated the potential of tissue-specific stem cells 
development (Nelson et al., 2002, Mueller and Fusenig, 2004). Interestingly, 
Clarke et al. demonstrated that adult neural stem cells, which are isolated from 
the CNS of mice differentiated into other cell types when cultured in the early 
embryonic environment (Clarke et al., 2000). Similarly, Galli et al. indicated 
that neural stem cells differentiated into muscle cells when cultured with 
myoblasts or embryoid bodies (Galli et al., 2000). These studies suggest the 
importance of microenvironment in developmental potential of adult stem 
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cells. Studies on bone marrow stem cells, which have remarkable plasticity to 
differentiate into different cell types (Palermo et al., 2005, Borue et al., 2004, 
Oh et al., 2004), provide evidences of the contribution of microenvironment to 
the initiation of the CSCs (Direkze et al., 2004, Peters et al., 2005). It has 
demonstrated it is the influx of bone marrow stem cells caused by 
Helicobacter felis infection gave rise to stomach cancer, and not the local 
gastric epithelial cells (Houghton et al., 2004). Moreover, recent study have 
demonstrated that growth-stimulating factors or DNA-damaging chemicals in 
microenvironment produced by inflammatory cells can contribute to cancer by 
causing mutations (Mueller and Fusenig, 2004). Thus, it has the possibility 
that CSCa are derived from tissue-specific stem cell under mutations, which 
may be due to the microenvironment. 
A study in DePinho group suggested the possibility that differentiated cells 
can trans-differentiated into cancer stem cells in certain conditions (Bachoo et 
al., 2002). Their study demonstrated that activation of EGFR pathway 
combined loss of both p16INK4a and p19ARF induced astrocyte dedifferentiation. 
Moreover, both of neural stem cells and astrocytes with the loss of p16INK4a 
and p19ARF stimulated a high grade of glioma phenotype in vivo (Bachoo et al., 
2002). These observations provide a new possibility that differentiated cells 
may give rise to CSCs. 
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Figure 1.7 The origins of cancer stem cells (Bjerkvig et al., 2005) 
(Bjerkvig et al., 2005).  
The CSCs may be derived from the tissue-specific stem cells or early stem cell 
progenitors after mutations. CSCs also can be derived from differentiated cells 
after trans-differentiation, which may be regulated by the microenvironment. 
 
1.5.2 Cancer stem cell in cancer 
The evidence of CSC existence was firstly demonstrated in acute myeloid 
leukaemia (AML), in which CSCs were distinguished by surface markers and 
exhibited proliferative properties and the potential for self-renewal (Bonnet 
and Dick, 1997, Lapidot et al., 1994). In this case, Bonnet et al. identified and 
isolated CD34+CD38- leukemic stem cells (LSCs) from the AML cells and 
demonstrated that only this subset of AML cells had potential to give rise to 
leukaemia in mice model, while cells with CD34+CD38+ and CD34- were not 
able to induce leukaemia (Bonnet and Dick, 1997). 
Recently, cancer stem cells have also been identified and isolated from the 
solid tumors including mammary cancer (Al-Hajj et al., 2003), brain cancer 
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(Singh et al., 2004), prostate cancer (Collins et al., 2005, Patrawala et al., 
2006), colorectal cancer (Dalerba et al., 2007, O'Brien et al., 2007) and 
pancreas cancer (Li et al., 2007). Studies on breast cancer observed that only a 
small part of tumor cells had the ability to give rise to tumor in mice model, 
and these cells were observed with expression of CD44, but low or no 
expression of CD24. Most importantly, these CD44+CD24-/low cells exhibited 
stem-like cell properties, where it gave rise to CD44+CD24-/low cells, and also 
phenotypically diverse populations of nontumorigenic cells (Al-Hajj et al., 
2003). In the studies of brain tumors, Dirks et al. indicated that a small 
population of human brain cancer cells with expression of CD133 (Prominin-1) 
exhibited stem cell-like features in vitro (Singh et al., 2003). These CD133+ 
cells could generate all the cell types in the original tumors in vitro. 
Subsequently, this group reported that only these CD133+ cells had the 
capability to induce tumors in the brains of NOD-SCID mouse (non-obese 
diabetic, severe combined immunodeficient mouse) (Singh et al., 2004). 
Furthermore, Galli et al. reported the existence of CSCs isolated from the 
glioblastoma multiforme, and these cells exhibited long-term self-renewal in 
culture and tumorigenic potential in vivo (Galli et al., 2004). 
Numbers of studies have been studied on the identification and isolation of 
CSCs in human CRC by using several specific CSCs-surface markers. CD133 
is one of the CSCs markers identified in human CRC. Ricci-Vitiani et al. 
demonstrated that CD133+ human CRC cells exhibited the tumorigenic 
potential to induce tumor formation in immunodeficient mice (Ricci-Vitiani et 
al., 2007). Similarly, Dick group reported that colon cancer-initiating cell (CC-
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IC) in the population of CD133+ cells isolated from human CRC exhibited 
more than 200-fold enrichment compared to the unfractionated tumor cells 
(O'Brien et al., 2007). CD44 also has been reported as the CSC markers in 
human CRC. CD44+ CRC cells exhibited a greater stem-like capability to form 
a sphere in vitro and a higher tumorigenicity to generate a xenograft tumor in 
vivo compared to CD44- cells (Du et al., 2008). Additionally, multiple CSCs 
markers are also used for the identification and isolation of human CRC. 
Dalerba et al. demonstrated that cancer cells with CD44+/CD166+ exhibited 
higher tumorigenicity compared to CD44+/CD166- cells (Dalerba et al., 2007). 
Reported by the same group, epithelial cell adhesion molecule (EpCAM) was 
identified as a marker of human colorectal CSCs. Together with CD44, 
EpCAMhigh / CD44+ cells that isolated from primary human CRCs displayed 
higher tumorigenicity and gave rise to the full morphologic and phenotypic 
heterogeneity of the original tumors including EpCAMlow / CD44- cells 
(Dalerba et al., 2007). Similarly, Dylla et al. suggested that EpCAM+ / CD44+ 
CSC might be responsible for the resistance to chemotherapy of human 
colorectal cancers (Dylla et al., 2008). Other potential markers of colorectal 
CSCs, such as CD29, CD24 and Lgr5, have also been identified and utilized 
recently (Sagiv et al., 2006, Fujimoto et al., 2002, Barker and Clevers, 2010).  
 
1.5.3 Cancer stem cell in metastasis and EMT 
Metastasis is the major cause for the cancer-associated mortality in patients, in 
which tumor cells transfer from the primary original sites and colonized in the 
secondary tumor sites. People doubt how can these cancer cells successfully 
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navigate the multiple process of metastasis. The concept of CSCs sheds a new 
light on the understanding of the biology of metastasis.  
CSCs are considered to be associated with metastasis and the hypothesis of 
metastatic cancer stem cell has attracted much attention recently. Woo et al. 
demonstrated that the expression of CSC marker CD133 in lung 
adenocarcinomas was correlated with worse clinical outcome (Woo et al., 
2010). Lung adenocarcinomas with CD133 high expression with higher 
proliferative activity exhibited a higher risk of postoperative recurrence 
compared to those with CD133 low expression (Woo et al., 2010). 
Furthermore, the expression of CD133 has been indicated to associated with 
patient survival outcomes in high-grade tumors including oligodendroglia 
tumors (Beier et al., 2008), gastric adenocarcinoma (Zhao et al., 2010), rectal 
cancer (Wang et al., 2009), and lung cancer (Shien et al., 2012). In CRC 
patients with liver metastasis, a population of CD26+ CSCs was observed in 
primary and metastatic carcinomas, and isolated CD26+ CSCs induced distant 
metastasis in liver when injected into the mouse cecal wall (Pang et al., 2010). 
Dieter et al. identified a small population cells in human colon cancer termed 
as tumor-initiating cells (TICs), which contributed to metastasis in the 
xenotransplants, suggesting the existence of CSCs with metastatic potential on 
tumorigenic progression in CRC (Dieter et al., 2011). In addition, studies have 
demonstrated that the level of aldehyde dehydrogenases (ALDH) strongly 
correlates with CSC properties in human cancers. For example, Sun et al. 
identified a subpopulation of ALDHHigh CSCs in human adenoid cystic 
carcinoma (AdCC) exhibiting highly invasiveness in vitro and metastatic 
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ability in vivo (Sun and Wang, 2010). Similarly, ALDH+ CSC population in 
human breast cancer has been demonstrated responsible for the bone 
metastasis (Patel et al., 2011). 
The correlation of CSCs and EMT has been indicated in recent studies. CSCs 
commonly have the mesenchymal-like features, and exhibit higher potential of 
metastasis. Some studies proposed that mesenchymal stem cell (MSC) derived 
from bone marrow might be recruited in large numbers to the stroma, resulting 
in tumor development (Hall et al., 2007). Weinberg group demonstrated that 
MSCs derived from bone marrow stimulated the weakly metastatic human 
mammary carcinoma cells to form a tumor xenograft when injected into mice 
model with the cell mixture of MSCs and breast cancer cells (Karnoub et al., 
2007). Cancer stem cells with high potency of metastasis may be derived from 
stationary cancer stem cells undergoing EMT and acquiring the capability to 
disseminate to form metastatic colonies (Brabletz et al., 2005). Mani et al. 
demonstrated that EMT induction in immortalized human mammary epithelial 
cells (HMLEs) resulted in an acquisition of stem cell-like properties with 
increased capability of mammospheres formation (Mani et al., 2008). 
Furthermore, naturally arising stem-like cells isolated from the HMLEs 
exhibited similar phenotypes to the cells undergoing EMT (Mani et al., 2008). 
More interestingly, stem-like cells isolated from mammary glands or 
mammary carcinomas in mouse and human expressed markers associated with 
an EMT (Mani et al., 2008). These results suggested a potential link between 
the acquisition of stem cell properties and EMT. Similarly, it has been 
demonstrated that cells possessing stem-like properties may be resulted from 
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non-tumorigenic epithelial cells that undergo an EMT-like state (Morel et al., 
2008). In addition, Banerjee et al. demonstrated that ARTEMIN-induced 
TWIST1-dependent EMT in the estrogen receptor negative mammary 
carcinoma (ER-MC) cells was correlated with the acquisition of cancer stem 
cell-like properties (Banerjee et al., 2012, Banerjee et al., 2011).  
The conceptual framework of CSCs may contribute to a further understanding 
of the initiation of tumors and identification of potential targets for tumor 
therapies to prevent metastasis or the relapse due to metastasis. 
 
1.6 Project rationale 
Abundant evidence has suggested the contribution of hGH in the development 
of progression of tumors. It has been demonstrated that autocrine hGH 
promotes cell proliferation, reduces apoptosis, promotes oncogenic 
transformation and stimulates EMT in mammary carcinoma cells. However, 
the potential role of autocrine hGH in colorectal cancer is not yet defined. 
Moreover, clinical studies have demonstrated the association of tumor hGH 
expression and metastasis in patients with mammary and endometrial 
carcinoma, suggesting a potential role of hGH in stimulating metastasis. 
Metastasis is the major cause for cancer relapse and cancer death, thus 
attracting researchers attention for years. Patients with colorectal cancer also 
suffer the risk of metastasis. Understanding of the potential role of hGH in 
metastasis, as well as metastasis-associated EMT and stem-like cell self-
renewal in colorectal cancer may contribute to a potential target for anti-cancer 
therapy to lead to a better clinical outcome. 
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Thus, the specific aims of this study is to determine: 
1. The role of autocrine hGH in enhancing oncogenicity in colorectal 
carcinoma cells 
2. The role of autocrine hGH in stimulating EMT and metastatic potential in 
colorectal carcinoma cells 
3. The role of autocrine hGH in stimulating cancer stem cell-like behavior in 


















Chapter 2 Materials and Methods 
 
2.1 Materials 
2.1.1 Chemicals and reagents 
Chemicals and Reagents Source 
100bp DNA ladder Promega, WI USA 
2-Mercaptoethanol Sigma, MO USA 
3-[4,5-dimethyl-thiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) Sigma, MO USA 
30% Acrylamide/Bis Solution Bio-Rad, CA USA 
4',6-diamidino-2-phenylindole (DAPI) Vector Laboratories, USA 
Agarose Bio-Rad, CA USA 
AlamarBlue Invitrogen, CA USA 
Ammonium persulfate (APS) Sigma, MO USA 
Ampicillin Sigma, MO USA 
Bovine serum albumin (BSA) Sigma, MO USA 
Dimethyl-sulphoxide (DMSO) MP Biomedicals, Illkirch France 
Dithiothreitol (DTT) Sigma, MO USA 
DC protein assay reagents Bio-Rad, CA USA 
Ethanol Merk, Darmstadt Germany 
Ethylenediaminetetraacetic acid 
(EDTA) Sigma, MO USA 
Fetal Bovine Serum (FBS) Biowest, Nuaillé France 
FuGENE 6 Transfection reagents Promega, WI USA 
Geneticin (G418) Sigma, MO USA 
Glycerol Sigma, MO USA 
Glycine Bio-Rad, CA USA 
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Hoechst 33258 Sigma, MO USA 
Hydrochloric acid Sigma, MO USA 
Isopropanol Merk, Darmstadt Germany 
Matrigel BD, NJ USA 
Methanol Merk, Darmstadt Germany 
Milk powder Fontevva, SDE Malaysia 
Penicillin-Streptomycin solution (100×) Biowest, Nuaillé France 
PVDF membrane Bio-Rad, CA USA 
Platinum PCR SuperMix High Fidelity Invitrogen, CA USA 
Protein marker Gnedirex, LV USA 
Proteinase inhibitor Sigma, MO USA 
RNeasy Mini Kit Qiagen, Hilden Germany 
RPMI 1640 medium Nacalai Tesque, Kyoto Japan 
Sodium dodecyl sulfate (SDS) 1st BASE, Singapore 
Super Script cDNA Synthesis Kit Invitrogen, CA USA 
Tetramethyl-ethylendiamin (TEMED) Sigma, MO USA 
Tris(hydroxymethyl)aminomethane 
(Tris) 1st BASE, Singapore 
Triton X-100 Sigma, MO USA 
Trypsin (10×) Biowest, Nuaillé France 
Tween-20 Sigma, MO USA 
West Pico Chemiluminescent Substrate Thermo, IL, USA 
 
Table 2.1 List of chemicals, reagents and their sources 
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2.1.2 Drugs and Inhibitors 
The specific inhibitor of MAP kinase kinase (MAPK kinase or MEK kinase) 
PD98059 was provided in solid from Sigma and dissolved with DMSO in a 
store concentration (10 mM). Dissolved PD98059 was stored at -20°C.  
Fluorouracil (5-FU) was kindly provided by Professor Goh Boon Cher’s 
laboratory (CSI, Singapore) at 50mg/ml and stored in RT. 
 
2.1.3 Media, solutions and buffers 
The compositions and formulations of each media, solution, and buffer are 
attached in the Appendices. 
 
2.2 General cell culture 
2.2.1 Human cell lines 
The human colorectal carcinoma cell lines DLD-1, Caco2, HT-29 and human 
umbilical vein endothelial cells (HUVECs) were all from the American Type 
Culture Collection (Manassas, VA, USA).  
 
Cell Line Description 
DLD-1 Colorectal adenocarcinoma cell line isolated by D.L. Dexter, Dukes’ type C, epithelial, invasive 
Caco2 Colorectal adenocarcinoma cell line isolated by J. Fogh, Dukes’ type B, epithelial, invasive 
HT-29 Colorectal adenocarcinoma cell line isolated by J. Fogh, Dukes’ type B, epithelial, invasive 
HUVEC Normal endothelial cell line from human umbilical vein/vascular endothelium 
Table 2.2 Human cell lines 
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2.2.2 Cell culture 
DLD-1, Caco-2 and HT-29 cells were cultured in RPMI 1640 media (Nacalai 
Tesque) with 10% fetal bovine serum (FBS)(heat-inactivated), 1% Penicillin-
streptomycin solution (100×) (BioWest, France). HUVEC cells were cultured 
in EBM-2 Basal media (Lonza, USA) supplemented with EGM-2 SingleQuots 
(FBS, 10 ml; HYDROCORTISONE, 0.2 ml; hFGF-B, 2 ml; VEGF 0.5 ml; 
R3-IGF-1, 0.5 ml; ASCORBIC ACID, 0.5 ml; hEGF, 0.5 ml; GA-1000, 0.5 ml; 
HEPARIN, 0.5 ml)(Lonza). All the cell culture work was performed in a 
Biosafety Cabinet (Gelman, Singapore) under sterile conditions, and cultured 
in tissue culture flasks or plates (Greiner, Germany) in a 37°C/5% CO2 
humidified incubator (Thermo Scientific, USA). Media was changed every 
three days. 
Passaging of human cell lines 
Cells were cultured in culture flasks until cells were 70%-80% confluent. To 
passage cell to a new flask or plate, cells were firstly removed the media and 
subsequently rinsed with PBS. Trypsin/EDTA was then added into the flask 
and incubated for one to four minutes. Trypsinized cells were checked with 
the microscope to make sure all of cells detached from the surface of the flask 
into single cells. Fresh media was then added into the flask and the cells were 
rinsed by plastic pipette. The suspension was subsequently transferred to a 15 
ml tube and centrifuged for five minutes at 500 rpm. After centrifugation, the 
media was removed and the pellet was resuspended in fresh media. For further 
culturing, an appropriate number of cells were seeded into a fresh culture flask 
or plates and cultured in a 37°C/5% CO2 incubator. 
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Cell counting 
Cell counts were carried out using a haemocytometer. 10 µl of the cell 
suspension was transferred into a haemocytometer (dilution was performed if 
needed), and the number of cells in 4 quadrants of 9 squares was counted. The 
average of these counted squares was used to determine the amount of cells 
per ml by the following mathematical formula: 
(Cells of 4 quadrants/4) ×104 ×Dilution factor = Cells/ml 
Cells/ml ×Final volume = Total Number of cells 
Cell storage 
To store cells, cells were trypsinised and then resuspended in fresh media, and 
then centrifuged for five munites at 500 rpm. Following the centrifugation, the 
supernatant was removed while the cells were resuspended in freezing media 
(90% FBS, 10% DMSO). The cell suspension was divided into cryogenic vials 
(Nalgene, USA) (1ml suspension /vial), which were later transferred into 
frosty freezing chambers (Nalgene, USA) and transferred into -80 °C freezer 
(Thermo Scientific, USA) for at least 24 hours. For long-term storage, frozen 
cells were stored in liquid nitrogen. 
Revival of cell lines 
Cells stored in -80 °C freezer or liquid nitrogen were thawed in water bath at 
37°C and immediately transferred to a 15 ml tube with 5 ml of 37°C complete 
culture media, and centrifuged for five minutes at 500 rpm.  After removing 
the media, cells were resuspended with warm fresh media, and transferred into 
a tissue culture flask in the incubator. Media was changed every three days. 
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2.3 Cell culture methods 
2.3.1 Transfection of cells 
To transfect specific DNA vectors into cells, FuGENE 6 Transfection Reagent 
(Promega, USA) was used in this study for both transient transfection and 
stable transfection. Compared to transient transfection, the additional selection 
by appropriate antibiotics was performed in stable transfection. 
Transient Transfection 
Cells were seeded in 6-well plates one day before the transfection. In order to 
achieve optimum transfection efficiency, cells are to be approximately 50-80% 
confluent on the day of transfection. For each well (6-well plate), 100 µl of 
serum-free media was mixed with 3 µl FuGENE 6 Transfection Reagent in 
Eppendorf tubes, and incubated for five minutes at room temperature (RT). 
Appropriate amount of DNA (the ratios of FuGENE 6 Transfection Reagent 
and DNA were 3:1 to 6:1) was added into the tube and mixed well. This 
reagent and DNA complex was incubated for 15 minutes at RT. After 
removing the culture media in 6-well plates and changing into 1.9 ml of 
serum-free media, the reagent/DNA complex solution was directly added 
dropwise into each well. Following 4-8h incubation at 37°C, 1ml of complete 
media was added into each well. 2 ml of fresh complete media was applied to 
each well after 24 hours. 
Stable Cell Line Transfection: 
For stable transfection, cells were plated at approximately 50-80% confluence 
into a 25cm2 flask and transfected FuGENE 6 Transfection Reagent as 
described in transient transfection section. In order to generate the stable cell 
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line expressing hGH, DLD-1, Caco2 and HT-29 cells were transfected with an 
expression vector (pcDNA 3.1), which contained the full length hGH gene or 
an empty pcDNA3.1 vector as a control. Following transfection and 
incubation for 24 hours, transfectants were selected with complete media, 
containing 1000 µg/ml (DLD-1), 700 µg/ml (Caco2) or 800 µg/ml (HT-29) 
G418 for three to four weeks. The media was changed every two days initially 
and later every three to four days. Transfected cells were trypsinised and 
transferred into a new 75 cm2 flask for expansion after selection, and then 
stored for experiments. These cells were respectively termed as DLD-1-
hGH/vector, Caco2-hGH/vector and HT-29-hGH/vector.  
 
2.3.2 RNAi transfection 
To knock down FN1 in DLD-1 and Caco2 stable cells, validated FN1 Stealth 
RNAiTM siRNA duplexes and Stealth RNAiTM siRNA negative control 
duplexes were purchased from Invitrogen and used in this study. siRNA and 
control duplexes were transfected into DLD-1 and Caco2 stable cells using 
LipofectamineTM RNAiMAX (Invitrogen, USA). Cells were seeded into 6-
well plates one day before the transfection and would be 30-50% confluent at 
the time of transfection. 250 µl of Opti-MEM® Media was mixed with 5 µl 
LipofectamineTM RNAiMAX in a Eppendorf tube, and appropriate amount of 
siRNA (the final concentration of RNA was 25 nM to 100 nM) was also 
mixed with 250 µl of Opti-MEM® Media in another Eppendorf tube. Both 
tubes were incubated for five minutes at RT. After incubation, diluted siRNA 
was added into diluted LipofectamineTM RNAiMAX and mixed well. This 
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complex solution was incubated for 15-20 minutes at RT. After removing the 
culture media in 6-well plates and changing into 1.5 ml of serum-free media 
without antibiotics, the siRNA/ LipofectamineTM RNAiMAX complex 
solution was directly added into each well. Following 24 hours incubation at 
37°C, fresh complete media was applied to each well. The expression of 
mRNA and protein of the gene, which was knocked down, were measured by 
RT-PCR analysis and western blot analysis respectively to identify the 
efficiency of siRNA duplex. 
 
Validated siRNA duplex 
StealthTM siRNA Negative Control Med GC 
FN1 (HSS177362) 
Table 2.3 Validated siRNA duplexes 
 
2.3.3 Total cell number assay 
Cells were seeded in a 6-well plate at a density of 5×103 cells/well (the density 
of cells would be optimized in different experimental conditions for different 
cell lines) and cultured in complete media overnight at a 37°C/5% CO2 
incubator. 0.5% FBS or 10% FBS supplemented media with or without drug 
was change into cultured cells. Assays were set up in triplicate and cell 
number was counted by haemocytometer every two days over eight to ten days. 
 
2.3.4 Bromodeoxyuridine (BrdU) cell proliferation assay 
Bromodeoxyuridine (BrdU) assay was performed by using Millipore©’s BrdU 
Cell Proliferation Assay Kit and followed the protocol of its manual. 
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Cell Plating 
Cells were seeded in a 96-well tissue culture plate, and plated at 2×104 cell/ml 
in 100 µl /well of media. Two controls were set up: Blank, added only tissue 
culture supernatant; Background, cells were present in the wells but not have 
any added BrdU reagent. 
Addition of BrdU 
BrdU was added into culture cells at least 2 hours before analysis. Better 
sensitivity and signal to noise ratios were obtained with longer BrdU labeling 
times. 500X BrdU stock was diluted 1:500 by adding cell media. 20 µl of the 
diluted BrdU label was added into the each well. The cells/BrdU complex was 
incubated for 2-24 hours. 
Fixing 
Cells were fixed by 200 µl /well of the Fixing Solution and incubated at RT. 
for 30 minutes. Fixed cells could be stored for up to one month at 2°C to 8°C 
if dried plates were sealed in a dry plastic bag. 
Washing 
50X Wash Buffer was diluted 1:50 by adding distilled water. The wells were 
filled with wash buffer completely and washed for three times. The wash 
solution was aspirated after wash and then blot dried on paper towels. 
Incubating with Antibodies 
100 µl /well of diluted anti-BrdU monoclonal antibody were placed into each 
well and then incubated for 1 hour at RT After incubation, each well was 
washed as in wash step above. Following washing, 100 µl /well diluted Goat 
anti-Mouse IgG solution were added into each well and then incubated for 30 
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minutes at RT. After that, each well was washed with washing buffer and 
performed a final wash by flooding distilled water. 
Addition of Substrate and Stop Solution 
TMB Peroxidase Substrate (100 µl /well) was added into each well and 
incubated for 30 minutes at RT in the dark. The acid Stop Solution (100 µl 
/well) was provided into each well to stop the reaction. The plate was read at 
wavelength of 450 nM using a spectrophotometer microplate reader. 
 
2.3.5 Caspase-3/7 activity assay 
Apoptotic cell death was examined by Caspase-Glo® 3/7 Assay Kit (Promega, 
USA) according to the protocol of its manual. 
Cultured cells in 96-well plates were change with serum-free media with or 
without drug treatment. Caspase-Glo® 3/7 Reagent (100 µl) was added into 
each well (Blank: added only tissue culture supernatant; Background: cells 
were present in the wells but not have any added Caspase-Glo® 3/7 reagent). 
The plates were incubated at RT for at least 30 minutes, depending on the cell 
culture system and read the plate in a luminometer by the luminometer 
manufacturer.  
 
2.3.6 Foci formation assay 
Cells were plated at different concentrations (DLD-1 and HT-29 stables 1×103 
cells/well; Caco2 stables 3000 cells/well) and cultured for 10 days and the 
media was changed every two days. On day 10, cells were washed with PBS 
and fixed with 4% paraformaldehyde (PFA) (RT, 20 minutes). The PFA 
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solution was subsequently poured off and the plates left open to dry overnight. 
The next day the cells were stained with 0.1% crystal violet (diluted in 20% 
ethanol) for 30 minutes at RT. The plates were washed by submerging in tap 
water four times and left to completely dry. Images were scanned by scanner， 
and the number of colonies was counted. 
 
2.3.7 Colony formation in soft agar 
Cells were cultured to 70-80% confluence in 75 cm2 flask in complete media. 
Each well of a 96-well plate was covered with a base agar layer of 0.5% 
agarose in serum free RPMI media. Dissolved DNA grade agarose at 0.5% 
(100 µl /well of 96-well plate) was added and left to set at RT for 30 minutes. 
DNA grade agarose (0.7%) was prepared with serum free culture media and 
incubated in a water bath at 42°C. This temperature was used to maintaining 
cellular viability and to avoid polymerisation of the agarose. An equal amount 
of serum free culture media was also warmed up to 42°C. Cells were 
trypsinized, resuspended in complete media and pipetted up and down 
approximately 30 times to ensure a single cell suspension. Cells (1×103 cells) 
were resuspended in RPMI serum free media and warm 0.7% agarose via 
pipetting. This mixture was added to each well on top of the base agarose (100 
µl/well for 6 well plates). All plates were left at RT for one hour to allow 
agarose to set and 100 µl of RPMI complete media was then added to each 
well. For the assay measuring colony formation with the drug treatment, cells 
(1×104) were plated in 6 well plates and left to attach overnight. Subsequently 
the cells were treated with drug for 6 hours prior to embedding in agarose. The 
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media (with or without drug) was changed every day for two weeks. Each 
experiment was performed in triplicate. 
At day 14, the media was removed and then each well was washed once with 
ice-cold 1X PBS. All wells were stained with 50 µl of 5 mg/ml MTT and 
incubated for 4-8 hours. After incubation, the MTT solution was aspirated and 
the cells solubilised in 100 µl DMSO (Sigma, USA). The absorbance was read 
at 570 nm and 690 nm. 
 
2.3.8 Two-dimensional and three-dimensional culture of cells in Matrigel 
Matrigel™ was purchased from BD Biosciences and thawed overnight at 4°C. 
The Matrigel™ was added to each well (50 µl/well for 96 well plate), and 
placed in the incubator for 30 minutes to allow the basement membrane to 
solidify. Concurrently, cells were trypsinised and resuspended in 2 ml of 
complete media and then centrifuged at 1100 rpm for 5 minutes. Cells were 
then suspended in 1 ml of media and pipetted up and down 30 times to ensure 
a single-cell suspension. Cells  (2.5×104) were mixed with 4% Matrigel™ in 
5% serum media (4% Matrigel final concentration). The 4% Matrigel™ 
solution (1×103 cells/well) (200 µl) was plated onto the solidified Matrigel™ 
in each well. Cells were cultured in a 5% CO2 humidified incubator at 37°C 
for two weeks. Every two days, 4% Matrigel™ in 5% serum media was added 
to the wells. After incubated for two weeks, 200 µl of 1× AlamarBlue 
(Invitrogen, USA) was added into each well. The plates was then incubated in 
the dark for 4 hours in a 5% CO2 humidified incubator at 37°C following 
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which the plate was read spectrophotometrically (absorbance at 570 nm and 
600 nm) or spectrofluorometrically (exitation 530-560 nm; emission 590 nm). 
 
2.3.9 Wound healing assay 
Cells were grown in a 6-well plate until they reached 100% confluence. Three 
perpendicular straight wounds were performed with a pipette tip followed by 
several gentle washes with warm PBS in order to eliminate floating cells. 
Cells were then treated with 5% FBS media with or without drug treatment. 
Pictures were then taken at 0, 24, 48 and 72 hours. 
 
2.3.10 Colony scattering assay 
In cell colony scattering assay, cells were seeded in a low density (500 
cells/well) in 6-well plates and cultured for two weeks with complete media. 
Fresh media was changed into each well every three days. After two weeks, 
the colonies formed by stable cells were counted dependent on different 
categories (Scattered, central distance of the cells were all more than 20 µm; 
Loose, central distance of the cells were between 10 and 20 µm; Compact, 
central distance of the cells were all less than 10 µm). 
 
2.3.11 Invasion/migration assay 
Migration/ invasion assay was performed using BD cell culture inserts (8 µm 
pores, 24-well format) on 24-well culture plates to create a barrier for cells to 
travel to the other side of culture plate. For invasion assays, inserts were 
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coated with growth factor reduced Matrigel (1/10 dilution of Matrigel into 
serum free media) before plating the cells. 
For the migration and invasion assays, cells were seeded (2×104 cells for 
invasion assay and 1×104 cells for migration assay) with serum free media in 
the upper chamber only, while complete media in the bottom well was used as 
a chemoattractant. For migration and invasion assays using PD98059, cells 
(2×104) were treated with drug for 6 hours prior to be seeded in serum free 
media in the upper chamber. Control cells were treated with DMSO.  
After incubation for 24 or 48 hours, the transwell inserts were washed with 
PBS and fixed with 4% PFA. Migrated or invaded cells at lower surface of the 
insert were stained with Hoescht solution (1% triton X 100 and 4 µg/ml 
Hoechst 33258 in PBS) and incubated in the dark at RT for 15 minutes. After 
rinsing with PBS, cells were counted under fluorescence microscope. 
 
2.3.12 Immunofluorescence and microscopy 
Cells were cultured on sterile coverslips in complete media until 70% 
confluent, and then fixed with 4% PFA for 10-15 minutes, washed with PBS 
for three times and treated with 0.5% Triton X-100 for 5 minutes. Cells were 
washed again for three times in PBS and incubated with 1% BSA in PBST for 
30 minutes. After that, cells were incubated with diluted primary antibodies 
(1:200 dilution) in 1% BSA in PBST for 1 hour at RT or overnight at 4°C. 
After three washes, cells were incubated with secondary antibodies diluted at 
1:200 for 1 hour at RT in dark. After removing secondary antibody solution 
and washing with PBS three times, slides were mounted with mounting 
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medium and stained with 4',6-diamidino-2-phenylindole (DAPI). After that, 
slides were sealed with nail polish and visualized under Nikon A1R-A1 
Confocal Microscope System. 
 
2.3.13 Endothelial cell adhesion and trans-migration assay 
For endothelial cell adhesion assay, endothelial cells, HUVEC cells were 
seeded in 24-well plates with 10% FBS supplementary media until 100% 
confluent, and then stained with CellTraceTM Calcein Red-Orange (Life 
technologies, USA) with 1:200 dilution and incubated at 37°C for 30 minutes. 
At the same time, colorectal carcinoma cells was harvested and stained with 
CellTraceTM Calcein Green (Life technologies, USA) and then incubated at 
37°C for 30 minutes. After incubation, stained colorectal carcinoma cells were 
centrifuged and the media was removed. Subsequently, cell pellet was 
resuspended with fresh media and added to HUVEC cell layer (media was 
removed), and incubated at 37°C for 1 hour. After removing the media and 
washing with cold PBS, co-cultured cells were fixed with 4% PFA and then 
visualized under Fluorescence Microscope System. 
For endothelial cell trans-migration assay, HUVEC cells were seeded in BD 
cell culture inserts (8 µm pores, 24-well format) with complete media until 
100% confluent. After removing the media from the inserts and washed with 
PBS, CellTraceTM Calcein Green labeled colorectal carcinoma cells were 
seeded (10,000 cells/well) in the upper chamber only with serum free media 
and complete media in the bottom well was used as a chemoattractant. 
Following 24 or 48 hours, cells that had invaded through the HUVEC cell 
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layer to the lower surface of the insert were fixed with 4% PFA and counted 
under fluorescence microscope after stained with Hoescht solution. 
 
2.3.14 Colonsphere formation 
Cells plated in 6-well plates were trypsinised and resuspended in 2 ml of 
complete media and then centrifuged at 800 rpm for 5 minutes. After that, 
cells were then suspended in 1ml of media and pipetted up and down 30 times 
to ensure a single-cell suspension. After removing the media, cells were mixed 
with DMEM-12F media (colonosphere media) supplemented with EGF (20 
ng/ml), bFGF (20 ng/ml), B27 (2%), heparin (4 ug/ml, 0.0004%), 
hydrocortisone (0.5 ug/ml) and FBS (1%). Colonosphere media (1000 
cells/well) (100 µl) was plated into each well of 96-well plates with ultra-low 
attachment surface (Corning Incorporated, USA). Cells were cultured in an 
incubator at 37°C for 1-2 weeks. Every two days, colonosphere media (50 µl) 
was added into the wells. After 1-2 weeks, colonies formed in this first 
generation were counted under microscope. 
In order to examine cell properties of self-renewal, the colonosphere from first 
generation were trypsinized and re-seeded into ultra-low attachment 96-well 
plates under the same procedure described above for the second and third 
generations. Similarly, colonospheres formed in second and third generations 




2.3.15 ALDEFLUOR assay 
The population of cells with aldehyde dehydrogenase (ALDH) activity was 
determined via ALDEFLUORTM Reagent System (STEMCELL, USA) by 
flow cytometry. Single cells (2×105) were suspended in 200 µl 
ALDEFLUORTM Assay Buffer, and mixed well with or without DEAB (3 µl). 
After that, 1 µl ALDH1 was added into cells for each tube and then incubated 
in dark (37°C) for 30 minutes. After incubation, cells were centrifuged and 
resuspended in 500 µl ALDEFLUORTM Assay Buffer on ice, and analyzed via 
flow cytometer immediately. 
 
2.4 Molecular biology methods 
2.4.1 RNA isolation 
RNeasy Mini Kit (QIAGEN, Germany) was used to extract the total RNA 
isolated from exponentially growing cells (70%-80% confluence). In this 
experiment, cells were harvested from culture flasks or plates before RNA 
extraction. Lysis buffer RLT (350 µl) was added into harvested cells and 
mixed well with pipettes. One volume (350 µl) of 70% ethanol was added into 
the homogenized lysate and mixed well by pipetting. A maximum of 700 µl of 
the mixtures were transferred into RNeasy spin columns, which were placed in 
the 2 ml collection tubes, and then centrifuged for 15 seconds at 13,000 rpm. 
After discarding the flow-through, spin column was washed with 700 µl 
Buffer RW1 and 500 µl Buffer RPE respectively. For final wash, spin column 
was added with 500 µl Buffer RPE and centrifuged for two minutes. After 
discarding the flow-through, the spin column was centrifuged for one minute. 
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The RNase-free water (30 µl) was directly added into spin column and 
incubated at RT for one minute and then centrifuged for 1 minute to elute the 
RNA. NanoDrop® ND-1000 Spectrophotometer (Thermo Scientific, USA) 
was used to measure the concentration of RNA. The purity of RNA was 
examined by the ratios A260/A280 nm and A260/A230 nm (a ratio less than 
1.8 indicates the presence of contaminants within the sample). 
 
2.4.2 cDNA isolation 
SuperScript® VILOTM cDNA Synthesis Kit was used to convert the total RNA 
to cDNA for semi-quantitative or RT-PCR Real-Time quantitative PCR 
(Invitrogen, USA). The components were added into a PCR tube as follows: 
5X VILOTM Reaction Mix (4 µl), 10X SuperScript® Enzyme Mix (2 µl), RNA 
(up to 2.5 µg), DEPC-treated water (up to 20 µl). The complex was gently 
mixed and the PCR tubes were placed into a PCR machine. The reaction was 
started at 25°C for 10 minutes, 42°C for 60 minutes, and terminated at 85°C 
for 5 minutes. The cDNA was placed at -20°C for storage. 
 
2.4.3 Semi-quantitative RT-PCR 
Platinum® PCR SuperMix High Fidelity Kit (Invitrogen, USA) was used to 
perform the semi-quantitative RT-PCR. The reaction complex was prepared as 
the following protocols (Negative control: includes all the components except 





Platinum® PCR SuperMix High Fidelity 18 µl 
Forward Primer (200nM) 0.5 µl 
Reverse Primer (200nM) 0.5 µl 
cDNA 1 µl 
Total volume 20 µl 
Table 2.4 Reaction components for Semi-quantitative RT-PCR analysis 
 
RT-PCR reactions were performed using the GeneAmp® PCR System 9700 
(Applied Biosystems, CA, USA). The reaction started with 30 minutes at 50 
°C, followed by 15 minutes at 94°C for reverse transcription, and then 
following with three steps with indicated cycles: 30 seconds at 94°C for 
denaturation; 30 seconds at specified temperature for annealing; 1-2 minutes at 
72°C for extension. The annealing temperature and number of cycles as well 
as the primer sequences for individual reaction are listed in Table 2.5.  
 















110 59 37 
hPRLR F: CATCTTTCCGCCAGTTCCT R: GGAAGCTTTCTACCTCCCTCT 650 60 32 
β-actin F: ATGATATCGCCGCGCTCG  R: CGCTCGGTGAGGATCTTCA 568 60 22 
Table 2.5 Primers and PCR conditions for RT-PCR analysis 
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PCR products were resolved on a 1.5% agarose gel prepared with Tris-EDTA 
buffer (TAE 1X) (see Appendices) containing of 1X GelRedTM Nucleic Acid 
Gel Stain (10,000X)(BIOTIUM, USA). When the gel was polymerised, it was 
transferred into TAE 1X buffer. A defined amount (8 µl) of RT-PCR product 
was mixed with 2 µl DNA loading dye (5X)(BIO-RAD, USA) and then loaded 
into each well of the gel. A 100bp DNA ladder (Promega, USA) was utilized 
as a molecular weight marker. The electrophoresis was carried out at 100 V 
for 30 minutes. The separated PCR products were visualized under UV light. 
 
2.4.4 Real-Time quantitative PCR 
This experiment was performed in collaboration with Dr. Pandey. For 
quantitative real-time PCR, the 5ng of the converted cDNA was added to a 20 
µl reaction complex containing SYBR® GreenERTM qPCR SuperMix, and 
200 nM of each primer (Table 2.6) in a 384-well plate. Real-time PCR and its 
analysis were both performed by using an ABI 7900HT® Real-Time PCR 
system (Applied Biosystems, USA). The reactions were performed by a two-
step amplification program as follows (1) 95°C for 10 minutes; (2) 40 cycles: 
95°C for 20 seconds, 60°C for 30 seconds; (3) 95°C for 1 minute, re-annealing 
at 55°C for 1 minute (a melting curve analysis step). The standard curves were 
obtained from each experimental plate using serial five-fold dilutions of 
untreated cDNA. The analysis of qPCR was performed as previously 
described in Dr. Pandy’s research paper (Pandey et al., 2008). Each reaction 
was performed in triplicate, and the change of gene expression is presented as 
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“fold change” with the average of the three reactions. Three housekeeping 
genes β-ACTIN, HPRT, and GAPDH were used to normalize the relative 
expression of marker genes. 
 
Gene Primer sequence (5’ to 3’) 
CDH1 F: CGAGAGCTACACGTTCACGG R: GGGTGTCGAGGGAAAAATAGG 
OCLN F: TGCCGCGTTGGTGATCTTT R: GCCCAGGATAGCACTCACTATT 
CTNNA1 F: CCATGCAGGCAACATAAACTTC R: GGCTCCAACAGTCTCTCAACT 
CTNNB1 F: CCCACTGGCCTCTGATAAAGG R: ACGCAAAGGTGCATGATTTG 
CTNND2 F: TTCATCACAGGTGCTGCGTAA R: CCATCACACTCTCTCATCCTTCTG 
TWIST1 F: GTCCGCAGTCTTACGAGGAG R: GCTTGAGGGTCTGAATCTTGCT 
VIM F: CCTTGAACGCAAAGTGGAATC R: GACATGCTGTTCCTGAATCTGAG 
FN1 F: GGTGACACTTATGAGCGTCCTAAA R: AACATGTAACCACCAGTCTCATGTG 
CDH2 F: AGCCAACCTTAACTGAGGAGT R: GGCAAGTTGATTGGAGGGATG 
SNAI1 F: AATCGGAAGCCTAACTACAGCG R: GTCCCAGATGAGCATTGGCA 
SNAI2 F: AAGCATTTCAACGCCTCCAAA R: GGATCTCTGGTTGTGGTATGACA 
FOXC2 F: CCTCCTGGTATCTCAACCACA R: GGTCGAGTTCTCAATCCCCA 
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ZEB1 F: TTACACCTTTGCATACAGAACCC R: TTTACGATTACACCCAGACTGC 
ZEB2 F: GCGATGGTCATGCAGTCAG R: CAGGTGGCAGGTCATTTTCTT 
MET F: TGGTGCAGAGGAGCAATGG R: CATTCTGGATGGGTGTTTCCG 
MMP2 F: CAAAAACAAGAAGACATACATCTT R: GCTTCCAAACTTCACGCTC 
MMP9 F: AGACGGGTATCCCTTCGACG R: AAACCGAGTTGGAACCACGAC 
MTA1 F: GCTGTTACACCACACAGTCTT R: GGACTCATGTTACTGCGGTTT 
MTA2 F: CCGACGGCCTTATGCTCCT R: CTGGGCCACCAGATCTTTGAC 
NME1 F: CTGCAGCCGGAGTTCAAAC R: GCAATGAAGGTACGCTCACAGT 
PLAU F: CACGCAAGGGGAGATGAA R: ACAGCATTTTGGTGGTGACTT 
PLAUR F: AATGGCCGCCAGTGTTACAG R: CAGGAGACATCAATGTGGTTC 
SERPINB5 F: CTACTTTGTTGGCAAGTGGATGAA R: ACTGGTTTGGTGTCTGTCTTGTTG 
CD24 F: CTCCTACCCACGCAGATTTATTC R: AGAGTGAGACCACGAAGAGAC 
CD44 F: CCCATCCCAGACGAAGACAG R: ACCATGAAAACCAATCCCAGG 
KLF4 F: CCCACATGAAGCGACTTCCC R: CAGGTCCAGGAGATCGTTGAA 
SRC F: TGGCAAGATCACCAGACGG R: GGCACCTTTCGTGGTCTCAC 
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EGFR F: AGGCACGAGTAACAAGCTCAC R: ATGAGGACATAACCAGCCACC 
NCAM1 F: TGTGTGGTTACAGGCGAGGA R: TTGGCGCATTCTTGAACATGA 
ALDH1 F: GCACGCCAGACTTACCTGTC R: CCTCCTCAGTTGCAGGATTAAAG 
WNT5A F: ATTCTTGGTGGTCGCTAGGTA R: CGCCTTCTCCGATGTACTGC 
WNT5B F: GTGCAGAGACCCGAGATGTTT R: TTGGCTCCCTCCCCTATGTAG 
BMI1 F: GCTGCCAATGGCTCTAATGAA R: TGCTGGGCATCGTAAGTATCTT 
LIN28A F: AGCGCAGATCAAAAGGAGACA R: CCTCTCGAAAGTAGGTTGGCT 
NANOG F: TTTGTGGGCCTGAAGAAAACT R: AGGGCTGTCCTGAATAAGCAG 
SOX2 F: GCCGAGTGGAAACTTTTGTCG R: GGCAGCGTGTACTTATCCTTCT 
POU5F1 F: CTTGAATCCCGAATGGAAAGGG R: CCTTCCCAAATAGAACCCCCA 
SALL4 F: GGGCCGACACTCTGAAGAC R: GGCTTGTTTCAAGGCATCCAG 
β-ACTIN F: GTCTGCCTTGGTAGTGGATAATG R: TCGAGGACGCCCTATCATGG 
HPRT F: TGACACTGGCAAAACAATGCA R: GGTCCTTTTCACCAGCAAGCT 
GAPDH F: TGCACCACCAACTGCTTAGC R: GGCATGGACTGTGGTCATGAG 
Table 2.6 Oligonucleotide primers used for quantitative real-time PCR 
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2.4.5 Bacterial strains and growth of bacterial cultures 
The Escherichia coli (E.Coli) strain used in this study is DH5α, which was 
obtained from Invitrogen (Groningen, The Netherlands). All bacteria were 
cultured in either solid Luria-Bertani (LB)/agar plates or liquid LB (See 
Appendices) at 37°C.  
 
2.4.6 Bacterial transformation of plasmids 
Plasmid amplification was performed in DH5α (Invitrogen, Carlsbad, CA, 
USA) by bacterial transformation. Competent DH5α bacteria were mixed with 
an appropriate amount of plasmids and then placed on ice for 30 minutes. The 
mixture of bacteria and DNA were placed in a 42°C water bath (Grant 
Instruments Ltd., Cambridge, UK) for a heat shock for 2 minutes, and 
immediately cooled on ice for 5 minutes. After that, 1ml of LB solution with 
specific antibiotics was added to the bacteria and incubated at 37°C for 1 hour. 
Following this, bacteria were transferred to a LB agar plate containing specific 
antibiotics for further culture. Antibiotics were served as selectable markers 
for positively transformed colonies, as the plasmid contains a resistance 
cassette that makes transformed bacteria resistant to the corresponding 
antibiotics. In this study, 50 µg/mL of Ampicillin was used to select the 
bacteria transformed with the plasmids pcDNA3.1. After incubation for 20 
hours, single colonies from each plate was picked and transferred into 400ml 
of LB solution containing 50 µg/mL Ampicillin. Transformed bacteria were 
cultured with shaking (250 rpm) in an incubator shaker (Edwards Instrument 
Co., Narellan, NSW, Australia) at 37°C for a further 20 hours. 
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2.4.7 Plasmid DNA purification 
Following a 20 hours culture (37°C) in the liquid LB containing antibiotics, 
plasmid DNA of transformed DH5α bacteria was extracted and purified by 
using PureLink® HiPure Plasmid DNA Purification Kits (Invitrogen, USA). 
The bacteria were harvested via centrifugation at 4000g for 10 minutes at 4°C. 
The harvested pellet was completely suspended in 10ml of Resuspension 
Buffer R3 by vortexing, and then followed with 10ml of Lysis Buffer L7.  
After 5 minutes incubation at RT, 10ml of chilled Precipitation Buffer N3 was 
immediately mixed with the sample and then centrifuged at 12,000g for 10 
minutes at RT The plasmid DNA containing supernatant was transferred onto 
the equilibrated column. In order to improve the level of purification, washing 
steps were performed in the following steps. After the solution in the column 
was drained by gravity flow, 60ml of Washing Buffer W8 was added into the 
column. After all the solution drained, Elution Buffer E4 (15 ml) was added 
into the column and a new 50 ml centrifuge tuber was placed under the 
column to gather the eluate that contained the plasmid DNA. Isopropanol 
(10.5 ml) was added into the eluate and mixed well and then centrifuged at 
8,500g for 55 minutes at 4°C to precipitate the DNA. After that, the DNA 
pellet was washed with 5 ml of 70% ethanol at RT and then re-precipitated by 
centrifuging at 12,000g for 30 minutes. After that, the supernatant was 
carefully removed and the pellet was washed with 5 ml of 70% ethanol. After 
centrifuged for 5 minutes, plasmids were air dry and then redissolved with 
ultrapure water (50-100 µl). The plasmid DNA was stored at -20°C.
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Qiagen Miniprep Kit (Qiagen, Germany) was used for small-scale plasmid 
DNA extraction. According to the manufacturer’s instructions, bacteria were 
harvested by the centrifugation at 16000g for 15 minutes. After removing the 
suspension, the cell pellet was suspended in Suspension Solution. Followed 
with Suspension Solution, Lysis Solution and Neutralization Solution were 
added into the cell lysate. The lysate was then centrifuged at 14,000 rpm for 
10 minutes (RT), and the supernatant was transferred to spin columns. 
Following with centrifugation, the column was washed with Washing Solution 
and eluted with 50 µl ultrapure water. 
 
2.5 Protein Methods 
2.5.1 Protein extraction  
Cells were cultured at 60-70% confluence, and then washed with PBS and 
harvested by mechanical scraping. The scraped cells were suspended in RIPA 
Lysis Buffer (See Appendices) and placed on ice for 30 minutes with 
vortexing at every 5 minutes. The concentration of protein was measured in 
triplicate using DC protein assay (Bio-Rad) or NanoDrop® ND-1000 
Spectrophotometer (Thermo Scientific, USA). 
 
2.5.2 DC protein assay 
Bio-Rad DC Protein Assay (Bio-Rad Laboratories, USA) was performed to 
measure the concentration of protein. According to the instruction, working 
reagent A was firstly prepared by mixing 20 µl of reagent S to 1 ml of reagent 
A. Diluted BSA was used for a protein standard containing from 0 mg/ml to 5 
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mg/ml protein. Standards and protein samples (5 µl) were added into 96-well 
plates. Working reagent A (20 µl) was added into each well, followed by 200 
µl reagent B. The plates were incubated in dark for 15 minutes. After 
removing bubbles with clean, dry pipette tips, absorbance was measured under 
the wavelength of 750 nm by a Biotek Synergy 2 plate reader. The 
concentration of sample protein was calculated from the standard curve that is 
plotted based on the absorbance of standards. 
 
2.5.3 Western blot analysis 
Polyacrylamide gel electrophoresis (PAGE) 
The PAGE gel was assembled by the Bio-Rad Mini-PROTEAN II system. The 
solution of the separating gel and stacking gel was prepared according to the 
attachment in appendices. The separating gel was firstly poured into the plates 
and polymerized by the addition of 0.1% ammonium persulfate (APS) and 
0.01% Tetramethylethylenediamine (TEMED). After the polymerization of 
separating gel, the stacking gel solution was poured into the plates with a 
comb inserted on the top of the plates and also polymerized by the addition of 
APS and TEMED.  Meanwhile, protein samples were prepared by mixing with 
5X sample buffer (see in the appendices) and heating at 100°C for 10 minutes. 
Prepared protein samples, as well as protein makers were loaded into each 
well of the gel. After loading, the gel was runned under electrophoresis with 
1X SDS-PAGE running buffer (see in the appendices) at a voltage of 120 V 
for 1-2 hours until the dye front had reached the bottom of the glass plates. 
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Western blot analysis 
After electrophoresis, the gel was removed from the glass plates and 
transferred to the transfer buffer (see in the appendices) after cutting off the 
part of stacking gel. Simultaneously, the Polyvinylidene Difluoride (PVDF) 
membrane (Bio-Rad Laboratories, USA) was transferred into transfer buffer 
after incubating in methanol for 1 minute, as well as the filter paper and fibre 
pads. The transfer cassette was assembled as follows: black side, fibre pad, 
filter paper, gel, membrane, filter paper, fibre pad, white side. The cassette 
was firmly closed without air bubbles inside and transferred in filled transfer 
buffer with a voltage of 100 V for 1-2 hours. 
After electrophoresis, proteins were transferred onto the PVDF membranes, 
which were then blocked with 5% non-fat dry milk in PBST (see in the 
appendices) or 5% BSA in PBST overnight at 4°C, and then incubated with 
the specific primary antibodies for 2 hours at RT or overnight at 4°C (Table 
2.7). Then the blots were washed three times during 10-15 minutes and 
incubated with the secondary antibodies for 1 hour. Finally, the membrane 
washed again for three times, and then incubated with the West Pico 
Chemoluminescence Substrate (Thermo Scientific, USA) for 5 minutes in the 
dark, according to the instructions. The X-ray film was developed in a Kodak 
film processor. 
For reblotting, the antibodies were removed by stripping the membrane for 5 
minutes in stripping buffer (0.2 M NaOH). The membranes were then washed 
with milliQ water and PBST respectively for 10 minutes. The membrane was 
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then re-blocked with blocking solution (5% milk or 5% BSA), and incubated 
with the respective antibodies as described above. 
 
Antibody Origin Supplier Band size (kDa) 
β-actin (sc-58222) Mouse Santa Cruz 42 
ERK (sc-93) Rabbit Santa Cruz 44/42 
p-ERK (sc-7383) Mouse Santa Cruz 44/42 
E-Cadherin 
(ab1416) Mouse Abcam 110 
Fibronectin1 
(ab2413) Rabbit Abcam 262 
hGH Rabbit National Hormone and Peptide Program 20/22 
Occludin 
(ab31721) Rabbit Abcam 59 
Vimentin 
(ab20346) Mouse Abcam 54 
Table 2.7 Antibodies used in western blot analysis 
 
 
2.5.4 Promoter activity assay 
Promoter activities of E-CADHERIN and FN1 were determined by Dual-
Luciferase® Reporter Assay Systems (Promega, USA). Cells were transfected 
with pGL3-Basic Vector (Promega, USA) containing full length of E-
CADHERIN gene promoter (E-CADHERIN promoter Luciferase reporter 
vectors were kindly provided by Dr. Pandey), or pXP2 Vector containing full 
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length of FN1 gene promoter (FN1 promoter luciferase reporter vectors were 
kindly provided by Professor Andrei Bakin from Roswell Park Cancer 
Institute). At the same time, cells were transfected with vectors containing 
Renilla Luciferase as a control. After transfection and incubation for 24 hours, 
cells were rinsed with PBS and dispensed with 500 µl 1X lysis reagent PLB 
into each well (6-well plate). The PLB/cells complex was mixed well by 
pelleting and transferred into a new tube. 100 µl of LAR ΙΙ was predispensed 
into a luminometer tube, and then 20 µl of PLB lysate was transferred into 
LAR ΙΙ. The Firefly Luciferase activity was measured immediately via 
Berthold Luminometer. After that, 100 µl of Stop & Glo® Reagent was 
dispensed into the tube and the Renilla luciferase activity was measured 
immediately via Berthold Luminometer. 
 
2.5.5 In situ hybridization (ISH) and immunohistochemistry (IHC) 
The tissue samples were collected from 101 patients with colorectal cancer 
and 20 patients with benign colorectal disease from the First Affiliated 
Hospotal of Anhui Medical University (Hefei, Anhui, People’s Republic of 
China).  ISH analysis was performed with digoxin-labeled antisense 
oligonucleotide probes for hGH as previously described (Wu et al., 2011). 
IHC analysis was performed with polyclonal anti-hGH antibody (Santa Cruz, 
CA) by using peroxidase-conjugated streptavidin complex method, as 
previously described (Wu et al., 2011). The scoring of hGH staining was 
performed independently by two investigators without the knowledge of the 
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patients clinicopathological information as described previously (Wu et al., 
2011). 
 
2.6 In vivo study 
2.6.1 Xenograft analysis 
Xenograft studies were performed essentially as described previously (Tang et 
al., 2010b). DLD-1-vector or DLD-hGH cells (800 cells) were suspended in 
125 µl Matrigel/PBS (1:1, v/v) and subcutaneously injected into the 
subscapular region of the immunodeficient nude mice (Shanghai Slaccas Co., 
Shanghai). The tumor volumes were measured every 3-4 days after injection 
for 1 week. TUNEL analysis was performed as previously described (Pandey 
et al., 2008). Immunostaining with Ki-67, E-CADHERIN and FN1 were using 
IHC analysis with following antibodies: anti-Ki-67 (Angiobio & Beijing 
Zhongshan Jinqiao Biotechnology Co.), anti-E-CADHERIN (BD Biosciences) 
and anti-FN1 (BD Biosciences). 
 
2.7 Bioinformatics Tools 
2.7.1 Statistical analysis 
The statistics software GraphPad Prism V5 (Mathlab) was used in conjunction 
with Microsoft Excel for statistical analyses presented in this thesis. The 
graphical presentations were generated using these two softwares. All of the 
experiments in this study were performed at least three times and a single 
representative figure is shown. All of the numerical data were expressed as 
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means +/- standard error (SEM) of triplicate determinants. Data were analyzed 
using the student’s t test. 
 
2.6.2 Primer design 
For design of primers for RT-PCR and Real time PCR, the primer design 
software available on the invitrogen website (www.invitrogen.co.nz) was 
utilized. The software PRIMER 5 or DNAMAN was also used for primer 
design. For verification of designed primers, sequences were also checked on 

















Growth hormone (GH) is the key endocrine regulator of postnatal growth, and 
stimulates differentiation and cell proliferation in target tissues (Isaksson et al., 
1982, Madsen et al., 1983). Recently, the association of GH with cancer has 
been well established in humans and animals (Perry et al., 2006). Increased 
expression of hGH has been indicated in endometriosis and endometrial 
adenocarcinoma compared to the normal uterine epithelium (Slater et al., 
2006), suggesting an oncogenic potential of autocrine hGH in cancer 
progression. Furthermore, previous studies from our laboratory have 
demonstrated that hGH is frequently expressed in mammary and endometrial 
carcinomas and positively associated with worse clinical outcomes in patients 
with these carcinomas (Wu et al., 2011). Autocrine hGH has been shown to 
promote cell proliferation (Kaulsay et al., 1999) and survival (Kaulsay et al., 
2001) of mammary carcinoma cells. Moreover, forced expression of hGH in 
immortalized human mammary epithelial cells has also been observed to 
promote cell anchorage independent growth in vitro and tumor formation in 
vivo (Zhu et al., 2005a), which strongly demonstrates the oncogenic potential 
of hGH in the cancer development.  
The functional effects of GH are exerted either directly, or indirectly through 
the action of GH-induced insulin-like growth factor 1 (IGF-1) (Strobl and 
Thomas, 1994). The functional role of IGF-1, as well as its receptor IGF-1R in 
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oncogenic progression is also well established (Khandwala et al., 2000, 
Baserga et al., 2003). Additionally, a GH-related hormone, prolactin (PRL), 
has also been involved in the cancer progression (Wu et al., 2011). In humans, 
hGH binds to growth hormone receptor (GHR) as well as PRL receptor 
(PRLR) to stimulate signaling pathways including JAK2/STATs, MAPK/ERK, 
and PI3K/AKT pathways (Perry et al., 2013, Wennbo and Tornell, 2000). 
Colorectal cancer (CRC) is one of the most common cancers in the world and 
contributes heavily to cancer mortality (Manzano and Perez-Segura, 2012). 
Increased levels of GHR expression have been observed in CRC compared to 
the normal mucosal tissue, and the expression of GHR is significantly 
associated with tumor size, tumor differentiation and pathological stage (Wu 
et al., 2007, Yang et al., 2005). However, the knowledge of the potential role 
of autocrine hGH, as opposed to endocrine hGH in CRC progression is yet to 
be explored. In this chapter, I investigated the oncogenic potential of autocrine 
hGH in colorectal carcinoma cells, as well as the potential mechanisms. 
 
3.2 Results 
3.2.1 Expression of hGH in colorectal normal tissue and carcinoma 
In order to investigate the potential role of hGH in CRC progression, in situ 
hybridization (ISH) and immunohistochemistry (IHC) were performed by in 
collaboration (according to previously described (Wu et al., 2011)) to examine 
the expression of hGH mRNA and protein in colorectal normal tissue and 
carcinoma respectively (Figure 3.1). High expression of hGH mRNA was 
observed in the colorectal carcinoma, while low expression was observed in 
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the colorectal normal tissue (Figure 3.1A). hGH protein expression was also 
significantly different between colorectal carcinoma and normal tissue (Figure 
3.1B). The statistical analysis of hGH mRNA expression in 101 colorectal 
carcinoma specimens and 20 colorectal normal tissue specimens demonstrated 
that 50.5% of colorectal carcinoma specimens were positive for hGH mRNA, 
whereas only 20% of the colorectal normal tissues from patients with benign 
disease were positive for hGH mRNA (P = 0.012) (Table 3.1). These results 
suggested hGH mRNA was more frequently expressed in colorectal carcinoma 







Figure 3.1 Expression of hGH in colorectal normal tissue and carcinoma. 
(A) In situ hybridization analysis of hGH mRNA expression in colorectal 
normal tissue and carcinoma. Left panels, Low expression of hGH mRNA in 
colorectal normal tissue derived from patients with benign colorectal disease. 
Right panels, High expression of hGH mRNA in colorectal carcinoma (arrow). 
(B) Immunohistochemical analysis of hGH protein expression in colorectal 
normal tissue and carcinoma. Left panels, Low expression of hGH protein in 
colorectal normal tissue derived from patients with benign colorectal disease. 
Right panels, High expression of hGH protein in colorectal carcinoma (arrow). 








hGH mRNA expression 
n Negative, n (%) Positive, n (%) 








Note: * P=0.012.       
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3.2.2 Correlation between hGH mRNA expression and clinicopathological 
features of colorectal carcinoma 
To ascertain a potential correlation between expression of hGH and the 
clinicopathological features of colorectal carcinoma, the statistical correlation 
of hGH mRNA expression in colorectal carcinoma with the 
clinicopathological parameters from colorectal cancer patients was performed 
by in collaboration (according to previously described (Wu et al., 2011)). As 
presented in Table 3.2, hGH mRNA expression was positively correlated with 
tumor size (p = 0.001) and lymph node metastasis (p = 0.003). No significant 
correlation was observed between hGH mRNA expression with patient age, 
grade and tumor stage. 
 
Table 3.2. Correlation of hGH mRNA expression with clinicopathological 
parameters from colorectal cancer patients 
Parameter n hGH positive expression, n (%) p value 
Age (years)    
≤ 55 40 16 (40.0) 0.088 
> 55 61 35 (57.4)  
Tumor size (cm)    
≤ 5 60 22 (36.7) 0.001 
> 5 41 29 (70.7)  
Lymph node metastasis    
Absent 38 12 (31.6) 0.003 
Present 63 39 (61.9)  
Grade    
Well 8 4 (50.0) 0.397 
Moderate 50 22 (44.0)  
Poor 43 25 (58.1)  
Stage    
I + II 38 18 (47.4) 0.625 




3.2.3 Expression of hGH, hGHR and hPRLR mRNA in colorectal 
carcinoma wild type cells 
In order to select suitable cell lines as cell models to study the potential role of 
hGH in CRC progression in vitro, I examined the mRNA expression of hGH, 
as well as its receptors hGHR and hPRLR in five colorectal carcinoma cell 
lines DLD-1, HT-29, SW480, Caco2 and HCT116 (Figure 3.2). The results of 
semi-quantitative RT-PCR analysis indicated that the mRNA levels of hGH in 
these five CRC cell lines are relatively low. However, detectable hGH mRNA 
expression was observed in DLD-1, HT-29 and Caco2 cells after 40 cycles of 
RT-PCR, whereas there was no detectable expression of hGH mRNA in 
SW480 and HCT116 cells. High expression of hGHR mRNA was observed in 
HT-29, SW480 and Caco2 cells, and detectable but low expression of hGHR 
mRNA in HCT116 cells, whereas hGHR mRNA expression was not 
detectable in DLD-1 cells. Additionally, the expression of hPRLR mRNA was 
observed in DLD-1, HT-29 and Caco2 cells, whereas no detectable expression 
of hPRLR mRNA was observed in SW480 and HCT116 cells. Hence, DLD-1 
cells expressed detectable mRNA levels of hGH and hPRLR, and both of HT-
29 and Caco2 cells expressed detectable mRNA levels of hGH, hGHR and 




Figure 3.2 hGH, hGHR and hPRLR mRNA expression in CRC wild type 
cells.  
Semi-quantitative RT-PCR analysis of hGH (40 cycles), hGHR (37 cycles) 
and hPRLR (32 cycles) mRNA levels in five CRC cell lines. β-actin (22 cycles) 
was used as a loading control. bp, base pair. 
 
3.2.4 Forced expression of hGH in CRC cells stably transfected with hGH 
gene 
To study the effect of autocrine hGH on CRC progression in vitro, stable cell 
lines were generated in DLD-1, HT-29 and Caco2 cells. These cells were 
transfected with a vector containing the full length of hGH gene (described in 
Section 2.3.1) or an empty vector as control. The cell lines were named as 
DLD-1-vector and DLD-1-hGH, or HT-29-vector and HT-29-hGH, or Caco2-
vector and Caco2-hGH respectively. RT-PCR was performed to examine the 
mRNA expression of hGH in these stable cell lines. As the mRNA expression 
of hGH in DLD-1, HT-29 and Caco2 wild type cells was relatively low and 
only detected after 40 cycles of RT-PCR, DLD-1-vector, HT-29-vector and 
Caco2-vector cells did not exhibit detectable levels of hGH mRNA after 32 
cycles of RT-PCR used for this experiment, and similar to the respective wild 
type cells. However, DLD-1-hGH, HT-29-hGH and Caco2-hGH exhibited 
high levels of hGH mRNA expression after 32 cycles of RT-PCR (Figure 
3.3A). Subsequently, the protein levels of hGH were examined by western blot, 
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confirming that DLD-1-hGH, HT-29-hGH and Caco2-hGH expressed high 
levels of the 22kDa hGH protein. Low expression levels of hGH protein were 
observed DLD-1-vector and HT-29-vector cells and no detectable protein 
expression was observed in Caco2-vector cells (Figure 3.3B). These results 
verified that stable transfection of the hGH gene in DLD-1, HT-29 and Caco2 




Figure 3.3 Forced expression of hGH in colorectal carcinoma cells.  
(A) Semi-quantitative RT-PCR analysis was used to examine hGH mRNA 
levels in stably transfected DLD-1, HT-29 and Caco2 cells. β-ACTIN was used 
as a loading control. (B) The level of hGH protein in stably transfected 
colorectal carcinoma cells was determined by western blot analysis. The 
whole cellular extracts were run on an SDS-PAGE gel, and a rabbit anti-hGH 
polyclonal antibody was used to detect the hGH protein. β-ACTIN was used 




3.2.5 Autocrine hGH increased colorectal carcinoma cell number in 10% 
and 0.5% FBS supplemented media 
In order to examine the effect of autocrine hGH on CRC cellular function, I 
firstly investigated the effect of forced expression of hGH in CRC cells on 
total cell number. A total cell number assay was performed in both full serum 
media (10% FBS) and serum-reduced media (0.5% FBS) and significant 
differences between DLD-1-vector and DLD-1-hGH cells, as well as Caco2-
vector and Caco2-hGH cells were observed (Figure 3.4). In 10% FBS culture 
condition, DLD-1-hGH and Caco2-hGH cells grew significantly faster than 
the respective control cell lines, DLD-1-vector and Caco2-vector cells after 4 
days. Total cell number in cells with forced expression of hGH was 
significantly higher than the control vector cells after 10 days of culture 
(Figure 3.4A and C). Interestingly, when cells were cultured in serum-reduced 
media (0.5% FBS), secretion of autocrine hGH resulted in an increase of total 
cell number in DLD-1 and Caco2 cells. However, control vector cells could 
not survive over 8 days in this culture condition (Figure 3.4B and D). These 
results suggested that forced expression of hGH in CRC cells resulted in 




Figure 3.4 Autocrine hGH increased colorectal carcinoma cell number.  
(A, C) Total cell number in DLD-1-vector and DLD-1-hGH, as well as Caco2-
vector and Caco2-hGH over 10 days of culture in 10% FBS media. (B, D) 
Total cell number in DLD-1-vector and DLD-1-hGH, as well as Caco2-vector 
and Caco2-hGH over 8 days in 0.5% FBS media. **P<0.01. 
 
3.2.6 Autocrine hGH stimulated cell proliferation in colorectal carcinoma 
cells 
Increased total cell number may result from increased cell proliferation or 
decreased cell apoptosis (Zhang et al., 2003). Therefore, I proceeded to 
examine the effect of autocrine hGH on cell proliferation in CRC cells. DLD-1 
and Caco2 stable cells were incubated for 24 hours with BrdU, which is a 
thymidine analog and is incorporated into DNA during the S phase of the cell 
cycle as a substitute for thymidine and thereby serves as a marker for 
proliferation (Lehner et al., 2011). The percentage of nuclear BrdU 
incorporation in stable cells was subsequently examined (described in section 
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2.3.4). As shown in Figure 3.5, DLD-1-hGH cells exhibited a significantly 
higher BrdU incorporation with a 2.15-fold increase compared to DLD-1-
vector cells. Similarly, forced expression of hGH in Caco2 cells also resulted 
in a higher BrdU incorporation when compared to its relative vector cells 
(1.47-fold increase). These results suggested that forced expression of hGH 




Figure 3.5 Autocrin hGH promoted cell proliferation in colorectal 
carcinoma cells.  
BrdU cell proliferation assay performed to examine the cell proliferation (S 
phase) in DLD-1 and Caco2 cells. Cells were incubated with BrdU for 24 
hours, and results were presented as percentage relative to the respective 
vector cells. **P<0.01. 
 
 
3.2.7 Autocrine hGH reduced apoptosis in colorectal carcinoma cells 
To determine the effect of autocrine hGH on cell apoptosis in CRC cells, the 
activities of caspase-3/7, which promote cell apoptosis by DNA fragmentation 
(Wolf et al., 1999), were examined in DLD-1 and Caco2 stable cells. In this 
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experiment, cells were cultured in serum-free media for 24 hours to induce 
apoptosis, and then the activities of caspase-3/7 were measured by a 
fluorescence-based caspase assay (described in section 2.3.5). Results 
demonstrated that the caspase-3/7 activities were significantly decreased in 
DLD-1 and Caco2 cells with forced expression of hGH to 42.3% and 64.9% 
respectively, when compared with their respective vector cells. These results 
suggested that autocrine hGH protected CRC cells from apoptosis induced by 
starvation (Figure 3.6). 
 
 
Figure 3.6 Autocrine hGH reduced colorectal carcinoma cell apoptosis.  
Caspase-3/7 activities were examined in DLD-1 and Caco2 stable cells after 
serum starvation for 24 hours. Results were presented as percentage relative to 
the respective vector cells. **P<0.01. 
 
 
3.2.8 Autocrine hGH increased colorectal carcinoma cells oncogenic foci 
formation 
One capability of oncogenic transformed cells is the ability to form 
macroscopic foci (Hurlin et al., 1987, Zhu et al., 2005a). The foci formation 
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assay was used to evaluate the oncogenic potential of autocrine hGH in CRC 
cells. In this experiment, single cells were seeded in 6-well plates at a low 
density and cultured with complete media as described in section 2.3.6. As 
shown in Figure 3.7, there were more, and larger colonies formed by DLD-1-
hGH cells compared to DLD-1-vector cells. Similarly, most of the colonies 
formed by Caco2-hGH cells were larger than that formed by Caco2-vector 
cells. These results demonstrated that forced expression of hGH enhanced foci 
formation in CRC cells.  
 
 
Figure 3.7 Autocrine hGH increased colorectal carcinoma cells foci 
formation.  
(A) DLD-1-vector and DLD-1-hGH, (B) Caco2-vector and Caco2-hGH foci 
formation were examined by crystal violet staining after two weeks of culture 
in the media supplemented with 10% FBS. The numbers of colonies (colony 
diameter >1mm) are counted. *P<0.05, **P<0.01. 
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3.2.9 Autocrine hGH enhanced colorectal carcinoma cells anchorage-
independent growth 
Autocrine hGH-enhanced foci formation in CRC cells suggested a potential 
oncogenic role of hGH in CRC progression. Anchorage-independent cell 
growth also has been considered as one of the characteristics of oncogenic 
transformed cells (Zhang et al., 2003). In order to determine the effect of 
autocrine hGH on anchorage independent growth of CRC cells, colony 
formation in soft agar was used to evaluate this capability in these stable cells 
(Figure 3.8). An increased number of colonies formed by DLD-1-hGH cells 
were observed in soft agar with 10% FBS supplemented media, as well as with 
0.5% FBS supplemented media (Figure 3.8A). Cell viability of DLD-1-hGH 
and DLD-1-vector cells in soft agar colony formation was examined by the 
MTT assay. DLD-hGH cells grown in soft agar formation exhibited 
significantly higher cell viability with a 1.27-fold increase in 10% FBS 
supplemented media and 1.65-fold increase in 0.5% FBS supplemented media 
(Figure 3.8A). Similarly, forced expression of hGH in HT-29 cells increased 
colony number in soft agar and increased cell viability in both 10% FBS (1.27-
fold increase) and 0.5% FBS (1.64-fold increase) supplemented media (Figure 
3.8B). Cell viability of Caco2 stable cells grwon in soft agar colony formation 
was measured by an Alamarblue assay, and Caco2-hGH cells also exhibited 
higher cell viability with 1.56-fold increase in the media supplemented with 
10% FBS and 1.39-fold increase in the media supplemented with 0.5% FBS 
(Figure 3.8C). Such observations indicated that forced expression of hGH 
enhanced the anchorage-independent growth capacity of CRC. 
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Figure 3.8 Autocrine hGH increased colorectal carcinoma cells colony 
formation in soft agar.  
(A) DLD-1-vector and DLD-1-hGH, (B) HT-29-vector and HT-29-hGH, and 
(C) Caco2-vector and Caco2-hGH colony formation were examined after ten 
days of culture in 10% FBS or 0.5% FBS media. Cell viability was measured 
by a MTT assay in DLD-1 and HT-29 stable cells or an Alamarblue assay in 
Caco2 stable cells. *P<0.05, **P<0.01. 
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3.2.10 Autocrine hGH activated MAPK/ERK pathway in CRC 
In order to determine the potential mechanisms involved in the hGH-mediated 
oncogenicity, we performed western blot analysis to examine the 
phosphorylated states of key proteins involved in the signaling pathways 
including MAPK/ERK, AKT and STATs. Phosphorylated ERK1/2 (p-ERK1/2) 
and total ERK1/2 were detected as dual-band proteins at 44kDa and 42kDa 
(Figure 3.9). Forced expression of hGH in DLD-1 cells produced increases in 
the level of p-ERK1/2 compared with the vector cells, whereas the expression 
of total ERK1/2 was not changed. Similarly, forced expression of hGH in 
Caco2 cells also increased p-ERK1/2. However, the levels of p-AKT and p-
STAT3 were similar in DLD-1-hGH and Caco2-hGH cells compared with 
respective vector cells (data not shown). These results suggested that autocrine 
hGH preferentially activated the ERK pathway in CRC cells. It is possible that 
the activated ERK pathway may functionally promote hGH-induced 
oncogenicity in CRC cells. 
 
Figure 3.9 Autocrine hGH stimulated ERK activation in colorectal 
carcinoma cells.  
The levels of p-ERK1/2 and total ERK1/2 in stably transfected colorectal 
carcinoma cells was determined by western blot analysis. β-ACTIN was used 
as a loading control. 
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3.2.11 PD98059 inhibited the phosphorylation of ERK1/2 
To ascertain the potential function of the ERK pathway in autocrine hGH-
mediated oncogenicity in CRC cells, a MEK inhibitor PD98059, which 
specifically inhibited the phosphorylation of ERK1/2, was used in this study 
(Suthiphongchai et al., 2006). In order to determine the efficiency of this 
inhibitor and an appropriate concentration to use in my study, DLD-1-vector 
and DLD-1-hGH cells were treated with PD98059 at in different 
concentrations for two hours. The results of western blot analysis 
demonstrated that PD98059 inhibited the phosphorylation of ERK1/2 in a 
dose-dependent manner, and 20 µM of PD98059 could effectively abrogate 
autocrine hGH-stimulated activation of ERK1/2 in CRC cells (Figure 3.10). 
Thus, the concentration of PD98059 used in my study was 20 µM. 
 
 
Figure 3.10 PD98059 inhibited phosphorylation of ERK1/2.  
A MEK inhibitor PD98059 significantly inhibited the activation of ERK1/2 
with decreased level of p-ERK1/2 in a dose-dependent manner. Cells were 
incubated with different concentrations of PD98059 for two hours, and DMSO 
was also used as a control (0 µM). 
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3.2.12 Autocrine hGH increased cell total number via the ERK pathway 
in CRC 
To determine the role of the ERK pathway in autocrine hGH-increased cell 
number in CRC cells, total cell number assays with or without treatment with 
PD98059 (20µM) were performed in DLD-1 and Caco2 stable cells under 
10% FBS culture conditions. Treatment with PD98059 significantly reduced 
total cell number in both DLD-1-hGH and DLD-1-vector cells over eight days 
(Figure 3.11A). DLD-1-hGH cells exhibited significantly higher cell number 
at day 8 with 2.82-fold increase compared to DLD-1-vector cells without 
treatment of PD98059, whereas with the treatment of PD98059, DLD-1-hGH 
cells exhibited only 1.22-fold increased cell number compared with DLD-1-
vector cells at day 8. Similarly, Caco2 stable cells also exhibited a significant 
decrease in total cell number over eight days with the treatment with PD98059 
(Figure 3.11B). Without treatment with PD98059, Caco2-hGH cells exhibited 
significantly higher cell number compared with Caco2-vector cells with 2.66-
fold increase at day 8, whereas with treatment with PD98059, Caco2-hGH 
exhibited only 1.27-fold increase in total cell number compared with Caco2-
vector cells at day 8. These results demonstrated that treatment of PD98059 





Figure 3.11 PD98059 abrogated autocrine hGH-increased cell number in 
colorectal carcinoma cells. 
PD98059 abrogated hGH-induced increase in cell total number in (A) DLD-1 
and (B) Caco2 cells over eight days. The concentration of PD98059 used was 
20µM, and DMSO was used as a control. **P<0.01. 
 
3.2.13 Autocrine hGH promoted cell proliferation via ERK pathway in 
CRC 
As previously demonstrated that autocrine hGH increased cell proliferation in 
CRC cells and I therefore proceeded to examine the role of the ERK pathway 
in autocrine hGH-promoted cell proliferation in CRC cells. The percentage 
nuclear BrdU incorporation in stable cells with or without treatment with 
PD98059 (20µM) was examined using a BrdU incorporation assay (described 
in section 2.3.4). Results were presented as percentage relative to the untreated 
vector cells. Compared with DLD-1-vector cells, DLD-1-hGH cells exhibited 
higher BrdU incorporation to 179% of controls (Figure 3.12A). Treatment 
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with PD98059 significantly reduced the nuclear BrdU incorporation in both 
DLD-1-hGH (92.2% decrease) and DLD-1-vector cells (24.4% decrease) 
compared with their untreated cells respectively. Furthermore, the autocrine 
hGH-stimulated increase in BrdU incorporation in DLD-1 cells was abrogated 
by PD98059 with only 11.2% increase of BrdU incorporation was observed in 
treated group (DLD-1-hGH cells compared to DLD-1-vector cells), whereas 
79% increase in untreated group (DLD-1-hGH cells compared to DLD-1-
vector cells). Similarly, treatment with PD98059 reduced BrdU incorporation 
in both Caco2-hGH (68% decrease) and Caco2-vector (28% decrease) cells 
compared with their untreated cells respectively, and autocrine hGH-
stimulated increase in BrdU incorporation in untreated group (46% increase) 
was also abrogated by PD98059 compared with PD98059-treated group (6.0% 
increase) (Figure 3.12B). These results suggested that autocrine hGH-activated 
ERK pathway regulated cell cycle entry in CRC cells. 
 
 
Figure 3.12 PD98059 abrogated autocrine hGH-mediated cell 
proliferation in colorectal carcinoma cells.  
PD98059 abrogated hGH-stimulated increase in the nuclear BrdU 
incorporation in (A) DLD-1 and (B) Caco2 cells. Cells were incubated in 
BrdU reagent with or without PD98059 (20µM) for 24 hours. Results were 
presented as percentage relative to the respective untreated vector cells. 
**P<0.01. 
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3.2.14 Autocrine hGH suppressed caspase-3/7 activities via the ERK 
pathway in CRC 
As previously demonstrated, autocrine hGH suppressed the caspase-3/7 
activities induced by serum starvation in CRC cells and I therefore examined 
the effect of ERK pathway on autocrine hGH-stimulated abrogation in 
caspase3/7 activities. The activities of caspase-3/7 were measured in DLD-1 
and Caco2 stable cells with or without treatment with PD98059 as described in 
section 2.3.5. The caspase-3/7 activities were presented as percentage relative 
to vector-untreated cells. Compared to DLD-1-vector cells, DLD-1-hGH cells 
exhibited significantly decreased caspase-3/7 activities to 42.3% of control 
(Figure 3.13A). The treatment with PD98059 significantly increased caspase-
3/7 activities to 65.6% in DLD-1-hGH cells and 102.4% in DLD-1-vector 
cells compared to controls (untreated DLD-1-vector cells). However no 
significant difference was observed in DLD-1-vector cells with or without 
treatment of PD98059. Furthermore the decrease in caspase-3/7 activities 
observed in DLD-1-hGH cells compared with DLD-1-vector cells was also 
reduced by treatment with PD98059 from 57.7% to 36.8%. Similarly, forced 
expression of hGH decreased caspase-3/7 activities in Caco2 cells to 64.9% of 
control (untreated Caco2-vector cells) (Figure 3.13B). The treatment with 
PD98059 significantly increased caspase-3/7 activities to 116% in Caco2-
vector cells and 95.9% in Caco2-hGH cells compared to control cells. The 
decrease in caspase-3/7 activities observed in Caco2-hGH cells compared with 
Caco2-vector cells was reduced by treatment with PD98059 from 35.1% to 
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19.8%. These results suggested that autocrine hGH-stimulation of the ERK 
pathway regulated caspase-3/7 activities in CRC cells. 
 
Figure 3.13 PD98059 abrogated autocrine hGH-reduced caspase-3/7 
activities in colorectal carcinoma cells.  
Caspase-3/7 activities were examined in (A) DLD-1 and (B) Caco2 stable 
cells after serum starvation with or without PD98059 for 24 hours. Results 
were presented as percentage relative to the respective untreated vector cells. 
*P<0.05, **P<0.01. 
 
3.2.15 Autocrine hGH enhanced cell anchorage-independent growth via 
ERK pathway 
To determine the effect of ERK activation on autocrine hGH-stimulated 
anchorage-independent growth in colorectal carcinoma cells, PD98059 (20µM) 
was utilized in colony formation in the soft agar colony formation assay. The 
cell viability was presented as percentage relative to vector-untreated cells. 
When cultured in 10% FBS supplemented media, DLD-1-hGH cells exhibited 
significantly increased colony formation to 264.2% compared to controls 
(untreated DLD-1-vector cells) (Figure 3.14A). The treatment with PD98059 
significantly decreased colony formation to 76.4% in DLD-1-vector cells and 
110.7% in DLD-1-hGH cells compared to controls. Furthermore, the increase 
of colony formation observed in DLD-1-hGH cells compared with DLD-1-
vector cells was reduced from 164.2% in untreated group to 34.3% in treated 
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group. Similarly, when cultured in 0.5% FBS supplemented media, the 
treatment with PD98059 significantly decreased colony formation from 100% 
to 70% in DLD-1-vector cells and 281.8% to 83.8% in DLD-1-hGH cells 
compared to controls. The increased colony formation observed in DLD-1-
hGH cells compared with DLD-1-vector cells was also reduced by the 
treatment with PD98059 from 181.8% in untreated group to 13.3% in 
untreated group. Similar results were observed in Caco2 stable cells (Figure 
3.14B). These results suggested that inhibition of ERK activation abrogated 
autocrine hGH-stimulated increase in CRC cell anchorage-independent growth 
in soft agar. 
 
Figure 3.14 PD98059 abrogated autocrine hGH-mediated anchorage-
independent growth in colorectal carcinoma cells.  
(A) PD98059 abrogated autocrine hGH-induced colony formation in soft agar 
in DLD-1 cells in 10% FBS or 0.5% FBS media. (B) PD98059 abrogated 
autocrine hGH-induced colony formation in soft agar in Caco2 cells in 10% 
FBS or 0.5% FBS media. Results were presented as percentage relative to the 
respective untreated vector cells. *P<0.05, **P<0.01. 
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3.2.16 Autocrine hGH enhanced tumor growth of CRC cells in xenograft 
models in vivo 
To further determine the functional potential of hGH in CRC cells in vivo, 
xenograft analysis was performed in collaboration. DLD-1-vector or DLD-1-
hGH cells were subcutaneously injected into the subscapular region of the 
immunodeficient nude mice. Both of the cell lines formed palpable and 
measurable tumors after injection for 20 days. Tumors formed by DLD-1-hGH 
cells grew faster and exhibited a significant greater tumor volume (684.17 
mm3) after 41 days, compared to the tumors formed by DLD-1-vector cells 




Figure 3.15 Autocrine hGH promoted tumor growth of CRC cells in 
xenograft models in vivo. 
Xenograft tumor growth with subcutaneously injection of either DLD-1-vector 
or DLD-1-hGH cells into the subscapular region of nude mice. Tumor 




3.2.17 Autocrine hGH enhanced CRC cell proliferation in xenograft 
models in vivo 
As observed previously, autocrine hGH enhanced cell proliferation in CRC 
cells in vitro. To further examine the function role of hGH in CRC cell 
proliferation in xenograft models in vivo, Ki-67 staining analysis was 
performed in DLD-1-vector and DLD-1-hGH tumor sections (Endl and 
Gerdes, 2000). DLD-1-hGH tumors exhibited a slightly higher percentage of 
Ki-67 positive cells and a significant higher intensity of Ki-67 staining 
compared to DLD-1-vector tumors (Figure 3.16). 
 
 
Figure 3.16 Autocrine hGH promoted CRC cell proliferation in xenograft 
models in vivo. 
Cell proliferation was examined by Ki-67 staining on the sections of tumors 
generated from DLD-1-vector or DLD-1-hGH cells. Images were captured 
under 400 × magnification. *P<0.05. 
 
 
3.2.18 Autocrine hGH decreased CRC cell apoptosis in xenograft models 
in vivo 
As observed previously, autocrine hGH decreased cell apoptosis in CRC cells 
in vitro. To further examine the function role of hGH in CRC cell apoptosis in 
xenograft models in vivo, TUNEL assay was performed in DLD-1-vector and 
DLD-1-hGH tumor sections (Labat-Moleur et al., 1998). DLD-1-hGH tumors 
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displayed a lower percentage of TUNEL-labeled cells than the tumors 




Figure 3.17 Autocrine hGH decreased CRC cell apoptosis in xenograft 
models in vivo. 
Cell apoptosis in xenograft tumors was examined by TUNEL labeling on the 
sections of tumors generated from DLD-1-vector or DLD-1-hGH cells. Images 
were captured under 400 × magnification. **P<0.01. 
 
3.2.19 Autocrine hGH activated ERK1/2 pathway in CRC cells in 
xenograft models in vivo 
As observed previously, autocrine hGH activated ERK1/2 pathway in CRC 
cells in vitro. To further confirm its role in activation of ERK1/2 pathway in 
vivo, IHC analysis was performed to examine the levels of p-ERK1/2 on the 
sections of xenograft tumors. Activation of ERK1/2 results in its accumulation 
in the nucleus, which is essential for ERK1/2 to activate related transcription 
factors and effects on gene expression (Caunt and McArdle, 2012). Increased 
nuclear accumulation of p-ERK1/2 was observed in DLD-1-hGH tumors 
compared with DLD-1-vector tumors (Figure 3.18), which suggested ERK1/2 
was activated by autocrine hGH in DLD-1 cells in xenograft model in vivo.  
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Figure 3.18 Autocrine hGH activated ERK1/2 pathway in DLD-1 cells in 
xenograft models in vivo. 
The phosphorylation levels of ERK1/2 were examined by IHC analysis on the 
sections of tumors generated from DLD-1-vector or DLD-1-hGH cells after 
subcutaneously injection. Images were captured under 400 × magnification. 
 
3.3 Discussion 
IHC and ISH data in this study demonstrated a localized expression of hGH in 
colorectal carcinomas. Statistical analysis of hGH mRNA expression in 101 
colorectal carcinoma patient samples and 20 normal tissue samples 
demonstrated a more frequent expression of hGH in colorectal carcinoma 
compared with the normal colorectal tissues. Furthermore, this localized 
expression of hGH (mRNA) in colorectal carcinomas was associated with 
larger tumor size and lymph node metastasis. Similar association of localized 
expression of hGH and worse clinical outcomes has been demonstrated in 
mammary and endometrial carcinomas (Wu et al., 2011). The localized 
expression of hGH in mammary has been demonstrated to be positively 
associated with tumor stage and lymph nodes metastasis, and positively 
associated with FIGO grade, myometrial invasion and ovarian metastasis in 
endometrial carcinoma. These clinical findings suggested an oncogenic role of 
locally produced hGH in cancer progression, as well as in CRC progression. 
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In order to examine the effect of autocrine hGH on colorectal carcinoma cell 
oncogenicity in vitro, I generated a cell-based model, in which cells were 
stably transfected with a vector containing the full length of hGH gene. This 
cell-based model forced cells to produce hGH in an autocrine manner with 
continuous expression, which is different from endocrine hGH that acts in a 
pulsatile fasion.  The essential role of sustained expression of hGH on cancer 
cell oncogenicity has been demonstrated in some studies. Zhu et al. have 
observed that exogenous hGH temporarily activates p44/42 MAPK, whereas 
autocrine hGH can maintain the activation of p44/42 MAPK (Zhu et al., 
2005b). Such sustained activation of p44/42 MAPK by autocrine hGH is 
required for the transcription of certain genes involved in oncogenicity (Zhu et 
al., 2002, York et al., 1998). This model system was previously used in our 
laboratory to investigate the oncogenic effect of autocrine hGH on mammary 
and endometrial carcinomas. Forced expression of hGH in mammary and 
endometrial carcinomas significantly promotes cell proliferation with 
increased cell number and BrdU incorporation, cell survival with reduced 
apoptotic cells and anchorage-independent growth in soft agar (Mukhina et al., 
2004, Pandey et al., 2008, Brunet-Dunand et al., 2009).  
In this study, I demonstrated autocrine hGH enhanced oncogenicity in 
colorectal carcinoma cells with increased proliferation, reduced cell apoptosis 
and increased anchorage-independent cell growth in vitro. Additionally, 
autocrine hGH promoted tumor growth, proliferation and survival of CRC 
cells in xenograft model in vivo. These functional effects of hGH on 
oncogenicity have also been demonstrated in other studies. In mammary 
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carcinoma, autocrine hGH has been indicated to enhance MCF-7 cells 
anchorage-independent growth and increase cell number in suspension culture 
(Zhu et al., 2005a). Furthermore, autocrine hGH stimulates oncogenic 
transformation of immortalized human mammary epithelial cells with 
increased mitogenesis, reduced apoptotic cell death and enhanced anchorage-
independent cell growth in vitro, and tumor growth in vivo, which strongly 
supported the oncogenic role of autocrine hGH in mammary carcinomas (Zhu 
et al., 2005a).  
Binding of GH to the GHR results in activation of signal transduction 
pathways that are critical for cell proliferation and survival including 
JAK2/STATs, MAPK and PI-3K pathways (Perry et al., 2006, Le Roith et al., 
2001). In other studies, Tang et al. demonstrated that STAT3 mediated 
autocrine hGH-induced oncogenicity in human endometrial carcinoma (EC) 
cells (Tang et al., 2010a). Furthermore, activated STAT3 not only increased 
cell proliferation, anchorage-independent and xenograft growth, but also 
promoted EMT and invasiveness in EC cells (Tang et al., 2010a). However, no 
significant changes in activated STAT3 were detected in my study, whereas 
activation of the MAPK/ERK pathway was observed in the CRC cells with 
forced expression of hGH both in vitro and in vivo. The inhibition of ERK 
activity with PD98059 significantly suppressed autocrine hGH-stimulated cell 
proliferation, cell survival and anchorage-independent growth in CRC cells. 
This involvement of MAPK/ERK in cancer cell oncogenicity has also been 
indicated in other studies (Cerezo et al., 2009, Zhu et al., 2005b). It is 
postulated that the activation of the MAPK pathway in cell proliferation might 
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refer to its regulation of Cyclin D1, which is required for cell cycle 
progression (Du et al., 2013, Zhang and Liu, 2002).  
In addition to hGHR, hGH can also stimulate the activation of hPRLR, and the 
signaling pathways involved are also similar to that at hGHR (Bole-Feysot et 
al., 1998). Furthermore, it has been demonstrated that hPRLR is commonly 
expressed in CRC, and its expression is significantly associated with tumor 
progression including tumor size and grade (Harbaum et al., 2010). All of the 
three CRC cell lines used in this study (DLD-1, HT-29 and Caco2 cells) 
exhibited detectable expression of hPRLR. However no detectable expression 
of hGHR was observed in DLD-1 cells. The absence of hGHR in DLD-1 cells 
potentially suggests that autocrine hGH-mediated oncogenicity in this cell line 
is most probably mediated through the hPRLR instead of the hGHR. In 
addition, another hPRLR-binding hormone human prolactin (hPRL), which is 
also a pituitary derived hormone as hGH, has an essential role in human 
tumorogenesis (Fernandez et al., 2010) . It has been demonstrated that the 
expression of hGH combined with the expression of hPRL in mammary and 
endometrial carcinoma is associated with worse clinical outcomes with lower 
relapse-free survival (RFS) and overall survival (OS) in patients compared 
with hGH alone (Wu et al., 2011), suggesting a combinatorial role of hPRL 
and hGH on breast and endometrial cancer progression. In colorectal cancer, 
elevated serum levels of hPRL has been demonstrated in patients with CRC 
(Otte et al., 2003), and the expression of hPRL also has been detected in 
colorectal normal tissue and carcinomas, however no significant increased 
expression of hPRL has been observed in colorectal carcinomas compared 
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with normal colorectal tissues (Neradugomma et al., 2014). Thus, the 
interaction of hPRL in autocrine hGH-induced oncogenicity in CRC cells 
needs further investigation. 
The effect of autocrine hGH on oncogenicity may be mediated by hGH-
induced mediators such as other growth factor. IGF-1 is thought to be the 
predominant mediator of the actions of endocrine hGH (Perry et al., 2006). 
However, it is likely that mammary carcinoma cells secreted hGH has both 
autocrine and paracrine effects on neighbouring cells, and also results in 
secretion of IGF-1, which thereby enhances the oncogenic effect of autocrine 
hGH (Perry et al., 2006). Similarly, addition of exogenous IGF-1 to MCF-7 
cells with forced expression of hGH significantly promoted cell proliferation 
(Kaulsay et al., 1999), and systemic administration of hGH and IGF-1 greatly 
promotes mammary epithelial cell proliferation in rhesus monkeys compared 
to the administration of either hormone alone (Ng et al., 1997). Furthermore, it 
has been demonstrated that the expression of IGF-1 and IGF-1R is increased 
in CRC, and significantly correlated with tumor size and depth of invasion 
(Shiratsuchi et al., 2011), suggesting a potential effect of IGF-1 in autocrine 
hGH-stimulated oncogenicity in CRC. 
In addition to IGF-1, numbers of soluble secreted peptide factors which are 
regulated by autocrine hGH also may contribute to the oncogenic progression, 
such as trefoil factor 3 (TFF3) (Perry et al., 2006). Elevated serum level of 
TFF3 has been observed in patients with colorectal carcinoma, especially 
colorectal carcinoma with metastasis (Huang et al., 2013). Furthermore, 
localized expression of TFF3 is also associated with lymph node metastasis in 
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CRC, suggesting a potential role of TFF3 in colorectal carcinogenesis (Huang 
et al., 2013). It has demonstrated that the knockdown of TFF3 abrogates 
autocrine hGH-stimulated oncogenicity in mammary carcinoma cells (Xu et 
al., 2005), suggesting the potential effect of TFFs in hGH-induced 
oncogenicity in carcinomas. Furthermore, Xu et al. have indicated that 
autocrine hGH-stimulated oncogenic transformation is regulated by TFF3 in 
immortalized human mammary epithelial cells (Xu et al., 2005). Another 
mechanism for autocrine hGH to stimulate oncogenicity is regulation of 
secreted peptides involved in cell cycle and apoptosis. Autocrine hGH has 
been demonstrated to downregulate the expression of p53-regulated placental 
transformating growth factor (PTGF-β) to stimulate the expression of cyclin 
D1 required for cell cycle progression (Graichen et al., 2002). One of the 
homeodomain containing transcription factors, Homeobox A1 (HOXA1), is 
also regulated by autocrine hGH (Zhang et al., 2003). HOXA1 itself is a 
potent oncogene in mammary carcinomas and stimulates oncogenic 
transformation of immortalized human mammary epithelial cells 
(Mohankumar et al., 2007). The expression HOXA1 induced by autocrine 
hGH has been demonstrated to promote proliferation by upregulating of cyclin 
D1, c-myc, and increase cell survival by upregulating Bcl-2 (Zhang et al., 
2003).  
Thus, autocrine hGH promotes oncogenicity in carcinomas via multiple 
mechanisms, which can be directly stimulated by hGH signaling pathways, 
and also indirectly by other hGH-induced factors. Therapeutic strategies 
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targeting hGH signaling pathways or hGH-induced factors may therefore 
contribute to a better clinical outcome of CRC. 
 
3.4 Summary and conclusion 
In summary, hGH was expressed in colorectal carcinomas and its expression 
was positively associated with tumor size and lymph nodes metastasis. The 
expression of hGH and receptors binding hGH (hGHR or hPRLR) were 
observed in DLD-1, HT-29 and Caco2 wild type cells, which were later used 
to generate cell-based models to study the functional role of autocrine hGH on 
CRC progression. Forced expression of hGH in CRC cells significantly 
increased cell total number in both 10% FBS and 0.5% FBS supplementary 
media, promoted cell proliferation and reduced cell apoptosis. Furthermore, 
forced expression of hGH in CRC cells promoted foci formation and cell 
anchorage-independent growth in soft agar. Additionally, autocrine hGH 
activated ERK1/2 in CRC cells, and the inhibition of p-ERK1/2 by the 
treatment with PD98059 significantly abrogated autocrine hGH-stimulated 
increase in cell total number, proliferation, survival, foci formation and 
anchorage-independent growth in CRC cells. Moreover, autocrine hGH also 
promoted tumor growth of CRC cells with increased cell proliferation and 
survival in xenograft models in vivo. These results suggested autocrine hGH 
promoted oncogenicity in CRC both in vitro and in vivo. The effect of 




Chapter 4 Autocrine hGH stimulates EMT and metastatic 
potential in colorectal carcinoma cells 
 
4.1 Introduction 
The epithelial to mesenchymal transition (EMT) is a process by which 
epithelial cells lose cell-cell junctions and acquire the mesenchymal 
characteristics with invasive and motile properties (Thiery et al., 2009). EMT 
plays a critical role in embryonic development, adult tissue regeneration and 
repair, as well as cancer progression to promote the epithelial tumors leading 
to metastatic carcinomas (Thiery et al., 2009). Loss of epithelial cell adhesion 
molecule E-CADHERIN is one of the hallmarks of EMT (Yilmaz and 
Christofori, 2009), which is balanced by the increased expression of 
mesenchymal marker N-CADHERIN, resulting in a switch that modulates cell 
adhesion (Lamouille et al., 2014). Previous studies from our laboratory have 
demonstrated that autocrine hGH promotes EMT with altered cell morphology 
from an epithelial phenotype to a mesenchymal phenotype, increased cell 
migration and invasion, as well as the upregulation of mesenchymal markers 
and downregulation of epithelial markers in mammary carcinoma cells 
(Mukhina et al., 2004). Additionally, autocrine hGH has been recently 
demonstrated to promote EMT in endometrial carcinoma cells with 
phenotypic conversion, accompanied with the expression changes of the genes 
involved in EMT (Pandey et al., 2008).  
In addition, EMT is thought to be essential in cancer cell metastasis, where 
cancer cells detach from the primary tumor site and disseminate to other tumor 
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sites. EMT decreases cellular contacts and increases cell motility, allowing 
cancer cells to break through the basement membrane and invade into 
neighbouring tissues. The potential association of hGH and metastasis has 
been demonstrated in patients with mammary and endometrial carcinomas, in 
which the expression of hGH has been clinically associated with lymph node 
metastasis in these patients, resulting in poor survival outcomes (Wu et al., 
2011). As presented in chapter 3 of this thesis, the hGH expression was also 
significantly correlated with lymph nodes metastasis in the patients with 
colorectal carcinoma, which suggested a potential metastatic function of 
autocrine hGH in CRC progression. Thus, in this chapter, I investigated the 




4.2.1 Autocrine hGH altered the cellular morphology of CRC cells 
During cancer progression, increased invasiveness of carcinoma cells is 
commonly accompanied with phenotypic conversion including the changes in 
cell morphology, cell motility and gene expression (Thiery, 2002). In order to 
investigate the potential role of hGH in phenotypic conversion of CRC cells, I 
firstly examined the morphologic change in CRC cells with forced expression 
of hGH. In monolayer adherent culture, DLD-1-vector cells exhibited 
polygonal in shape with regular dimensions and grew in colonies with tight 
cellular contact (Figure 4.1A) and which is similar to their parental DLD-1 
wild type cells (data not shown). However, forced expression of hGH in DLD-
1 cells altered this epithelial-like morphology. DLD-1-hGH cells exhibited 
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elongated and irregular in shape with multiple cellular protrusions, appearing 
as a mesenchymal-like phenotype. Furthermore, the colonies formed by DLD-
1-hGH cells exhibited a more scattered morphology with loss of cellular 
contact, which was much different from the monolayer colonies formed by 
DLD-1-vector cells. Altered morphology was also observed in Caco2 cells 
with forced expression of hGH (Figure 4.1B). Caco2-vector cells formed 
circular colonies whereas Caco2-hGH cells formed irregular colonies with 
multiple cellular protrusions at the colony edge. 
 
 
Figure 4.1 Autocrine hGH modulated cellular morphology of colorectal 
carcinoma cells.  
(A) Autocrine hGH alters monolayer adherent morphology in DLD-1 cells. (B) 
Autocrine hGH alters colony morphology in Caco2 cells. Cultures were 




4.2.2 Autocrine hGH altered the organization of filamentous actin 
cytoskeleton in CRC cells 
The organization of actin cytoskeleton is associated with cell morphology, cell 
migration and adhesive properties (Hotulainen and Lappalainen, 2006). To 
determine the effect of autocrine hGH on cellular morphologic alteration, I 
examine the organization of the filamentous actin (F-actin) in DLD-1 stable 
cells (Figure 4.2). DLD-1-vector cells exhibited well-organized stress fiber 
near the cell periphery, as well as in cytoplasm with regular appearance of 
stress fibers. In contrast, DLD-1-hGH cells displayed accumulated F-actin at 
the cell periphery, loss of well-organized stress fibers in the cytoplasm and 
formed multiple lamellipodial protrusions at the leading edges. Similar results 
were observed in Caco2 stable cells (Figure 4.3). The reorganization of the 
actin cytoskeleton including the formation of lamellipodial protrusions, which 
provide the driving force of cell migration (Ballestrem et al., 2000), suggested 




Figure 4.2 Autocrine hGH modulated the organization of filamentous 
actin cytoskeleton in DLD-1 cells  
Autocrine hGH modulated the organization of F-actin in DLD-1 cells and 
stimulated formation of lamellipodial protrusions (arrows) at the leading edges. 
Cells were stained for F-actin by rhodamine phalloidin (red) and DAPI (blue), 
and images were obtained with confocal fluorescence microscope. Bar, 20 µm. 
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Figure 4.3 Autocrine hGH modulated the organization of filamentous 
actin cytoskeleton in Caco2 cells  
Autocrine hGH modulated the organization of F-actin in Caco2 cells and 
stimulated formation of lamellipodial protrusions (arrows) at the leading edges. 
Cells were stained for F-actin by rhodamine phalloidin (red) and DAPI (blue), 
and images were obtained with confocal fluorescence microscope. Bar, 20 µm. 
 
4.2.3 Autocrine hGH promoted cell scattering in CRC cells 
As the results observed above, DLD-1-hGH cells exhibited distinct cell 
morphology and formed more scattered colonies compared with DLD-1-vector 
cells. Cell scattering has been considered to indicate a migratory behavior of 
cells (Chen, 2005). In order to examine the effect of autocrine hGH on cell 
scattering properties, a colony-scattering assay was performed in DLD-1 
stable cells. In this experiment, cells were seeded at low density, and colonies 
were counted based on different categories (described in section 2.3.10). As 
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shown in Figure 4.4A, more than 20% of the colonies formed by DLD-1-hGH 
were scattered colonies, which was significantly higher than the percentage 
scattered colonies observed in DLD-1-vector cells (10%). The percentage of 
loose colonies formed by DLD-1-hGH (52.34%) was also significantly higher 
than DLD-1-vector cells (36.57%). A large proportion of compact colonies 
(53.42%) were observed in DLD-1-vector cells, whereas only 26.9% of 
colonies in DLD-1-hGH cells could be designated as compact. However, no 





Figure 4.4 Autocrine hGH promoted cell scattering in DLD-1 cells 
(A) Autocrine hGH increases colony scattering in DLD-1 cells. Cells were 
seeded at a very low density, and colonies formed by these cells were counted 
dependent on different category. (B) Colony morphology in DLD-1 and Caco2 




4.2.4 Autocrine hGH promoted CRC cell spreading and migration on 2D 
Matrigel 
Autocrine hGH-increased cell scattering suggesting a potential role of hGH in 
CRC cells in cell migratory behavior in monolayer culture, 2D Matrigel assays 
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were performed in CRC cells to determine the effect of autocrine hGH on cell 
migration on Matrigel, (Figure 4.5). Matrigel utilized in this 2D assay is a 
solubilized BM preparation extracted from the mouse sarcoma, which aims to 
resemble the complex extracellular environment in real tissues and allows the 
in vitro modeling of cell behaviors (Benton et al., 2009). DLD-1-vector cells 
grew as circular colonies when cultured on 2D Matrigel, whereas colonies 
formed by DLD-1-hGH cells exhibited a stellate organization with numerous 
protrusions, which were formed by the migrated cells extended from the main 
bulk of the colonies (Figure 4.5A). Similarly, colonies formed by Caco2-
vector cells on 2D Matrigel exhibited a rounded and regular organization, 
whereas the colonies formed by Caco2-hGH cells exhibited an irregular shape 
with several protrusions on the edge of colonies (Figure 4.5A). Additionally, 
cell viability of DLD-1 and Caco2 stable cells on 2D Matrigel growth was 
examined by AlamarBlue assay (Figure 4.5B). DLD-1-hGH cell growth on 2D 
Matrigel exhibited higher cell viability of 220% compared with DLD-1-vector 
cells (100%). Similarly, Caco2-hGH cells also exhibited increased cell 







Figure 4.5 Autocrine hGH increased colorectal carcinoma cell growth on 
2D Matrigel.  
(A) DLD-1 and Caco2 stable cells were grew on 2D Matrigel and stained with 
F-actin. Forced expression of hGH in CRC cells resulted in a distinct colonic 
morphology with numerous protrusions on the edge of the colonies (arrows) 
compared to vector cells. Images were captured under 40 × magnification 
(DLD-1) or 200 × magnification (Caco2). Bar, 200 µm (DLD-1), 50 µm 
(Caco2). (B) Cell viability on 2D Matrigel was measured by AlamarBlue 
assays. Results of cell viability were presented as percentage relative to the 




4.2.5 Autocrine hGH promoted CRC cell migration in wound healing 
assay 
To verify the effect of autocrine hGH on cell migration, a “wound healing” 
assay was also performed in CRC stable cells. In the wound healing assay, 
autocrine hGH stimulated DLD-1 and Caco2 cell migration with a more rapid 
closing of wound (Figure 4.6). After 24 hours, the space of the open wound 
was almost closed by DLD-1-hGH cells, while DLD-1-vector cells were 
unable to close the wound completely. Similarly, Caco2-hGH cells closed the 
wound completely after 48 hours, whereas the wound remained unclosed by 
Caco2-vector cells at the same time point. 
 
 
Figure 4.6 Autocrine hGH promoted wound healing in colorectal 
carcinoma cell.  
Autocrine hGH promotes DLD-1 and Caco2 cell motility in wound healing 




4.2.6 Autocrine hGH promoted cell migration in migration assay 
Transwell migration assays were also utilized to determine the migratory 
potential of autocrine hGH on CRC cells and performed as described in 
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section 2.3.11. After 48 hours, the relative numbers of DLD-1-hGH cells 
migrating through the transwell chambers increased significantly by 35% as 
compared with DLD-1-vector cells (Figure 4.7). Similarly, increased numbers 
of migrating cells were observed in HT-29-hGH cells (225%) and Caco2-hGH 




Figure 4.7 Autocrine hGH increased cell migration in transwell migration 
assay  
DLD-1, HT-29 and Caco2 stable cell migration was examined in transwell 
migration assay after incubating for 48 hours. Migrating cells were stained 
with Hoechst 33342 and counted under fluorescence microscope. Results were 
presented as percentage relative to the respective vector cells. **P<0.01. 
 
 
4.2.7 Autocrine hGH promoted colorectal carcinoma cell growth in 3D 
Matrigel 
3D culture in basement membrane matrix is widely utilized to stimulate the in 
vivo cell behavior in vitro, including cell invasion (Benton et al., 2009). To 
investigate the effect of autocrine hGH on 3D cell growth and invasion, 3D 
Matrigel cell culture was performed with CRC cells. The cell viability of 
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DLD-1, HT-29 and Caco2 stable cells in 3D culture was determined by use of 
the AlamarBlue assay (Figure 4.8A). DLD-1-hGH cells in 3D culture 
exhibited significantly higher cell viability (212%) compared with DLD-1-
vector cells. Similarly, increased cell viability was observed in HT-29-hGH 
cells (158 %) and Caco2-hGH cells (320%) in 3D culture compared with their 
respective vector cells. Additionally, most of the colonies formed by DLD-1-
vector cells in 3D Matrigel exhibited spheroidal morphology, whereas most of 
the colonies generated by DLD-1-hGH cells did not displayed a spheroidal 
organization, but rather an irregular organization with multiple protrusions 
(Figure 4.8B). The formation of protrusions resulted from the extension of 
cancer cells from the main bulk of the colonies. However, no protrusion 
formation was observed in Caco2-hGH cells, and the colony morphology of 





Figure 4.8 Autocrine hGH increased colorectal carcinoma cell growth in 
3D Matrigel.  
(A) Cell viability in 3D Matrigel assays was measured by AlamarBlue assays. 
Results were presented as percentage relative to the respective vector cells. (B) 
DLD-1 and Caco2 stable cells were grew in 3D Matrigel. Imaged were 
captured under 40 × magnification. Bar, 100 µm. *P<0.05, **P<0.01. 
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4.2.8 Autocrine hGH promoted CRC cell invasion in a transwell invasion 
assay 
To ascertain the invasive potential of autocrine hGH in CRC cells, transwell 
invasion assays were also performed as described in section 2.3.11. In this 
assay, the number of cells that invaded through the layer of Matrigel was 
counted under the microscope. Increased numbers of invaded cells were 
observed in DLD-1-hGH cells compared to DLD-1-vector cells (6.65-fold 
increase) (Figure 4.9). Similarly, the numbers of HT-29-hGH invaded cells 
were 2.25-fold higher than HT-29-vector cells, and the number of Caco2-hGH 
invaded cells were also significantly increased compared with Caco2-vector 




Figure 4.9 Autocrine hGH increased cell invasion in transwell invasion 
assay  
DLD-1, HT-29 and Caco2 stable cell invasion was examined in transwell 
invasion assay after incubating for 48 hours. Invading cells were stained with 
Hoechst 33342 and counted under fluorescence microscope. Results were 




4.2.9 Autocrine hGH promoted CRC cells attachment to, and 
transmigration through, an endothelial cell layer 
Dissemination of carcinoma cells into the circulation via intravasation is 
essential for the progression of metastasis (Chaffer and Weinberg, 2011). To 
determine the effect of autocrine hGH on this subsequent step in the metastatic 
cascade, I examined the abilities of DLD-1-vector and DLD-1-hGH cells to 
attach to, or trans-migrate through, an endothelial cell layer. 
In the endothelial adhesion assay, CellTraceTM Calcein Green labeled DLD-1 
stable cells were seeded on the surface of Calcein Red-Orange labeled human 
umbilical vein endothelial cell (HUVEC) layer, and the numbers of the cells 
that attached on the surface of the HUVEC cell layer were counted under the 
fluorescence microscope (Figure 4.10). The number of DLD-1-hGH cells 
attached to the HUVEC layer was significantly higher than DLD-1-vector 




Figure 4.10 Autocrine hGH stimulated colorectal carcinoma cell 
attachment to endothelial cell layer.  
(A) Forced expression of hGH in DLD-1 cells promoted adhesion to a cell 
layer of human umbilical vein endothelial cells (HUVECs). HUVEC cells 
were grown to near 100% confluence in 24-well plates and labeled with 
CellTraceTM Calcein Red-Orange. CellTraceTM Calcein Green labeled DLD-1-
hGH and DLD-1-vector cells were seeded on top and washed after one hour’s 
incubation. Images were visualized by fluorescence microscopy under 400 × 
magnification. Bar, 200 µm. (B) The numbers of DLD-1-hGH and DLD-1-
vector cells that attached to the HUVEC cell layer were counted under 
fluorescence microscope. Results were presented as percentage relative to the 
vector cells. **P<0.01. 
 
To determine the effect of autocrine hGH on cell transmigration through the 
endothelial cell layer, Calcein Green labeled DLD-1 stable cells were seeded 
in the transwell insert which was previously covered with a HUVEC layer 
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(100% confluent), and the number of the cells that transmigrated through the 
HUVEC layer were counted under fluorescence microscope (Figure 4.11). The 
number of DLD-1-hGH cells transmigrated through the HUVEC cell layer 
was significantly higher than DLD-1-vector cells with a 1.58-fold increase. 
 
 
Figure 4.11 Autocrine hGH stimulated colorectal carcinoma cells trans-
migration through endothelial cell layer.  
Forced expression of hGH in DLD-1 cells promoted transmigration through 
the cell layer of human umbilical vein endothelial cells (HUVECs). HUVEC 
cells were grown to near 100% confluence in transwell inserts and 
CellTraceTM Calcein Green labeled DLD-1-hGH and DLD-1-vector cells were 
seeded on top of HUVECs. The numbers of DLD-1-hGH and DLD-1-vector 
cells that transmigrated through the HUVEC cell layer were counted after 48 
hours under fluorescence microscope. Results were presented as percentage 
relative to the vector cells. **P<0.01. 
 
4.2.10 Autocrine hGH regulated the expression of genes involved in EMT 
and metastatic progression in CRC cells 
It was previously demonstrated in the earlier sub-section at chapter 4 that 
autocrine hGH altered cell morphology and promoted a mesenchymal 
phenotype with increased cell migration and invasion, suggesting that 
autocrine hGH might possess a potential function in stimulating EMT in 
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colorectal carcinoma cells. In addition, the correlation between endogenous 
hGH in colorectal carcinoma and lymph node metastasis (data described in 
section 3.2.1.2) also suggested a potential role of autocrine hGH in metastatic 
progression. In order to determine the potential role of hGH in EMT and 
metastastic progression, I performed quantitative-PCR (qPCR) analysis to 
examine the RNA expression of genes functionally involved in EMT and 
metastatic progression. As shown in Table 4.1, the epithelial marker gene 
CDH1 was significantly decreased in DLD-1-hGH cells and Caco2-hGH cells 
with 0.12-fold and 0.10-fold changes relative to its vector cells respectively. 
Similarly, OCLN was also decreased in DLD-1-hGH and Caco2-hGH cells 
with 0.26-fold and 0.16-fold changes relative to its vector cells respectively. 
Simultaneously, the mesenchymal marker gene VIM was observed to increase 
in both DLD-1-hGH (8.5-fold increase) and Caco2-hGH cells (3.44-fold 
increase) compared with the respective vector cells. Similarly, the expression 
of FN1 was elevated in DLD-1-hGH cells and Caco2-hGH cells with 6.58-fold 
increase and 10.55-fold increase compared with the respective vector cells 
respectively. Moreover, 5.22-fold increase and 28.18-fold increase of CDH2 
were observed in DLD-1-hGH and Caco2-hGH cells compared with the 
respective vector cells. The qPCR data also revealed a 12.42-fold increase and 
6.49-fold increase of IGF-1 in DLD-1-hGH and Caco2-hGH cells compared to 
its vector cells respectively. However, the transcriptional factor TWIST1 was 
observed to be up-regulated only in Caco2-hGH cells with a 5.71-fold increase 
compared with Caco2-vector cells, while SNAI1 was observed to be increased 
only in DLD-1 cells with forced expression of hGH (3.85-fold increase) 
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compared with vector cells. Interestingly, several metastatic marker genes 
MMP9, MTA1, MTA2, NME1 were significantly elevated in DLD-1-hGH cells 
with a 7.72-fold, 1.97-fold, 2.21-fold, 2.24-fold increase respectively when 
compared with DLD-1-vector cells. The expression of metastatic markers 
MET (4.33-fold increase), MMP2 (4.01-fold increase), PLAU (7.16-fold 
increase) and PLAUR (20.49-fold increase) were observed in Caco2-hGH cells 
when compared with Caco2-vector cells 
Table 4.1. qPCR analysis of the effect of forced expression of hGH in 
colorectal carcinoma cells on expression of genes involved in EMT and 
metastatic progression 







Epithelial CDH1 0.12 9.18E-05 0.10 0.0285 
 
OCLN 0.26 1.84E-04 0.16 0.0118 
 
CTNNA1 1.54 2.58E-04 0.73 0.0062 
 
CTNNB1 0.94 6.21E-03 0.80 0.0218 
 
CTNND1 2.17 3.55E-03 0.37 0.0286 
Mesenchymal TWIST1 1.15 2.72E-03 5.71 0.0043 
 
VIM 8.5 1.09E-03 3.44 0.0216 
 
FN1 6.58 1.47E-03 10.55 0.0260 
 
CDH2 5.22 5.33E-03 28.18 0.0108 
 
SNAI1 3.85 9.57E-04 1.52 0.2038 
 
SNAI2 1.15 1.06E-01 2.57 0.3227 
 
IGF-1 12.42 1.96E-03 6.49 0.0162 
 
ZEB1 1.27 2.60E-02 2.00 0.4663 
 
ZEB2 1.13 3.88E-02 1.84 0.6589 
Metastatic MET 1.69 8.65E-05 4.33 0.0297 
 
MMP2 1 4.46E-01 4.01 0.0359 
 
MMP9 7.72 5.24E-03 3.61 0.1914 
 
MTA1 1.97 5.19E-05 6.70 0.1663 
 
MTA2 2.21 5.53E-04 0.88 0.1341 
 
NME1 2.24 2.48E-04 2.55 0.1546 
 
PLAU 0.82 4.73E-02 7.16 0.0163 
 
PLAUR 0.91 3.32E-02 20.49 0.0080 
Results are represented as a fold change in mRNA levels in DLD-1-hGH or 
Caco2-hGH cells relative to the respective vector cells. 
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4.2.11 Autocrine hGH regulated the protein expression of EMT markers  
The data presented in Table 4.1 suggested forced expression of hGH in 
colorectal carcinoma cells regulated the RNA expression of several marker 
genes involved in EMT and metastatic progression. Hence, protein levels of 
these markers were also examined by western blot analysis (Figure 4.12). The 
mesenchymal marker FN1 was detected as a 262kDa protein in both DLD-1 
and Caco2 cells, and the expression levels of FN1 were higher in DLD-1-hGH 
and Caco2-hGH cells compared with DLD-1-vector and Caco2-vector cells 
respectively. E-CADHERIN was also detected in both DLD-1 and Caco2 cells 
as an 110kDa protein, and its protein expression levels were significantly 
decreased in DLD-1-hGH and Caco2-hGH cells compared with the respective 
vector cells. Similarly, the expression of OCCLUDIN, which was detected at 
59kDa in both DLD-1 and Caco2 cells, was also observed to decrease in the 
cells with forced expression of hGH when compared with the respective 
vector cells. VIMENTIN was detected as a 54kDa protein in Caco2 cells, and 
its expression level was higher in Caco2-hGH cells than Caco2-vector cells. 
However, no detectable protein expression of VIMENTIN was observed in 
DLD-1 cells. β-ACTIN, which was detected as a 42kDa protein in DLD-1 and 





Figure 4.12 Autocrine hGH regulated the protein expression of EMT 
markers.  
(A) Autocrine hGH in DLD-1 cells increased the protein expression of FN1 
and decreased the protein expression of E-CADHERIN and OCCLUDIN. (B) 
Autocrine hGH in Caco2 cells increased the protein expression of FN1 and 
VIMENTIN, and decreased the protein expression of E-CADHERIN and 
OCCLUDIN. β-ACTIN was used as an input control. The sizes of detected 
protein bands were shown on the right side. kDa, kiloDalton.  
 
4.2.12 Autocrine hGH regulated the localization of E-CADHERIN in 
CRC cells 
As described above, the protein expression of E-CADHERIN was decreased 
in the CRC cells with forced expression of hGH. Thus the localization of E-
CADHERIN was also examined in CRC stable cells. E-CADHERIN in DLD-
1 and Caco2 stable cells was localized by use of confocal laser scanning 
microscopy by use of an E-CADHERIN primary antibody and a FITC-
conjugated secondary antibody (Figure 4.13). Nuclear staining with DAPI was 
used as an in-cell reference point. Cell membrane and intercellular contact 
localization of E-CADHERIN was detected in DLD-1-vector and Caco2-
vector cells, whereas forced expression of hGH in DLD-1 and Caco2 resulted 
in decreased cell membrane and cellular contact localization of E-CADHERIN. 
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Thus, autocrine hGH regulated both expression and cell membrane 
localization of E-CADHERIN in CRC cells. 
 
Figure 4.13 Autocrine hGH regulated the localization of E-CADHERIN in 
CRC cells 
DLD-1 and Caco2 stable cells were fixed and stained with E-cadherin 
antibodies followed by fluorescent dye-tagged secondary antibodies. DAPI 
was used to stain nuclei. E-cadherin (green), and DAPI (blue) were visualized 
by confocal fluorescence microscopy under 1000 × magnification. Bar, 20 µm. 
 
4.2.13 Autocrine hGH promoted wound healing via ERK pathway in 
CRC 
I previously demonstrated that autocrine hGH promoted cell migration in the 
wound healing assay and the MAPK/ERK pathway has been demonstrated to 
mediate migration of various cell types (Huang et al., 2004), thus I performed 
the same assay in DLD-1 stable cells with or without treatment with PD98059 
to determine the effect of activated ERK1/2 on autocrine hGH-increased cell 
migration. In the control group (without treatment of PD98059), DLD-1-hGH 
cells exhibited increased cell migration to close the wound completely after 24 
hours, whereas DLD-1-vector cells were unable to close the wound 
completely (Figure 4.14). However, upon treatment with PD98059, it was 
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observed that DLD-1-hGH cells were unable to close the wound after 24 hours. 
These results suggested that autocrine hGH-stimulated activation of the ERK 
pathway promoted cell migration in wound healing in CRC cells. 
 
 
Figure 4.14 Autocrine hGH promoted wound healing via ERK pathway in 
colorectal carcinoma cell.  
PD98059 abrogated autocrine hGH-promoted cell migration in a wound-
healing assay. Cells were cultured in 10% FBS supplementary media with or 
without PD98059 (20 µM). Wounded areas (between the straight lines) were 
imaged under 100 × magnification.  
 
 
4.2.14 Autocrine hGH promoted cell migration via ERK pathway in CRC 
In order to determine the function of ERK activation in hGH-mediated cell 
migration, transwell migration assays were also performed in both DLD-1 and 
Caco2 stable cells. In this experiment, cells were seeded in the transwell 
inserts and treated with PD98059 (20 µM) or with DMSO as control, and the 
number of migrated cells was counted after 24 hours. Cell migration was 
presented as percentage relative to untreated-vector cells. Compared with 
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untreated DLD-1-vector cells (100%), the untreated DLD-1-hGH cells 
exhibited significantly increased cell migration (relative cell number) to 
165.5% of controls (Figure 4.15A). The treatment with PD98059 significantly 
decreased cell migration to 65.7% in DLD-1-vector cells and 84.2% in DLD-
1-hGH cells compared to controls. Furthermore, this increased cell migration 
observed in DLD-1-hGH cells compared with DLD-1-vector cells was 
reduced in the presence of PD98059 from 65.5% to 18.5% of controls. 
Similarly, Caco2 cells with forced expression of hGH exhibited increased cell 
migration to 216.6% compared to control cells (untreated Caco2-vector cells), 
and the treatment with PD98059 significantly decreased cell migration to 
48.1% in Caco2-vector and 60.2% in Caco2-hGH cells compared to controls 
(Figure 4.15B). Moreover, this increased cell migration observed in Caco2-
hGH cells compared to Caco2-vector cells was reduced by the treatment with 
PD98059 with a 116.6% increase in untreated group whereas a 12.1% increase 
in the treated group. These results suggested that autocrine hGH-stimulated 




Figure 4.15 PD98059 abrogated autocrine hGH-increased cell migration 
in CRC cells 
PD98059 abrogated autocrine hGH-increased cell migration in (A) DLD-1 and 
(B) Caco2 cells. Transwell migration assays with or without treatment of 
PD98059 (20 µM) were performed and the numbers of cells per well were 
counted under fluorescence microscope after staining with Hoechst 33342. 
Results were presented as percentage relative to the respective untreated 
vector cells. **P<0.01. 
 
4.2.15 Autocrine hGH promoted cell invasion via ERK pathway in CRC 
In order to determine the role of ERK activity in hGH-mediated cell invasion, 
invasion assays were performed in both DLD-1 and Caco2 stable cells. In 
these experiments, cells were cultured with or without PD98059 in the 10% 
Matrigel-coated transwell inserts, and the number of invaded cells was 
counted after 24 hours. Cell invasion was presented as percentage relative to 
untreated-vector cells. DLD-1-hGH cells exhibited significant increased cell 
invasion (relative cell number) to 294.2% compared to controls (untreated 
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DLD-1-vector cells) (Figure 4.16A). The treatment with PD98059 
significantly decreased cell invasion to 24.8% in DLD-1-vector cells and 
25.2% in DLD-1-hGH cells compared to controls. Furthermore, this increased 
cell invasion observed in DLD-1-hGH cells compared with DLD-1-vector 
cells was reduced by the treatment with PD98059 with 194.2% increase in 
untreated group and 0.4% increase in treated group, suggesting inhibition of 
ERK1/2 activation abrogated autocrine hGH-stimulated cell invasion in DLD-
1 cells. Similarly, Caco2 cells with forced expression of hGH exhibited 
significant increased cell invasion to 388% compared to the controls 
(untreated Caco2-vector cells), and upon PD98059 treatment significantly 
decreased cell invasion to 57.6% in Caco2-vector and 86.4% in Caco2-hGH 
cells compared controls (Figure 4.16B). Moreover, this increased cell invasion 
observed in Caco2-hGH cells compared to Caco2-vector cells was reduced by 
the treatment with PD98059 with a 288% increase in untreated group whereas 
a 29.6% increase in treated group. These results suggested that autocrine hGH-





Figure 4.16 PD98059 abrogated autocrine hGH-increased cell invasion in 
CRC cells 
PD98059 abrogated autocrine hGH-increased cell invasion in (A) DLD-1 and 
(B) Caco2 cells. Transwell invasion assays with or without treatment of 
PD98059 (20 µM) were performed and the numbers of invaded cells in each 
well were counted after 24 hours under fluorescence microscope after staining 
with Hoechst 33342. Results were presented as percentage relative to the 
respective untreated vector cells. *P<0.05, **P<0.01. 
 
4.2.16 Autocrine hGH suppressed E-CADHERIN promoter activity via 
the ERK pathway in CRC cells 
Previous results in section 4.2.10 demonstrated that autocrine hGH decreased 
mRNA expression of E-CADHERIN. To determine the effect of ERK 
activation on hGH repression of E-CADHERIN transcription, the activities of 
the E-CADHERIN promoter were examined in DLD-1 and Caco2 stable cells 
with or without PD98059 treatment. Promoter activity was presented as 
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percentage relative to untreated-vector cells. Compared with DLD-1-vector 
cells, DLD-1-hGH cells exhibited a significant decrease in E-CADHERIN 
promoter activity to 45.5% of controls (untreated DLD-1-vector cells) (Figure 
4.17A). Treatment with PD98059 increased E-CADHERIN promoter activity 
to 212.7% in DLD-1-vector and 190.7% in DLD-1-hGH cells compared to 
controls. Furthermore the difference between DLD-1-vector cells and DLD-1-
hGH cells were also decreased by PD98059 treatment from 54.5% difference 
in untreated group to 22% difference in treated group. Similar results were 
observed in Caco2 stable cells (Figure 4.17B) that forced expression of hGH 
decreased E-CADHERIN promoter activity in Caco2 cells and this autocrine 
hGH-stimulated decrease in E-CADHERIN promoter activity was abrogated 
by treatment with PD98059. These results suggested that autocrine hGH-
stimulated activation of the ERK pathway regulated E-CADHERIN promoter 
activities in CRC cells. 
 
 
Figure 4.17 PD98059 abrogated autocrine hGH-stimulated decrease in 
promoter activities of E-CADHERIN in colorectal carcinoma cells.  
(A) PD98059 inhibited autocrine hGH-induced decreased promoter activity of 
E-CADHERIN in DLD-1 cells. (B) PD98059 inhibited autocrine hGH-
induced decreased promoter activity of E-CADHERIN in Caco2 cells. Cells 
were incubated with 20 µM PD98059 or DMSO for 6 hours (DLD-1) or 24 
hours (Caco2) after transfected with plasmids containing E-CADHERIN 
promoter or Renilla. Promoter activity was measured with Dual-Luciferase® 
Reporter Assay Systems. Results were presented as percentage relative to the 
respective untreated vector cells. *P<0.05, **P<0.01. 
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4.2.17 Autocrine hGH stimulated FN1 promoter activity via the ERK 
pathway in CRC cells 
Previous results in section 4.2.10 demonstrated that autocrine hGH increased 
mesenchymal marker FN1 mRNA expression. To determine the effect of ERK 
activation on hGH stimulation of FN1 transcription, the FN1 promoter 
activities were examined in DLD-1 and Caco2 stable cells with or without 
PD98059 treatment. Promoter activity was presented as percentage relative to 
untreated-vector cells. Compared with DLD-1-vector cells, DLD-1-hGH cells 
exhibited a significant increase in FN1 promoter activity to 218.2% of controls 
(untreated DLD-1-vector cells) (Figure 4.18A). Treatment with PD98059 
decreased FN1 promoter activity to 60.0% in DLD-1-vector and 83.6% in 
DLD-1-hGH cells compared to controls. Furthermore the difference between 
DLD-1-vector cells and DLD-1-hGH cells were also decreased by PD98059 
treatment from 118.2%% difference in untreated group to 23.6% difference in 
treated group. Similar results were observed in Caco2 stable cells (Figure 
4.18B) that forced expression of hGH increased FN1 promoter activity in 
Caco2 cells and this autocrine hGH-stimulated increase in FN1 promoter 
activity was abrogated by treatment with PD98059. These results suggested 
that autocrine hGH-stimulated activation of the ERK pathway regulated FN1 
promoter activities in CRC cells. 
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Figure 4.18 PD98059 abrogated autocrine hGH-stimulated promoter 
activities of FN1 in colorectal carcinoma cells.  
PD98059 inhibited autocrine hGH-stimulated promoter activity of FN1 in 
DLD-1 and Caco2 cells. Cells were incubated with 20 µM PD98059 or DMSO 
for 6 hours after transfected with plasmids containing FN1 promoter or Renilla. 
Promoter activity was measured with Dual-Luciferase® Reporter Assay 
Systems. Results were presented as percentage relative to the respective 
untreated vector cells. *P<0.05, **P<0.01. 
 
4.2.18 Autocrine hGH decreased the protein expression of E-CADHERIN 
and increased the protein expression of FN1 via the ERK pathway in 
CRC cells 
Previous results suggested that autocrine hGH decreased E-CADHERIN 
protein expression and increased FN1 protein expression in DLD-1 and Caco2 
cells. Thus, in order to determine if autocrine hGH utilized the ERK pathway 
to mediate protein expression of E-CADHERIN and FN1, I used western blot 
analysis to examine the protein levels of E-CADHERIN and FN1 in DLD-1 
and Caco2 stable cells with or without PD98059 treatment. β-ACTIN was 
used as an input control in these cells.  Densitometric analysis of protein levels 
in DLD-1 stable cells with or without PD98059 treatment over three 
experiments normalized to the β-ACTIN control was also performed and 
presented underneath. As shown in Figure 4.19, DLD-1-hGH cells exhibited 
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increased level of p-ERK1/2 accompanied with decreased protein expression 
of E-CADHERIN and increased protein expression of FN1 compared with 
DLD-1-vector cells. The presence of PD98059 inhibited the phosphorylation 
of ERK1/2 (no difference in the expression of total ERK1/2) and resulted in 
increased expression of E-CADHERIN and decreased expression of FN1 in 
both DLD-1-vector and DLD-1-hGH cells. Furthermore, the protein 
expression levels of E-CADHERIN and FN1 in PD98059-treated DLD-1-
vector and DLD-1-hGH cells were almost equal. In addition, no significant 
difference of the total ERK1/2 expression was observed in DLD-1 stable cells 
in both treated and untreated group. Similarly, the treatment with PD98059 
also abrogated autocrine hGH repression of E-CADHERIN protein expression 
and stimulation of FN1 protein expression in Caco2 cells. These results 
suggested that autocrine hGH stimulation of the ERK pathway decreased the 
protein expression of E-CADHERIN and increased the protein expression of 







Figure 4.19 PD98059 abrogated autocrine hGH-induced decrease in E-
CADHERIN protein expression and increase in FN1 protein expression in 
colorectal carcinoma cells.  
PD98059 inhibited autocrine hGH-induced decreased protein expression of E-
CADHERIN and increased protein expression of FN1 in DLD-1 and Caco2 
cells. Cells were incubated with 20 µM PD98059 for 6 hours (DLD-1) or 24 
hours (Caco2). Western blot analysis and densitometric analysis were 
performed. β-ACTIN was used as an input control. *P<0.05, **P<0.01, n.s., 
no significance. 
 
4.2.19 Forced expression of E-CADHERIN had no effect on the ERK 
activation in CRC 
As previously demonstrated, autocrine hGH utilized ERK to repress the 
promoter activity and protein expression of E-CADHERIN in CRC cells. In 
order to investigate whether E-CADHERIN was the downstream of the ERK 
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pathway in CRC cells, I examined the level of p-ERK1/2 in DLD-1 stable 
cells with forced expression of E-CADHERIN. β-ACTIN was used as an input 
control in these cells. Densitometric analysis of protein levels in DLD-1 stable 
cells with or without forced expression of E-CADHERIN over three 
experiments normalized to the β-ACTIN control was also performed and 
presented underneath. As shown in Figure 4.20, forced expression of E-
CADHERIN in DLD-1-vector cells resulted in a significant increase in E-
CADHERIN expression, however the level of p-ERK1/2 was almost equal to 
the control (DLD-1-vector cells that transfected with empty vectors as control). 
Similarly, forced expression of E-CADHERIN in DLD-1-hGH cells increased 
the protein expression of E-CADHERIN, but did not change the level of p-
ERK1/2, when compared with the controls (DLD-1-hGH cells that transected 
with empty vectors). In addition, no significant difference of the total ERK1/2 
expression was observed. 
 
 
Figure 4.20 Forced expression of E-CADHERIN had no effect on the 
ERK activation in DLD-1 cells.  
DLD-1-vector and DLD-1-hGH cells were transfected with a vector 
containing E-CADHERIN gene or an empty vector as a control. Western blot 
analysis and densitometric analysis were performed. β-ACTIN was used as an 
input control. *P<0.05, **P<0.01, n.s., no significance. 
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4.2.20 Forced expression of E-CADHERIN abrogated autocrine hGH-
stimulated cell migration and invasion in CRC 
Loss of E-CADHERIN expression is one of the most important alterations that 
characterize an invasive phenotype, suggesting a pivotal role of E-
CADHERIN in cell invasiveness (Frixen et al., 1991, Chen and Obrink, 1991). 
Previous results demonstrated that forced expression of hGH in CRC cells 
resulted in increased cell migration and invasion, accompanied with decreased 
expression of E-CADHERIN. In order to determine if decreased E-
CADHERIN expression was required for autocrine hGH-stimulated cell 
invasiveness in CRC, I examined cell migration and invasion in DLD-1 stable 
cells with forced expression of E-CADHERIN. Cell migration or invasion was 
presented as percentage relative to untreated vector cells. DLD-1-hGH cells 
exhibited significantly increased cell migration (relative number) to 234% 
compared to controls (untreated DLD-1-vector cells) (Figure 4.21A). Forced 
expression of E-CADHERIN significantly decreased cell migration to 24.6% 
in DLD-1-vector and 35.9% in DLD-1-hGH cells compared to controls. 
Furthermore the difference between DLD-1-vector cells and DLD-1-hGH cells 
were also decreased by the forced expression of E-CADHERIN to 11.3%, 
whereas 134% of difference was observed between untreated DLD-vector and 
hGH cells. Similar results were observed in DLD-1 stable cells in invasion 
assays (Figure 4.21B) that forced expression of hGH significantly increased 
DLD-1 cell invasion compared to vector cells, and such autocrine hGH-
stimulated cell invasion was abrogated by the forced expression of E-
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CADHERIN. These results suggested that a decrease in E-CADHERIN is 
required for autocrine hGH to stimulate migration and invasion in CRC cells. 
 
 
Figure 4.21 Forced expression of E-CADHERIN abrogated autocrine 
hGH-stimulated cell migration and invasion in DLD-1 cells.  
(A) Migration and  (B) invasion assays were performed to determine the effect 
of forced expression of E-CADHERIN on cell invasive potential in DLD-1 
stable cells. Cells were transfected with a vector containing E-CADHERIN 
gene or an empty vector as a control. Cell counting was performed under 
fluorescence microscopy after staining with Hoechst 33342. Results were 
represented as percentages relative to the DLD-1-vector cells in the control 
group. **P<0.01. 
 
4.2.21 knockdown of FN1 had no effect on the ERK activation in CRC 
As previously demonstrated, autocrine hGH utilized ERK to promote the 
promoter activity and protein expression of FN1 in CRC cells. In order to 
investigate whether FN1 was the downstream of the ERK pathway in CRC 
cells, I examined the level of p-ERK1/2 in DLD-1 stable cells with 
knockdown of FN1 by FN1siRNA. β-ACTIN was used as an input control in 
these cells. Densitometric analysis of protein levels in DLD-1 stable cells with 
or without knockdown of FN1 over three experiments normalized to the β-
ACTIN control was also performed and presented underneath. As shown in 
Figure 4.22, Knockdown of FN1 in DLD-1-vector cells resulted in a 
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significant decrease in FN1 expression, however the level of p-ERK1/2 was 
almost equal to the DLD-1-vector cells that transfected with control siRNA. 
Similarly, knockdown of FN1 in DLD-1-hGH cells decrease the protein 
expression of FN1, but did not change the level of p-ERK1/2, when compared 
with the DLD-1-hGH cells that transected with control siRNA. In addition, no 
significant difference of the total ERK1/2 expression was observed. Similar 
results were observed in Caco2 stable cells. 
 
 
Figure 4.22 Knockdown of FN1 had no effect on the ERK activation in 
CRC cells.  
DLD-1 and Caco2 stable cells were transfected with FN1siRNA or a control 
siRNA. Western blot analysis and densitometric analysis were performed. β-





4.2.22 Knockdown of FN1 abrogated autocrine hGH-stimulated cell 
migration and invasion in CRC 
FN1 is one of the most important mesenchymal markers involved in migration 
process including wound healing and metastasis (Waalkes et al., 2010). 
Previous results demonstrated that forced expression of hGH in CRC cells 
resulted in increased cell migration and invasion, accompanied with increased 
expression of FN1. In order to determine if increased FN1 expression was 
required for autocrine hGH-stimulated cell migration and invasion in CRC, I 
examined cell migration and invasion in DLD-1 and Caco2 stable cells with 
knockdown of FN1. Cell migration or invasion was presented as percentage 
relative to respective untreated vector cells. In cell migration assay, DLD-1-
hGH cells exhibited significantly increased cell migration (relative number) to 
188.8% compared to controls (untreated DLD-1-vector cells) (Figure 4.23A). 
Knockdown of FN1 significantly decreased cell migration to 27.2% in DLD-
1-vector and 38.7% in DLD-1-hGH cells compared to controls. Furthermore 
the difference between DLD-1-vector cells and DLD-1-hGH cells were also 
decreased by the knockdown of FN1 to 11.5%, whereas 88.8% of difference 
was observed between DLD-vector and hGH cells in untreated group. Similar 
results were observed in Caco2 stable cells that forced expression of hGH 
significantly increased Caco2 cell migration compared to vector cells, and this 
autocrine hGH-stimulated cell migration was abrogated by the knockdown of 
FN1. 
In cell invasion assay, DLD-1-hGH cells exhibited significantly increased cell 
invasion (relative number) to 283.2% compared to controls (untreated DLD-1-
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vector cells) (Figure 4.23B). Knockdown of FN1 significantly decreased cell 
invasion to 29.8% in DLD-1-vector and 40.1% in DLD-1-hGH cells compared 
to controls. Furthermore the difference between DLD-1-vector cells and DLD-
1-hGH cells were also decreased by the knockdown of FN1 to 10.3%, whereas 
183.2% of difference was observed between DLD-vector and DLD-1-hGH 
cells in untreated group. Similar results were observed in Caco2 stable cells 
(Figure 4.23B). These results suggested that an increase in FN1 is required for 
autocrine hGH to stimulate migration and invasion in CRC cells. 
 
Figure 4.23 knockdown of FN1 abrogated autocrine hGH-stimulated cell 
migration and invasion in CRC cells.  
(A) Migration and  (B) invasion assays were performed to determine the effect 
of knockdown of FN1 on cell invasive potential in DLD-1 and Caco2 stable 
cells. Cells were transfected FN1siRNA or a control siRNA. Cell counting 
was performed under fluorescence microscopy after staining with Hoechst 
33342. Results were represented as percentages relative to the vector cells in 
the control group. **P<0.01. 
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4.2.23 Autocrine hGH regulated the expression of E-CADHERIN and 
FN1 in CRC cells in xenograft models in vivo 
As observed previously, autocrine hGH stimulated EMT in CRC cells with 
decreased expression of E-CADHERIN and increased expression of FN1 in 
vitro. To further confirm the effect of autocrine hGH on regulation of E-
CADHERIN and FN1 expression in vivo, IHC analysis was performed to 
examine expression levels of EMT markers FN1 and E-CADHERIN on the 
sections of xenograft tumors. DLD-1-hGH tumors exhibited higher protein 
levels of FN1 and lower protein levels of E-CADHERIN compared to DLD-1-
vector tumors (Figure 4.24), suggestive that EMT was also stimulated by 
autocrine hGH in CRC cells in xenograft model in vivo. 
 
Figure 4.24 Autocrine hGH increased expression of FN1 and decreased 
expression of E-CADHERIN in CRC cells in xenograft models in vivo.  
The expression levels of FIBRONECTIN 1 (FN1) and E-CADHERIN in 
primary tumors were examined by IHC analysis after subcutaneously injection 
with DLD-1-vector or DLD-1-hGH cells. Images were captured under 400 × 
magnification. 
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4.2.24 Autocrine hGH stimulated local invasion of CRC cells in xenograft 
models in vivo 
Previous results demonstrated that autocrine hGH stimulated EMT in CRC 
cells. EMT has been demonstrated to play an essential role in local invasion, 
which is the first step of metastasis (Chaffer and Weinberg, 2011). To further 
determine whether autocrine hGH promoted local invasion of CRC cells in 
vivo, hematocylin/eosin (HE) staining was performed on the xenograft tumors 
with adjacent tissue. The tumors generated from DLD-1-vector cells exhibited 
well-defined boundary from surrounding normal tissues without any filtration, 
while the tumors generated from DLD-1-hGH cells did not formed a clear 
boundary with adjacent tissues and infiltrated into surrounding tissues to form 
another tumor mass (Figure 4.25). These results suggested that autocrine hGH 
stimulated local invasion of CRC cells in xenograft models in vivo. 
 
Figure 4.25 Autocrine hGH stimulated local invasion of CRC cells in 
xenograft models in vivo.  
Tumors with adjacent tissues were stained with hematoxylin and eosin. The 
local invasion of DLD-1-hGH tumor into adjacent tissue is indicated (black 
arrow). Images were captured under 200 × (Bar, 100 µm) and 400 × (Bar, 50 
µm) magnification respectively. 
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4.3 Discussion 
EMT is a transitional process, in which epithelial cells acquire the 
mesenchymal characteristics and convert into mesenchymal-like cells with 
increased cell motility (Thiery et al., 2009). In my studies, autocrine hGH 
stimulated morphologic conversion in CRC cells. Autocrine hGH in DLD-1 
cells resulted in a mesenchymal-like phenotype with multiple cellular 
protrusions and a more scattered morphology with loss of intercellular contact. 
However, autocrine expression of hGH neither resulted in loss of cell-cell 
contact nor a scattered morphology in Caco2 cells. Such difference may be 
explained by the later observation in Figure 4.12 that cell membrane and 
cellular contact localization of E-CADHERIN were almost lost in DLD-1-
hGH cells, whereas still remained in Caco2-hGH cells. The presence of E-
CADHERIN in cellular contact in Caco2-hGH cells may partly inhibit cell 
scattering. This different response of DLD-1 and Caco2 cells to autocrine hGH 
could be due to the different cell characteristics where DLD-1 cells carry 
mutant KRASG13D and exhibit a higher invasive potential compared to the 
KRAS wild type cell Caco2 cells (Makrodouli et al., 2011). However, 
autocrine production of hGH in Caco2 cells resulted in a reorganization of F-
actin and a formation of lamellipodial protrusions at the leading edges, which 
provided cell a force to migrate and invade (Lamouille et al., 2014). 
Acquisition of enhanced cell migration and invasion was also observed in 
Caco2-hGH cells compared to Caco2-vector cells.  
In addition to the altered cell morphology, increased cell migration and 
invasion was observed in CRC cells with forced expression of hGH compared 
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with respective control cells. These observations were consistent with previous 
findings that autocrine production of hGH promoted cell migration and 
invasion in mammary carcinoma and endometrial carcinoma cells (Mukhina et 
al., 2004, Pandey et al., 2008). Altered phenotype and enhanced cell migration 
and invasion are thought to be associated with the process of EMT. Generally, 
EMT is also characterized by the loss of E-CADHERIN expression and 
increased expression of mesenchymal markers, such as FN1 (Thiery et al., 
2009). E-CADHERIN is a member of cadherin superfamily and expressed in 
the adherence junctions of epithelial cells. Additionally, E-CADHERIN plays 
an essential role in maintaining cell polarity and intercellular adhesion, thus it 
is considered as a suppressor of cell invasion (Bae et al., 2013). It is well 
established that induction of EMT is accompanied with decreased expression 
of E-CADHERIN (Wang et al., 2013). Furthermore, knockdown of E-
CADHERIN in lung cancer cells has also been demonstrated to result in an 
induction of EMT and also an increase in cell invasion (Bae et al., 2013). 
Consistently, autocrine hGH in CRC cells stimulated EMT with 
downregulated expression of E-CADHERIN. However, Mukhina et al. have 
demonstrated that autocrine hGH-induced EMT in MCF-7 cells is not 
accompanied with decreased expression of E-CADHERIN, but downregulated 
expression of PLAKOGLOBIN (γ-catenin) which results in relocalization of 
E-CADHERIN and disruption of intercellular junctions (Mukhina et al., 2004). 
Similarly, autocrine production of hGH resulted in a disruption of cell-cell 
junctions by decreasing cell membrane and intercellular localization of E-
CADHERIN in DLD-1 cells. Interestingly, Hollestelle et al. has demonstrated 
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that forced expression of E-CADHERIN in a spindle mammary carcinoma cell 
line MDA-MB-231, which has undergone EMT and loss of E-CADHERIN 
expression, cannot revert the mesenchymal morphology to an epithelial 
morphology, nor can it result in any expression changes in other EMT markers, 
while in SKBR3 cells, forced expression of E-CADHERIN revert the cell 
morphology into an epithelial morphology (Hollestelle et al., 2013). Such 
results suggest that the causal connection of E-CADHERIN and EMT may not 
be simple, as EMT may be induced by the loss of E-CADHERIN, or the loss 
of E-CADHERIN may be not a necessity for EMT. In my study, autocrine 
hGH-stimulated migration or invasion, which was one of the EMT-associated 
cell behaviors, was abrogated by the forced expression of E-CADHERIN in 
CRC cells. This observation highlighted the functional role of E-CADHERIN 
in autocrine hGH-stimulated EMT in CRC cells, suggesting that loss of E-
CADHERIN was required for autocrine hGH stimulated EMT in CRC cells. 
FN1 is one of the ECM proteins and plays an essential role in cell adhesion 
and cell migration (Zou et al., 2012). FN1 has been demonstrated to induce 
cell migration by binding to the integrins, such as α5β1 integrin, resulting in the 
activation the receptor tyrosine kinase (RTK) to stimulate downstream 
signaling (Mitra et al., 2011). Decreased expression of E-CADHERIN and 
increased expression of FN1 are commonly observed in EMT, however few of 
studies have reported the relationship of E-CADHERIN and FN1. Some 
studies have demonstrated that FN expression is regulated by β-catenin (Gradl 
et al., 1999), which provide a possibility that loss of E-CADHERIN 
contributed to a nuclear localization of β-catenin (Conacci-Sorrell et al., 2002), 
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resulting in the regulation of FN1 expression. However this hypothesis needs 
further investigation. 
During cancer progression, EMT is thought to contribute to metastasis with 
enhanced cell invasiveness, especially in local invasion (Nguyen et al., 2009). 
In my study, autocrine hGH stimulated local invasion of CRC cells in 
xenograft models in vivo, suggested its potential functional role in metastasis. 
Metastasis is the major cause responsible for cancer death and the major factor 
limiting the success of cancer treatment (Geiger and Peeper, 2009, Steeg, 
2006). The process of metastasis is complex, in which tumor cells leave the 
primary tumor site, disseminate to a distant site through the circulatory system 
and finally colonize and form a secondary tumor in the foreign 
microenvironment. Metastasis is not an efficient process, and every step of the 
process is important for the success of final colonization (Valastyan and 
Weinberg, 2011). Enhancing the invasiveness of tumor cells to stimulate the 
local invasion is only the first step of metastasis. Another challenge for 
metastatic tumor cells is to penetrate the endothelial cell barriers to intravasate 
into circulation or extravasate into distant sites from circulation. Endothelial 
cell adhesion and trans-migration assays in my study were performed to 
investigate the capability of intravasation or extravasation in vitro. These 
strategies have been widely utilized to understand the in vivo processes of 
intravasation and extravasation in vitro (Banerjee et al., 2011, Simoneau et al., 
2012, Qi et al., 2005). In addition, the increased mRNA expression levels of 
metastatic marker genes in the colorectal carcinoma cells with forced 
expression of hGH also suggested the potential role of autocrine hGH in 
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promoting metastasis. However, in vitro studies cannot predict how autocrine 
hGH modulates CRC cell metastasis in vivo, some studies utilize animal 
models to investigating metastasis in vivo (Banerjee et al., 2011, Kong et al., 
2012). These studies use xenograft models with tail vein injection of 
transgenic cells and examine the lung and liver metastasis in the models. Such 
experiment investigates the later steps of metastasis, which are difficult to 
study in vitro. 
Autocrine hGH may stimulate EMT or metastasis via multiple mechanisms. It 
has demonstrated that autocrine hGH can activate JAK2/STATs, MAPK and 
PI-3K pathways in cancer cells (Perry et al., 2013), and all of these pathways 
have been demonstrated to be involved in the progression of EMT and 
metastasis (Tang et al., 2010a, Lehmann et al., 2000, Wander et al., 2013). As 
previously demonstrated, MAPK/ERK pathway was activated by autocrine 
hGH in CRC cells, and the inhibition of p-ERK1/2 by PD98059 significantly 
abrogated autocrine hGH-induced cell migration and invasion, as well as the 
autocrine hGH repression of E-CADHERIN expression. This role of 
MAPK/ERK in the repression of E-CADHERIN has been indicated in other 
studies (Lau et al., 2013), and is through MAPK/ERK-regulated expression of 
transcription factors such as SNAIL, TWIST, ZEB1, or ZEB2, which have 
been well established to suppress the expression of E-CADHERIN (Thiery et 
al., 2009). Some studies have demonstrated that E-CADHERIN can activate 
MAPK pathway by the recruitment and activation of EGFR to maintain 
adherent junctions (Pece and Gutkind, 2000). However, forced expression of 
E-CADHERIN did not change the activation of ERK1/2 pathway herein. 
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Other studies have demonstrated that Wnt/β-catenin pathway is activated 
during EMT, and this activation is associated with the loss of E-CADHERIN, 
which stimulates the translocation of β-catenin (Conacci-Sorrell et al., 2002). 
Interestingly, in colorectal carcinoma, the central parts of the primary tumors 
exhibit high expression of E-CADHERIN at the cell membrane with co-
localized β-catenin, whereas the mesenchymal-like tumor at the invasive front 
exhibits loss of the membranous E-CADHERIN and predominant nuclear 
localization of β-catenin (Brabletz et al., 2001). Activated β-catenin in the 
nucleus regulates transcription of specific genes, such as c-Myc, which is 
functionally involved in EMT (Cho et al., 2010). 
Another potentially interesting mechanism for the effects observed in my 
current studies is the potential role of autocrine hGH-induced IGF-1. The 
increased mRNA expression of IGF-1 was observed in colorectal carcinoma 
cells with forced expression of hGH, and the expression of IGF-1R was also 
detected in the colorectal carcinoma cells used herein (data not shown here). 
The functional effect of IGF-1 system may contribute to autocrine hGH-
induced EMT and metastatic potential. It has been demonstrated that IGF-1R 
is frequently overexpressed in human colon cancer cells and increased 
expression of IGF-1R is correlated with higher tumor stage (Hakam et al., 
1999). Inhibition of IGF-1R function in colorectal carcinoma cells has been 
observed to result in the loss of metastatic potential (Reinmuth et al., 2002). 
The mechanisms of IGF-1 in metastasis are associated with the activation of 
IGF-1R-dependent downstream pathways, including PI-3K/AKT, 
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Raf/MEK/ERK to regulate the expression of various genes involved in 
invasion and migration (Bahr and Groner, 2005).  
Understanding the mechanisms of autocrine hGH in promoting EMT in 
colorectal carcinoma, may potentially contribute to a novel targeted therapy 
for cancer treatment. 
 
4.4 Summary and conclusion 
In this study, autocrine hGH stimulated morphologic conversion from an 
epithelial phenotype to a mesenchymal phenotype in CRC cells. Forced 
expression of hGH in DLD-1 cells increased cell scattering properties with 
more scattered colonies generated by DLD-1-hGH cells compared with 
controls. However, no scattered colonies were observed in both Caco2-hGH 
and Caco2-vector cells. Furthermore, autocrine hGH increased cell growth on 
2D Matrigel, as well as cell migration in wound healing and migration assays. 
Moreover, forced expression of hGH in CRC cells promoted cell growth in 3D 
Matrigel and cell invasion in invasion assay. In addition, forced expression of 
hGH in DLD-1 cells promoted cell attachment to and transmigration through 
the endothelial cell layer.  
Consistently, forced expression of hGH in DLD-1 and Caco2 cells 
significantly decreased mRNA and protein levels of epithelial markers E-
CADHERIN and OCCLUDIN, and increased mRNA and protein levels of 
mesenchymal markers FIBRONECTIN1. Moreover, increased protein 
expression of VIMENTIN was also observed in Caco2-hGH cells, while no 
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detectable expression levels of VIMENTIN was observed in DLD-1 stable 
cells. 
As previously demonstrated, MAPK/ERK was activated by autocrine hGH. 
The inhibition of ERK pathway significantly abrogated autocrine hGH-
induced cell migration and invasion and autocrine hGH-stimulated loss of E-
CADHERIN, suggesting autocrine hGH stimulated EMT via MAPK/ERK 
pathway in CRC cells. In addition, forced expression of E-CADHERIN in 
CRC cells significantly suppressed autocrine hGH-stimulated cell migration 
and invasion, suggesting autocrine hGH increased cell migration and invasion 
in a E-CADHERIN-dependent manner.  
Additionally, autocrine hGH stimulated EMT in CRC cell in vivo with 
increased expression of FN1 and decreased expression of E-CADHERIN. 
Forced expression of hGH in DLD-1 cells also stimulated local invasion in 
xenograft models in vivo, suggested the potential role of autocrine hGH in 
















Chapter 5 Autocrine hGH stimulates cancer stem cell-like 
behavior in colorectal carcinoma cells 
 
5.1 Introduction 
Cancer stem cells (CSCs) are one small population of cancer cells that possess 
the capability of both sustaining tumor growth and tumor initiation (Karnoub 
et al., 2007). This subpopulation of tumor cells were initially identified in 
hematopoietic tumors, while now have been identified and isolated in various 
types of solid tumors, such as brain, breast, prostate, pancreas and colon (Al-
Hajj et al., 2003, Singh et al., 2004, Collins et al., 2005, Patrawala et al., 2006, 
Dalerba et al., 2007).  
Numbers of molecular markers are developed to identify or isolate the cancer 
stem cells from tumor. One of the most widely used markers is aldehyde 
dehydrogenase 1 (ALDH1), a detoxifying enzyme which plays an essential 
role in the intracellular aldehyde oxidation. Many studies have demonstrated 
that carcinoma cells with high ALDH1 expression exhibit increased stem cell 
properties compared to the cells with low ALDH1 expression (Ma and Allan, 
2011). It has also been demonstrated that only 500 ALDH1+ cells that isolated 
from breast cancer were able to form tumors in vivo when transplanted into 
mammary fat pads of NOD/SCID mice, whereas 50,000 ALDH1- cells failed, 
suggesting that ALDH1+ cancer cells exhibit higher stem cell properties 
compared to the ALDH1- cancer cells (Ginestier et al., 2007). More 
interestingly, with tracking the stem cell population during progression from 
normal tissue to mutant tissue to adenoma, Huang et al. have demonstrated 
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that the number of ALDH1+ cells increase and these cells become distributed 
further up the crypt (Huang et al., 2009). Moreover, ALDH1+ cancer stem 
cells display more aggressive characteristics and metastatic potential, which 
may lead to a poor prognosis in patients with cancer (van den Hoogen et al., 
2010, Sun and Wang, 2010).  
Recently, more and more studies have suggested that CSCs are associated with 
EMT and metastasis, as well as a chemo-resistant cancer phenotype, resulting 
in poor clinical outcomes in cancer patients (Mani et al., 2008, Scheel et al., 
2011, Dean et al., 2005). Previous findings also demonstrated that ARTEMIN-
induced TWIST1-dependent EMT in the estrogen receptor negative mammary 
carcinoma (ER-MC) cells was also correlated with the acquisition of cancer 
stem cell-like properties (Banerjee et al., 2011, Banerjee et al., 2012). I 
previously demonstrated that autocrine hGH stimulated EMT and metastatic 
potential in colorectal carcinoma cells in chapter 4. Thus, investigating the 
role of autocrine hGH in cancer stem cell-like behavior may contribute to 
further understanding of hGH-induced poor clinical outcomes and provide a 
novel therapy to prevent metastasis. 
 
5.2 Results 
5.2.1 Autocrine hGH decreased sensitivity to 5-FU in CRC cells 
One characteristic of CSCs is the ability to resist chemotherapeutic agents 
such as fluorouracil (5-FU), which is the most common and widely used 
chemotherapeutic drug for the treatment for various cancers, including 
colorectal cancer (Dean et al., 2005, Fu et al., 2014). Concordantly, I observed 
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that autocrine hGH regulated the 5-FU sensitivity in CRC cells (Figure 5.1). 
Forced expression of hGH significantly suppressed the reduction of cell 
viability in response to increasing concentration of 5-FU in both DLD-1 and 
Caco2 cells. The half maximal inhibitory concentration (IC50) of 5-FU in 
DLD-1 and Caco2 stable cells was calculated by software (Prism) after 
normalization. The IC50 of 5-FU in DLD-1-hGH cells was 10.17 µg/ml, which 
was higher than DLD-1-vector cells (4.83 µg/ml). Similarly, Caco2-hGH cells 
(88.40ng/ml) also exhibited higher IC50 of 5-FU compared with Caco2-vector 
cells  (33.69ng/ml). 
 
Figure 5.1 Autocrine hGH enhanced chemo-resistance to 5-FU in 
colorectal carcinoma cells.  
(A) DLD-1 and (B) Caco2 cells with forced expression of hGH were seeded in 
10% serum containing media with different concentration of 5-FU. After 72 
hours, cell viability was measured by AlamarBlue assays. *P<0.05, **P<0.01. 
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5.2.2 Autocrine hGH promoted CRC cell spheroid formation  
Cancer stem cells have the ability to survive from anoikis and grow under 
ultra-low attachment conditions to give rise to spheroidal colonies (Hinohara 
et al., 2012). To investigate the effect of autocrine hGH on this CSC behavior 
in CRC cells, colonosphere formation was examined in DLD-1 and Caco2 
stable cells (Figure 5.2). DLD-1 cells with forced expression of hGH 
significantly promoted colonosphere formation with a 1.55-fold increase in 
colonospheres formation compared with the respective vector cells. Similarly, 
an increased number of colonospheres was observed in Caco2-hGH cells 
compared with Caco2-vector cells (2.22-fold increase). Furthermore, the 
colonospheres formed by DLD-1-hGH and Caco2-hGH cells were observed 







Figure 5.2 Autocrine hGH enhanced colonosphere formation in colorectal 
carcinoma cells.  
DLD-1 and Caco2 cells with forced expression of hGH or vector cells were 
seeded in ultra low attachment plates in colonosphere culture media for 7 days 
(DLD-1) or 10 days (Caco2). Images of colonospheres of DLD-1 and Caco2 
stable cells were captured under 200 × magnification. Bar, 20 µm (DLD-1); 50 
µm (Caco2). Results were presented as percentage relative to the respective 
vector cells. **P<0.01. 
 
5.2.3 Autocrine hGH promoted self-renewal potential of colorectal 
carcinoma cells 
To further confirm that autocrine hGH-induced colonosphere formation 
resulted from the self-renewal of individual cells rather than cell aggregation, I 
examined the colonosphere formation of DLD-1 and Caco2 stable cells in 
serial passage (Banerjee et al., 2012). The number of colonospheres generated 
by DLD-1 and Caco2 stable cells in each generation was counted for three 
generations (Figure 5.3). In the first generation (G1), DLD-1-hGH cells 
exhibited increased colonosphere formation compared with DLD-1-vector 
cells with 1.6-fold increase. Subsequently, in the second and third generation, 
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a respective 2.08-fold and 2.26-fold increase in colonosphere formation was 
observed in DLD-1-hGH cells compared to control cells. Similarly, increased 
colonosphere formation was also observed in Caco2-hGH cells compared with 
Caco2-vector cells in each generation with 1.48-fold increase in G1, 1.83-fold 
increase in G2 and 2.04-fold increase in G3.  
 
 
Figure 5.3 Autocrine hGH enhanced the CSC-like self-renewal in 
colorectal carcinoma cells. 
DLD-1 and Caco2 cells with forced expression of hGH or vector cells were 
grown under colonosphere conditions and cultured from first generation (G1) 
till third generation (G3). The numbers of colonospheres were counted in each 
generation after culturing for 7 days (DLD-1) or 10 days (Caco2). Results 




5.2.4 Autocrine hGH regulated the mRNA expression of stem cell 
markers in colorectal carcinoma cells 
To further investigate the effect of autocrine hGH on the acquisition of cancer 
stem cell-like behavior in colorectal carcinoma cells, I examined the 
expression levels of several CSC marker genes in DLD-1-vector and DLD-1-
hGH cells by use of qPCR analysis (Figure 5.4). Up-regulation of CSC surface 
marker genes CD24, CD44 and ALDH1 (Al-Hajj et al., 2003, Ginestier et al., 
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2007) was observed in DLD-1-hGH cells compared with DLD-1-vector cells. 
The mRNA levels of transcription factors KLF4, NANOG, POU5F1 and 
SALL4 (Kim and Orkin, 2011, Shan et al., 2012, Zhang et al., 2006) were also 
increased in response to forced expression of hGH in DLD-1 cells. The 
expression of other key genes involved in stem cell self-renewal such as BMI1 
and LIN28A (Biehs et al., 2013, Shyh-Chang and Daley, 2013) was also up 
regulated in DLD-1-hGH cells compared with DLD-1-vector cells. However, 
no significant difference in mRNA levels of SRC, WNT5A, WNT5B and SOX2 
were observed in DLD-1-hGH cells when compared to DLD-1-vector cells. 
 
 
Figure 5.4 Autocrine hGH regulated the mRNA expression of stem cell 
markers in colorectal carcinoma cells.  
qPCR analysis was performed to examine the effect of forced expression of 
hGH in DLD-1 cells on expression of stem cell markers. Results are 
represented as a fold change in mRNA levels in DLD-1-hGH cells relative to 
the vector cells. *P<0.05, **P<0.01. 
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5.2.5 Autocrine hGH modulated ALDH1+ cell population in colorectal 
carcinoma cells 
ALDH1 is one of the markers utilized for identification of cancer stem cell in 
cancers including colorectal cancer (Huang et al., 2009). In order to determine 
the effect of autocrine hGH on the population distribution of cancer stem cell 
like cells in colorectal carcinoma cells, I examined the cell population of 
ALDH1+ cells in DLD-1 and Caco2 stable cells by flow cytometry analysis. 
Cells were incubated with Aldefluor substrate to define ALDH1 positivity, 
and a specific inhibitor of ALDH1, diethylaminobenzaldehyde (DEAB), was 
used as control to establish the baseline fluorescence. Results of flow 
cytometry analysis demonstrated that autocrine hGH significantly increased 
the ALDH1+ cell population in DLD-1 and Caco2 cells. It was determined that 
12.4% of DLD-1-hGH cells were the ALDH1+ cell population, compared to 
DLD-1-vector cells where only 3.6% were ALDH1+ cells (Figure 5.5A). 
Similarly, more than 15% of Caco2-hGH cells were ALDH1+, while only 
7.3% of Caco2-vector cells are ALDH1+ cells (Figure 5.5B). Such observation 
indicated that in the presence of autocrine hGH, the ALDH1+ cell population 
was enriched in CRC. 
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Figure 5.5 Autocrine hGH increased ALDH1+ population in colorectal 
carcinoma cells.  
The ALDH1+ population was determined in DLD-1 (A) and Caco2 (B) stable 
cells. Cells were incubated with Aldefluor substrate (BAAA, BODIPY®-
aminoacetaldehyde) to define the ALDH1 positive, and a specific inhibitor of 
ALDH1, diethylaminobenzaldehyde (DEAB), was used as control to establish 
the baseline fluorescence. Flow cytometry analysis was used to indicate side 
scatter (SSC) and fluorescence intensity. 
 
 
5.2.6 Autocrine hGH regulated the ALDH1+ cell population in a E-
CADHERIN-dependent manner in colorectal carcinoma cells 
E-CADHERIN plays an essential role in neural stem cell self-renewal 
(Karpowicz et al., 2009), and E-CADHERIN-related EMT has also been 
associated with cancer stem cell properties (Lamouille et al., 2014), suggesting 
a potential role of E-CADHERIN in cancer stem cell behavior. Thus, I 
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examined the functional role of E-CADHERIN in autocrine hGH-induced 
ALDH1+ cell population in DLD-1 and Caco2 stable cells. Cells were 
transfected with vectors containing full length of E-CADHERIN gene (termed 
as E-CADHERIN group) or empty vectors (termed as control group). As 
shown in Figure 5.6, in the control group, 15.6% of DLD-1-vector cells and 
31.4% of DLD-1-hGH cells were the ALDH1+ cell population (Figure 5.6A), 
whereas only 5.8% of DLD-1-vector cells and 3.6% of DLD-1-hGH cells were 
the ALDH1+ cell population in the E-CADHERIN group (Figure 5.6B), 
suggesting that forced expression of E-CADHERIN in DLD-1 stable cells 
significantly decreased ALDH1+ cell population of DLD-1 stable cells. In 
addition, the atuocrine hGH-stimulated increase in the ALDH1+ cell 
population of DLD-1 cells was also reduced by forced expression of E-
CADHERIN. Such observations suggested that forced expression of E-
CADHERIN in DLD-1 stable cells abrogated the autocrine hGH-induced 
ALDH1+ cell population. However, forced expression of E-CADHERIN only 
slightly decreased the percentage of ALDH1+ cell population in Caco2-vector 





Figure 5.6 Forced expression of E-CADHERIN abrogated autocrine 
hGH-stimulated increase in ALDH1+ cell population in DLD-1 cells.  
(A) DLD-1 stable cells were transfected with empty vectors or (B) vectors 
containing full length of E-CADHERIN genes. The ALDH1+ cell population 
was determined after incubation with Aldefluor substrate (BAAA). An 
ALDH1 inhibitor, diethylaminobenzaldehyde (DEAB), was used to measure 
the baseline fluorescence. Flow cytometry analysis was used to indicate side 




Figure 5.7 Forced expression of E-CADHERIN slightly decreased 
ALDH1+ cell population in Caco2 stable cells.  
(A) Caco2 stable cells were transfected with empty vectors or (B) vectors 
containing full length of E-CADHERIN genes. The ALDH1+ cell population 
was determined after incubation with Aldefluor substrate (BAAA). An 
ALDH1 inhibitor, diethylaminobenzaldehyde (DEAB), was used to measure 
the baseline fluorescence. Flow cytometry analysis was used to indicate side 
scatter (SSC) and fluorescence intensity. 
 
5.3 Discussion 
The increasing evidence suggests that stem cells have a critical role not only in 
the development of normal tissues, but also in cancer progression (Jordan et al., 
2006). Cancer stem cells share properties in common with normal stem cells, 
such as self-renewal that the majority of other cancer cells do not have. Recent 
study has demonstrated a functional role of GH in stem and progenitor cells 
(Lombardi et al., 2014). In this study, Lombardi et al. demonstrated that GHR 
is co-expressed with stem cell markers in a subpopulation of normal human 
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breast epithelium cells (HMECs), and these GHR positive cells have the 
ability to form mammospheres and exhibit a higher differentiation potential 
compared to GHR negative cells. Additionally, activation of GHR with GH 
treatment enhances mammosphere formation in the GHR positive cells 
(Lombardi et al., 2014). In my study, I demonstrated the functional effect of 
autocrine hGH on cancer stem cell-like behavior in CRC cells that autocrine 
hGH significantly promoted self-renewal capability in colorectal carcinoma 
cells with increased spherical formation under ultra-low attachment conditions, 
suggesting a potential role of autocrine hGH in acquisition of cancer stem cell 
properties.  
Chemo-resistance is a major problem that limits the efficiency of 
chemotherapies for cancer treatments, and is responsible for over 90% of drug 
failure in metastatic cancers (Longley and Johnston, 2005). CSCs are also 
thought to play an integral role in relapse following chemotherapy through 
chemo-resistance (Abdullah and Chow, 2013). In my study, I observed that 
forced expression of hGH functionally decreased CRC cell sensitivity to the 
chemotherapeutic agent, 5-FU, which is commonly used for the systemic 
treatment of CRC (Dean et al., 2005, Fu et al., 2014). These results are 
concordant with previous findings that demonstrated the effect of hGH on 
acquisition of chemo-resistance (Bougen et al., 2011, Zatelli et al., 2009, 
Minoia et al., 2012). These studies have demonstrated that autocrine hGH 
decreased breast cancer and endometrial cancer cell sensitivity in response to 
doxorubicin or mitomycin C. Similarly, Mojarrad et al. have demonstrated 
that autocrine hGH in mammary carcinoma cell MCF-7 exhibits resistance to 
 183 
tamoxifen (Mojarrad et al., 2010). This effect may be due to the autocrine 
hGH-upregulated G-coupled estrogen receptor, GPR30, which can mediate the 
expression of a variety of mitogenic genes, such as c-fos, cyclin A, cyclin D 
and cyclin E (Mojarrad et al., 2010). Although the potential correlation of 
chemo-resistance and cancer stem cell-like properties was not discussed in 
their studies, autocrine hGH-induced chemo-resistance may potentially result 
from its role in the acquisition of CSC-like behavior. 
Moreover, increased expression of cancer stem cell marker genes in the cells 
with forced expression of hGH and increased CSC population identified by 
ALDH1 strongly supported my hypothesis. However, the specific mechanisms 
for autocrine hGH-induced cancer stem cell-like behavior in CRC cells are 
still unclear and require further study. One potential mechanism of autocrine 
hGH in acquisition of CSC-like properties is its effect on EMT. Although the 
origin of CSCs is debatable, a number of studies suggest that they may arise 
by undergoing EMT (Brabletz et al., 2005). The induction of EMT by 
overexpressing transcription factors SNAIL or TWIST in HMLE cells results 
in the acquisition of stem cell-like properties, while isolated stem cell-like 
cells from mammary glands or carcinomas exhibit expression of EMT markers 
(Mani et al., 2008). Moreover, high expression of EMT markers stimulate 
stem cell-like behavior in breast, ovarian and colorectal carcinoma cells, and 
correlates with chemo- or radio-resistance and the metastatic potential (Fang et 
al., 2011, Kurrey et al., 2009, Hwang et al., 2011). Interestingly, forced 
expression of E-CADHERIN in DLD-1 cells largely abrogated autocrine 
hGH-induced ALDH1+ cell population, however slightly decreased ALDH1+ 
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cell population in Caco2 stable cells. The role of E-CADHERIN in cancer 
stem cell properties may potentially be associated with Wnt/β-catenin pathway, 
which can be activated by the accumulation of β-catenin in cytoplasm caused 
by the loss of E-CADHERIN as discussed in section 5.3. The essential role of 
Wnt signaling in cancer progression has been well established in CRC. 
Activated mutations in Wnt pathway has been observed in nearly 90% of 
colorectal cancer, mainly due to the mutation of adenomatous polyposis coli 
(APC), which is a key component for the degradation of β-catenin (Miyaki et 
al., 1994). In my study, both DLD-1 and Caco2 cells have the mutation in 
APC with different truncation, however the APC mutations in DLD-1 cannot 
inhibit the degradation of β-catenin (Yang et al., 2006a), while Caco2 cells 
exhibit highly active Wnt signaling (Jones and Veale, 2003). The different 
effects of APC mutations on β-catenin degradation in DLD-1 and Caco2 cells 
may provide an explanation of their different response to the forced expression 
of E-CADHERIN. 
In addition, with the frequent expression of IGF-1 and IGF-1R in colorectal 
carcinoma including the cells used in current studies, autocrine hGH-promoted 
cancer stem cell-like behavior may potentially be mediated by the functional 
effect of the IGF-1 system. It has been demonstrated that IGF signaling not 
only stimulates the expression of transcription factors involved in EMT 
program to induce EMT, but also regulates a variety of pathways involved in 
cell pluripotency and stemness maintenance (Malaguarnera and Belfiore, 
2014). IGF-1R activation through PI3K/AKT/GSK3β has been observed to 
mediate up-regulation of OCT-4 and the formation of β-catenin/OCT-4/SOX2 
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complexes, which is essential for the activation of NANOG promoter and 
maintenance of self-renewal properties in lung cancer stem-like cells (Xu et al., 
2013a).  
 
5.4 Summary and conclusion 
In this study, I investigated the effect of autocrine hGH exerted on cancer stem 
cell-like behavior in CRC cells. Firstly, I demonstrated that autocrine hGH 
decreased sensitivity to 5-FU and promoted colonosphere formation in DLD-1 
and Caco2 cells. Furthermore, the results of colonosphere formation in serial 
passage demonstrated that autocrine hGH significantly promoted the 
properties of CSC-like self-renewal in DLD-1 and Caco2 cells. Also, I 
determined the mRNA expression of several CSC markers and demonstrated 
that autocrine hGH significantly increased mRNA expression of ALDH1, 
BMI1, LIN28A, NANOG and POU5F1. Increased expression of CSC markers 
suggested a potential role of autocrine hGH in stimulating CSC-like behavior 
in CRC cells. Thus, I investigated the cancer stem cell population in DLD-1 
and Caco2 stable cells with stem cell surface marker ALDH1, and 
demonstrated that autocrine hGH significantly increased ALDH1+ cell 
population in DLD-1 and Caco2 stables. In addition, this autocrine hGH-
stimulated ALDH1+ cell population in DLD-1 cells was significantly reduced 
by forced expression of E-CADHERIN, while Caco2 stable cells exhibited 




Chapter 6 Conclusions and future directions 
 
Abundant evidence indicates the functional role of autocrine human growth 
hormone (hGH) in the development and progression of cancers (Perry et al., 
2006). Up-regulation of hGH expression has been implicated in endometrial 
adenocarcinoma and endometriosis (Slater et al., 2006). Moreover, hGH has 
also been demonstrated to be frequently expressed in mammary and 
endometrial cancer, and its expression is positively associated with poor 
clinical outcomes in patients with mammary or endometrial carcinomas (Wu 
et al., 2011). Recent studies have demonstrated that autocrine hGH promotes 
cell proliferation, cell survival and oncogenicity in human mammary and 
endometrial carcinoma cells (Zhu et al., 2005a, Pandey et al., 2008). 
Furthermore, autocrine hGH has the capability to stimulate EMT and promote 
cell invasiveness in mammary and endometrial cancers (Pandey et al., 2008, 
Mukhina et al., 2004). Additionally in colorectal cancer, expression of GHR 
has been implicated in clinicopathological features, where increased 
expression is significantly correlated with tumor size, differentiation and 
pathological stage (Wu et al., 2007, Yang et al., 2005), suggesting the 
potential role of hGH in CRC. However, the functional role of autocrine hGH 
in CRC progression has not yet been explored. 
The aim of the current thesis was initially to investigate the functional role of 
autocrine hGH in oncogenicity, EMT and metastatic potential in colorectal 
carcinoma cells. Subsequently, I also extended this interest to the potential 
role of autocrine hGH in promoting the properties of cancer stem cells, which 
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is thought to be the essential elements of successful metastasis formation and 
responsible for the relapse after anti-cancer therapy (Chaffer and Weinberg, 
2011).   
I firstly investigate the role of autocrine hGH in the regulation of oncogenicity 
of colorectal carcinoma. Our collaborator and I have demonstrated that hGH 
was locally expressed in colorectal carcinomas as well as colorectal normal 
tissue, however it was found that hGH was more frequently expressed in 
colorectal carcinoma compared with normal tissue. Furthermore, the mRNA 
expression of hGH was positively associated with tumor size and lymph nodes 
metastasis in the patients with colorectal carcinoma. In order to study the role 
of autocrine hGH in CRC progression, I generated a cell-based model in 
which cells were stably transfected with a vector containing full length of hGH 
gene to maintain continuous expression of hGH. Using this cell model, I 
demonstrated that forced expression of hGH in CRC cells significantly 
increased total cell number by promoting cell proliferation and suppressing 
cell apoptosis. Furthermore, autocrine production of hGH in CRC cells 
resulted in an enhanced foci formation and anchorage-independent growth in 
soft agar, suggesting the oncogenic potential of autocrine hGH in CRC cells. 
Furthermore, autocrine hGH in DLD-1 cells promoted tumor growth in 
xengraft models in vivo with increased cell proliferation and survival. These 
results demonstrated that autocrine hGH promoted oncogenicity of CRC cells 
both in vitro and in vivo. 
To investigate the potential mechanism involved in autocrine hGH-stimulated 
oncogenicity, I examined several key proteins involved in GH-mediated 
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signaling pathways and demonstrated ERK1/2 was activated by autocrine 
hGH. The inhibition of ERK1/2 activation by PD98059 significantly 
abrogated autocrine hGH-induced promotion of total cell number, cell 
proliferation and anchorage-independent growth, as well as reduction of cell 
apoptosis. Additionally, activated ERK1/2 was also observed in CRC cells 
with forced expression of hGH in xenograft models in vivo. These results 
suggested that autocrine hGH promoted oncogenicity in CRC cells via the 
MAPK/ERK pathway.  
I then investigated the potential role of autocrine hGH in EMT and metastatic 
potential in colorectal carcinoma. It has been demonstrated that autocrine hGH 
stimulated cell morphologic conversion from an epithelial phenotype to a 
mesenchymal phenotype in CRC cells. Furthermore, autocrine hGH promoted 
cell growth in 2D and 3D Matrigel, and increased cell migration and invasion 
in CRC cells. This phenotypic conversion was associated with the progression 
of EMT. I thus examined the expression of EMT markers in the cells with 
forced expression of hGH and demonstrated that autocrine hGH significantly 
decreased mRNA expression of epithelial markers and increased mRNA 
expression of mesenchymal markers. Consistently, protein expression of 
epithelial markers E-CADHERIN and OCCLUDIN was downregulated, while 
mesenchymal markers FN1 was upregulated by autocrine hGH in CRC cells. 
Additionally, increased expression of FN1 and decreased expression of E-
CADHERIN were also observed in CRC cells with forced expression of hGH 
in xenograft models in vivo. Autocrine product of hGH in CRC cells 
stimulated local invasion in vivo. Moreover, autocrine hGH-induced cell 
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migration and invasion, as well as loss of E-CADHERIN were abrogated by 
the inhibition of MAPK/ERK pathway, suggesting autocrine hGH stimulated 
EMT through MAPK/ERK pathway in CRC cells. Furthermore, forced 
expression of E-CADHERIN abrogated autocrine hGH-induced cell migration 
and invasion, suggesting that the loss of E-CADHERIN was required in the 
autocrine hGH-stimulated EMT. Knockdown of FN1 also abrogated autocrine 
hGH-induced cell migration and invasion, suggesting increased FN1 
expression was also required in the autocrine hGH-stimulated EMT. Such 
observations suggested that autocrine hGH stimulated EMT via MAPK/ERK 
pathway in an E-CADHERIN-dependent and FN1-dependent manner in CRC. 
Further studies would determine the specific mechanisms in the regulation of 
E-CADHERIN or FN1 in EMT. In addition, autocrine hGH promoted CRC 
cells to attach to and transmigrate through endothelial cell layer, suggesting 
the potential role of autocrine hGH in intravasation and extravasation. 
Furthermore, autocrine hGH also increased mRNA expression of several 
metastatic markers, such as MMP9, SERPINB5, indicating a potential role of 
autocrine hGH in metastasis in CRC. Further studies would determine the 
effect of autocrine hGH in metastasis in vivo and confirm the specific 
mechanisms involved. 
The last focus of this study was to investigate the potential role of autocrine 
hGH in the acquisition of cancer stem cell-like behavior. Cancer stem cells 
have been demonstrated to be associated with EMT and metastasis, as well as 
chemo-resistant cancer phenotype, resulting in poor clinical outcome in cancer 
patients (Mani et al., 2008, Scheel et al., 2011, Dean et al., 2005). It has been 
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demonstrated in my study that autocrine hGH decreased sensitivity to 5-FU 
and promoted colonosphere formation in CRC cells. Furthermore, autocrine 
hGH also promoted colonosphere formation in serial passage, which was 
utilized to examine the property of self-renewal in CRC cells. Additionally, 
autocrine hGH increased the mRNA expression of several cancer stem cell 
markers, such as ALDH1, BMI1, LIN28A, NANOG. In order to determine the 
cancer stem cell population in CRC cells, I used ALDH1 as a cancer stem cell 
surface marker. It has been demonstrated that autocrine hGH increased 
ALDH1+ cell population in CRC cells, and this autocrine hGH-induced 
ALDH1+ cell population was abrogated by the forced expression of E-
CADHERIN, suggesting autocrine hGH stimulated cancer stem cell-like 
behavior is regulated in a E-CADHERIN-dependent manner. Further studies 
would determine the potential mechanisms involved in E-CADHERIN-
mediated stemness in CRC cells. 
GH is predominantly secreted by the pituitary gland and is a key endocrine 
regulator of the postnatal growth in regulating the body composition and 
metabolism in adults as well as regulating longitudinal growth during 
childhood (Perry et al., 2013). Moreover, it has been known that GH is also 
expressed in several extrapituitary sites. Increased expression of GH or the 
GHR has been indicated in a variety of cancers including breast, prostate, 
melanoma, endometrial, lung and colorectal cancer (Perry et al., 2006, 
Chhabra et al., 2011), suggesting a role of autocrine or endocrine hGH in 
oncogenesis. One of the essential roles of autocrine hGH in cancer is its ability 
to promote proliferative and anti-apoptotic effect. It has been demonstrated 
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that autocrine hGH enhances cell proliferation and cell survival in vitro, and 
promotes tumor growth in vivo (Kaulsay et al., 1999, Pandey et al., 2008). In 
addition, autocrine hGH has been demonstrated to induce a oncogenic 
transformation of the immortalized mammary epithelial cells with increased 
proliferation (Zhu et al., 2005a). Another crucial role of autocrine hGH in 
cancer is the ability to stimulate phenotypic conversion and metastasis. It has 
been demonstrated that autocrine expression of hGH in mammary carcinoma 
cells alters cell morphology and promotes a mesenchymal phenotype by 
stimulating EMT with increased cell migration in vitro and local invasion in 
vivo (Mukhina et al., 2004). In my study, I demonstrated a functional role of 
autocrine hGH in colorectal carcinoma progression by stimulating 
oncogenicity, EMT and cancer stem cell-like behavior. Thus, the functional 
inhibition of GH may contribute to a novel anti-CRC therapeutic strategy. 
Functional antagonism of hGH receptor contributes an important approach for 
therapeutic application. Pegvisomant is a commercially available GHR 
antagonist, which is approved by FDA for the treatment of acromegaly. 
Pegvisomant is a pegylated peptide inhibitor with a mutated GH molecule, 
which prevents GHR dimerization, and thereby inhibits the GH-mediated 
signal transduction (van der Lely and Kopchick, 2006). It has been 
demonstrated that treatment with pegvisomant reduces growth rate of 
xenografts in meningioma and colon cancer cells (Friend, 2001). A number of 
xenograft studies have demonstrated that administration of pegvisomant 
significantly inhibits tumor growth by suppressing cancer cell proliferation 
and inducing apoptosis (Divisova et al., 2006, Dagnaes-Hansen et al., 2004). 
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Additionally, the protein component of pegvisomant, B2036, has been widely 
used in cell-based model system to investigate the therapeutic potential. 
B2036 has been demonstrated to abrogate autocrine hGH-mediated 
transcriptional activation, cell survival from apoptosis and cell spreading on 
the collagen matrix (Kaulsay et al., 2001). Recently, hGH induced cell 
proliferation, survival and invasiveness have also been demonstrated to be 
abrogated by treatment with B2036 in mammary and endometrial carcinoma 
cells (Chiesa et al., 2011, Pandey et al., 2008). Moreover, Brunet-Dunand et al. 
demonstrated that B2036 suppresses endothelial cell HMEC-1 cell 
proliferation and motility, as well as tube formation in vitro, and which 
potentially suppresses autocrine hGH-induced angiogenesis (Brunet-Dunand 
et al., 2009). Furthermore, autocrine hGH-induced chemo-resistance is also 
prevented by B2036 treatment in endometrial carcinoma cells (Bougen et al., 
2011). However, the regulation of GH in CRC progression is complex with 
multiple mechanisms, which remains a challenge for single GH-targeted 
therapy. Thus, combination therapies that inhibit GH function with additional 
combinatorial treatments may be required for a more efficient anti-cancer 
treatment. The identification of genes, involved in autocrine hGH regulated 
oncogenicity, EMT and cancer stem cell properties, as well as the components 
involved in GH-mediated signaling pathway, provide potential targets for the 
therapeutic strategy combining with GH-targeted treatment.  
One of the potential therapeutic targets is hPRLR. As discussed in section 3.3, 
hPRLR serves as a receptor of hGH and the signaling pathways involved are 
also similar to that at hGHR (Bole-Feysot et al., 1998). Furthermore, it has 
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been demonstrated that hGH binds to hPRLR prior to hGHR (Xu et al., 2013b), 
and hPRLR is commonly expressed in CRC (Harbaum et al., 2010). These 
observations highly suggest a requirement of combination of GHR-targeted 
and PRLR-targeted treatment in autocrine hGH-mediated CRC progression. 
One of PRLR antagonists utilized in preclinical trials is LFA102, which aims 
to interfere the dimerization of the receptor (Damiano and Wasserman, 2013). 
Studies have observed that the treatment with LFA102 significantly 
suppresses breast tumor growth in rats (Damiano et al., 2013), suggesting its 
therapeutic effect on PRLR-dependent cancer treatment. The combination of 
LFA102 treatment and GH-targeted therapy may have a potential effect on the 
CRC treatment. 
Another potential therapeutic target is E-CADHERIN. E-CADHERIN has an 
essential role in maintaining cell polarity and adherent junctions. Loss of E-
CADHERIN is associated with invasive phenotype and increased cell motility 
(Thiery et al., 2009). In my study, autocrine hGH significantly decresed 
expression of E-CADHERIN in CRC cells, and autocrine hGH-stimulated cell 
migration and invasion, as well as cancer stem cell population was regulated 
by E-CADHERIN. DNA methylation of CDH1 is one of the causes 
responsible for the loss of E-CADHERIN (Oliveira et al., 2009). It has been 
demonstrated that autocrine hGH increases the expression of DNA 
methyltransferase 3A and 3B (DNMT3A and DNMT3B), resulting in a 
decrease of PLAKOGLOBIN gene transcription by hypermethylation of its 
promoter (Shafiei et al., 2008). Thus, autocrine hGH stimulated decrease in E-
CADHERIN expression may potentially result from autocrine hGH-induced 
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expression of DNMTs. Therefore, using DNA methylation inhibitors or DNA 
de-methylation agents to inhibit the methylation of CDH1 promoter to induce 
gene expression may act as a potential therapeutic strategy to combine with 
GH-targeted therapy for cancer treatment (Oliveira et al., 2009). 
In addition, inhibition of GH-mediated signaling pathways may also act as a 
potential targeted therapy. In my study, inhibition of ERK1/2 by PD98059 
significantly suppressed autocrine hGH-induced oncogenicity and EMT, 
suggesting the crucial role of MAPK/ERK pathway in autocrine hGH-
mediated CRC progression. MEK1/2 inhibitors are widely used to specifically 
inhibit the activation of ERK1/2, such as PD98059 that was utilized in my 
study (Suthiphongchai et al., 2006). However, PD98059 is commonly used in 
academic research, but not the clinical trial because of its pharmaceutical 
limitations (Fremin and Meloche, 2010). CI-1040 and PD0325901 were firstly 
applied into clinical trials, which have already been discontinued because of 
high toxicity (Fremin and Meloche, 2010). Several new MEK1/2 inhibitors, 
such as GSK1120212, GDC-0973, RDEA119, are being evaluated in clinical 
trials currently. Preclinical studies have demonstrated that the combination of 
MEK1/2 inhibitors and other inhibitors, such as PI3K inhibitor, exhibits a 
significant synergistic effect on cancer regression (Engelman et al., 2008, Wee 
et al., 2009). Thus, studies of the effects of the combination of MAPK/ERK-
targeted therapy and GH-targeted therapy on the treatment of CRC may be of 
interest. 
Furthermore, with the frequent expression of IGF-1 and IGF-1R in colorectal 
carcinomas including the cells used in current studies, autocrine hGH-induced 
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EMT, metastatic potential and stemness may potentially be mediated by the 
functional effect of IGF-1 system. Thus, therapies targeting IGF-1 signaling 
may potentially contribute to a novel treatment strategy for colorectal cancer. 
Several antagonists have been developed to disrupt IGF-1R-mediated signal 
transduction through multiple mechanisms, including receptor-specific 
antibodies, such as CP-751871, and receptor kinase inhibitors (Pollak, 2008). 
Although some early in vitro and in vivo studies have demonstrated that 
inhibition of IGF-1 signaling with some of these antagonists prevent tumor 
growth and metastasis (Goffin et al., 2007), the efficacy is limited in the 
clinical trials (Gallagher and LeRoith, 2011, Pollak, 2012, Yee, 2012). The 
failure of IGF-1 targeting therapies may be due to the lack of a proper 
biomarker and the complexity of IGF-1R signaling, as well as the nature of the 
GH/IGF-1 system (Pollak, 2008). Thus, combined therapies targeting IGF-1 
and GH might contribute to a more effective treatment of cancer including 
colorectal cancer.  
In conclusion, this study demonstrated that autocrine hGH promoted 
oncogenicity in CRC cells via the MAPK/ERK pathway. Furthermore, 
autocrine hGH stimulated EMT and metastatic potential in CRC cells through 
the MAPK/ERK pathway requiring the represson of E-CADHERIN or 
stimulation of FN1. Additionally, autocrine hGH stimulated cancer stem cell-
like behavior associated with loss of E-CADHERIN in CRC cells. The 
functional role of autocrine hGH in colorectal cancer progression may 
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Experiment Buffers/Solutions Composition 
Bacterial 
Transformation 
liquid LB  
BactoTM Tryptone, 10g 
BactoTMYeast extract, 5g 
NaCl, 5g  
Milli-Q H2O, 1L  
Autoclaved and stored at 4°C. 
Ampicillin, 100 µg/ml (added 
before use) 
Solid LB  
Agarose, 15g 
Liquid LB medium, 1L  
Autoclaved and stored at 4°C 
Ampicillin, 100 µg/ml (added 
before use) 
Cell culture Complete RPMI media 
RPMI medium, 450ml 
Heat-inactivated FBS, 50ml 




DMEM-12F media  
EGF (20ng/ml),  
bFGF (20ng/ml),  
B27 (2%),  
Heparin (4ug/ml, 0.0004%),  
Hydrocortisone (0.5ug/ml)  
FBS (1%) 





Milli-Q H2O, 1L 
Adjust pH to 7.4 
Freezing medium 
10% DMSO,  
90% heat inactivated FBS. 
DNA 
electrophoresis 
10X TBE buffer 
Tris 108g, 
EDTA 7.44g 
Boric acid 55g 
1L Milli-Q H2O 
pH 8.3 
1-2% agarose gel 
Agarose, 1-2g 
1X TBE buffer, 100ml 
 230 
Protein extraction RIPA buffer 
NaCl (150mM), 





5% Stacking gel 
40% acrylamide, 830 µl,  
1M Tris-HCl (pH 6.8), 630 µl   
10% SDS, 50 µl, 
Milli-Q H2O, 3.4ml, 
TEMED, 5 µl,  
10% APS, 50 µl. 
12% Separating gel 
40% acrylamide, 3.3ml,  
1.5M Tris-HCl (pH 8.8), 
2.5ml   
10% SDS, 100 µl, 
Milli-Q H2O, 4ml, 
TEMED, 4 µl,  
10% APS, 100 µl. 
5X protein loading dye 
0.5M Tris-HCl (pH 6.8), 
12.5ml, 
10% SDS, 20ml, 
Glycerol, 10ml, 
BPB, 10mg, 
Milli-Q H2O, fill up to 45ml, 
14.4M 2-Mercaptoethanol,  
200 µl/800 µl sol. 
 231 




Milli- Q H2O, fill up to 3L 
1X Running buffer 
10X Running buffer, 100ml 
Milli-Q H2O, 900ml 




Milli-Q H2O, fill up to 1L. 
1X Transfer buffer 
10X Transfer buffer, 100ml  
MeOH, 200ml 
 Milli-Q H2O, up to 1L 
0.1% PBS-Tween 
10x PBS, 100ml 
Milli-Q H2O, 900ml 
Tween-20, 1ml 
Blocking buffer 
Non-fat dry milk powder, 5g 
(BSA, 5g) 
0.1% PBS-Tween, 100ml 
 232 
Others 
1.5 M Tris-HCl 
Tris, 27.3g 
Milli-Q H2O, 80ml 
pH 8.8 
Milli-Q H2O, up to 150ml 
1M Tris HCL 
Tris, 18.2 g 
Milli-Q H2O, 80 ml 
pH 6.8 
Milli-Q H2O, up to 150ml 
 
 
